

COVID-19 Immunogenicity Analysis Report  
mock Study

USG COVID-19 Response Biostatistics Team

April 24, 2021



# Contents

<b>1</b>	<b>Tabular Description of Immunogenicity Data</b>	<b>15</b>
<b>2</b>	<b>Graphical Description of Immunogenicity Data</b>	<b>409</b>
2.1	Pairs plots of antibody markers for overall per-protocol cohort . . . . .	409
2.2	RCDF plots of antibody markers for overall per-protocol cohort . . . . .	429
2.3	Scatter plots of antibody markers versus age for overall per-protocol cohort . . . . .	456
2.4	Box plots of antibody markers for overall per-protocol cohort . . . . .	461
2.5	Spaghetti plots of antibody markers over time for the overall per-protocol cohort . . . . .	478
2.6	RCDF plots of antibody markers by demographics for per-protocol cohort . . . . .	481
2.7	Boxplots of antibody markers by demographics for per-protocol cohort . . . . .	554



# List of Tables

1.1	Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort . . . . .	15
1.2	Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort . . . . .	17
1.3	Table 3a. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by All participants . . . . .	18
1.4	Table 3b. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age . . . . .	20
1.5	Table 3c. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Risk for Severe Covid-19 . . . . .	24
1.6	Table 3d. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Risk for Severe Covid-19 . . . . .	28
1.7	Table 3e. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Sex . . . . .	37
1.8	Table 3f. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, sex . . . . .	41
1.9	Table 3g. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Hispanic or Latino ethnicity . . . . .	49
1.10	Table 3h. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Race . . . . .	56
1.11	Table 3i. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Underrepresented minority status . . . . .	73
1.12	Table 3j. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Underrepresented minority status . . . . .	78
1.13	Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants	89
1.14	Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age . . . . .	90
1.15	Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19 . . . . .	92
1.16	Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19 . . . . .	94

1.17 Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex . . . . .	97
1.18 Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex . . . . .	99
1.19 Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity . . . . .	102
1.20 Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race . . . . .	105
1.21 Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status . . . . .	111
1.22 Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status . . . . .	113
1.23 Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants . . . . .	117
1.24 Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age . . . . .	121
1.25 Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19 . . . . .	129
1.26 Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19 . . . . .	137
1.27 Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex . . . . .	153
1.28 Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex . . . . .	161
1.29 Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity . . . . .	177
1.30 Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race . . . . .	189
1.31 Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status . . . . .	220
1.32 Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status . . . . .	228
1.33 Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants . . . . .	244
1.34 Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age . . . . .	247
1.35 Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19 . . . . .	253
1.36 Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19 . . . . .	259
1.37 Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex . . . . .	270
1.38 Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex . . . . .	276

1.39 Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity . . . . .	287
1.40 Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race . . . . .	296
1.41 Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status . . . . .	320
1.42 Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status	326
1.43 Table 7a. The ratios of GMTs/GMCs between groups by Age . . . . .	340
1.44 Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19 . . . . .	344
1.45 Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19	348
1.46 Table 7d. The ratios of GMTs/GMCs between groups by Age >= 65, Risk for Severe Covid-19	354
1.47 Table 7e. The ratios of GMTs/GMCs between groups by Sex . . . . .	360
1.48 Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity . . . . .	364
1.49 Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status . . . . .	370
1.50 Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm . . . . .	376
1.51 Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2 . . . . .	378
1.52 Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age . . . . .	380
1.53 Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19 . . . . .	383
1.54 Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19 . . . . .	386
1.55 Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age >= 65, Risk for Severe Covid-19 . . . . .	390
1.56 Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex . . . . .	394
1.57 Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity . . . . .	397
1.58 Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status . . . . .	401
1.59 Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo) . . . . .	405
1.60 Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo) . . . . .	406
1.61 Table 11. Antibody levels in the per-protocol cohort (vaccine recipients) . . . . .	407
1.62 Table 12. Antibody levels in the per-protocol cohort (placebo recipients) . . . . .	408



# List of Figures

2.1	Pair plots of D29 Ab markers: baseline negative vaccine arm . . . . .	410
2.2	Pair plots of D57 Ab markers: baseline negative vaccine arm . . . . .	411
2.3	Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm . . . . .	412
2.4	Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm . . . . .	413
2.5	Pair plots of D1, D29 and D57 Binding Antibody to N: baseline negative vaccine arm . . . . .	414
2.6	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm . . . . .	415
2.7	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm . . . . .	416
2.8	Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline negative vaccine arm . . . . .	417
2.9	Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline negative vaccine arm . . . . .	418
2.10	Pair plots of D29 Ab markers: baseline positive vaccine arm . . . . .	419
2.11	Pair plots of D57 Ab markers: baseline positive vaccine arm . . . . .	420
2.12	Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm . . . . .	421
2.13	Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm . . . . .	422
2.14	Pair plots of D1, D29 and D57 Binding Antibody to N: baseline positive vaccine arm . . . . .	423
2.15	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm . . . . .	424
2.16	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm . . . . .	425
2.17	Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline positive vaccine arm . . . . .	426
2.18	Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline positive vaccine arm . . . . .	427
2.19	RCDF plots for D29 Ab markers: by baseline status x randomization arm . . . . .	429
2.20	RCDF plots for D57 Ab markers: by baseline status x randomization arm . . . . .	430
2.21	RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm . . . . .	431
2.22	RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm . . . . .	432
2.23	RCDF plots for D29 bAb markers: by baseline status for the vaccine arm . . . . .	433
2.24	RCDF plots for D29 nAb markers: by baseline status for the vaccine arm . . . . .	433
2.25	RCDF plots for D57 bAb markers: by baseline status for the vaccine arm . . . . .	434
2.26	RCDF plots for D57 nAb markers: by baseline status for the vaccine arm . . . . .	435
2.27	RCDF plots for D29 over D1 fold-rise bAb markers: by baseline status for the vaccine arm . . . . .	436
2.28	RCDF plots for D29 over D1 fold-rise nAb markers: by baseline status for the vaccine arm . . . . .	437

2.29 RCDF plots for D57 fold-rise over D1 bAb markers: by baseline status for the vaccine arm . . . . .	438
2.30 RCDF plots for D57 fold-rise over D1 nAb markers: by baseline status for the vaccine arm . . . . .	439
2.31 RCDF plots for D29 bAb markers: baseline negative vaccine arm . . . . .	440
2.32 RCDF plots for D29 nAb markers: baseline negative vaccine arm . . . . .	441
2.33 RCDF plots for D57 bAb markers: baseline negative vaccine arm . . . . .	442
2.34 RCDF plots for D57 nonbAb markers: baseline negative vaccine arm . . . . .	443
2.35 RCDF plots for D29 fold-rise over D1 bAb markers: baseline negative vaccine arm . . . . .	444
2.36 RCDF plots for D29 fold-rise over D1 nAb markers: baseline negative vaccine arm . . . . .	445
2.37 RCDF plots for D57 fold-rise over D1 bAb markers: baseline negative vaccine arm . . . . .	446
2.38 RCDF plots for D57 fold-rise over D1 nAb markers: baseline negative vaccine arm . . . . .	447
2.39 RCDF plots for D29 bAb markers: baseline positive vaccine arm . . . . .	448
2.40 RCDF plots for D29 nAb markers: baseline positive vaccine arm . . . . .	449
2.41 RCDF plots for D57 bAb markers: baseline positive vaccine arm . . . . .	450
2.42 RCDF plots for D57 nonbAb markers: baseline positive vaccine arm . . . . .	451
2.43 RCDF plots for D29 fold-rise over D1 bAb markers: baseline positive vaccine arm . . . . .	452
2.44 RCDF plots for D29 fold-rise over D1 nAb markers: baseline positive vaccine arm . . . . .	453
2.45 RCDF plots for D57 fold-rise over D1 bAb markers: baseline positive vaccine arm . . . . .	454
2.46 RCDF plots for D57 fold-rise over D1 nAb markers: baseline positive vaccine arm . . . . .	455
2.47 Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm . . . . .	457
2.48 Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm . . . . .	458
2.49 Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm . . . . .	459
2.50 Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm . . . . .	460
2.51 Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms . . . . .	462
2.52 Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms . . . . .	463
2.53 Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms . . . . .	464
2.54 Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms . . . . .	465
2.55 Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms . . . . .	466
2.56 Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms . . . . .	467
2.57 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms . . . . .	468
2.58 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms . . . . .	469
2.59 Boxplots of D29 Ab markers: baseline positive + negative vaccine arm . . . . .	470
2.60 Boxplots of D57 Ab markers: baseline positive + negative vaccine arm . . . . .	471
2.61 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm . . . . .	472
2.62 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm . . . . .	473
2.63 Boxplots of D29 Ab markers: baseline positive + negative placebo arm . . . . .	474
2.64 Boxplots of D57 Ab markers: baseline positive + negative placebo arm . . . . .	475

2.65 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm . . . . .	476
2.66 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm . . . . .	477
2.67 Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm . . . . .	479
2.68 Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm . . . . .	480
2.69 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups. . . . .	482
2.70 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups. . . . .	483
2.71 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	484
2.72 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	485
2.73 RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition. . . . .	486
2.74 RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition. . . . .	487
2.75 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition. . . . .	488
2.76 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition. . . . .	489
2.77 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.	490
2.78 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.	491
2.79 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition. . . . .	492
2.80 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition. . . . .	493
2.81 RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth. . . . .	494
2.82 RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth. . . . .	495
2.83 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth. . . . .	496
2.84 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth. . . . .	497
2.85 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth. . . . .	498
2.86 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth. . . . .	499
2.87 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth. . . . .	500
2.88 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth. . . . .	501
2.89 RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity. . . . .	502
2.90 RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity. . . . .	503
2.91 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.	504
2.92 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.	505
2.93 RCDF plots for D29 Ab markers: baseline negative vaccine arm by race. . . . .	506
2.94 RCDF plots for D57 Ab markers: baseline negative vaccine arm by race. . . . .	507

2.95 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. . . . .	508
2.96 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. . . . .	509
2.97 RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	510
2.98 RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	511
2.99 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	512
2.100RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	513
2.101RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	514
2.102RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	515
2.103RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	516
2.104RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	517
2.105RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups. . . . .	518
2.106RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups. . . . .	519
2.107RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups. . . . .	520
2.108RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups. . . . .	521
2.109RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	522
2.110RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	523
2.111RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	524
2.112RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	525
2.113RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	526
2.114RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	527
2.115RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	528
2.116RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	529
2.117RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	530
2.118RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	531
2.119RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	532
2.120RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	533
2.121RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	534

2.122RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	535
2.123RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	536
2.124RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	537
2.125RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity. . . . .	538
2.126RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity. . . . .	539
2.127RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	540
2.128RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	541
2.129RCDF plots for D29 Ab markers: baseline positive vaccine arm by race. . . . .	542
2.130RCDF plots for D57 Ab markers: baseline positive vaccine arm by race. . . . .	543
2.131RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. .	544
2.132RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. .	545
2.133RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	546
2.134RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	547
2.135RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	548
2.136RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	549
2.137RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	550
2.138RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	551
2.139RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	552
2.140RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	553
2.141Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group. . . . .	555
2.142Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group. . . . .	556
2.143Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth. . . . .	557
2.144Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth. . . . .	558
2.145Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. .	559
2.146Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. .	560
2.147Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . . .	561
2.148Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . . .	562

2.149Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	563
2.150Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group. . . . .	564
2.151Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	565
2.152Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	566
2.153Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. . .	568
2.154Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. . .	569
2.155Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	570
2.156Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. . . . .	571
2.157Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	572
2.158Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. . . . .	573
2.159Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	574
2.160Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. . . . .	575
2.161Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	576
2.162Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. . . . .	577
2.163Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . .	578
2.164Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . .	579
2.165Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. . . . .	580
2.166Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. . . . .	581
2.167Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	582
2.168Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. . . . .	583
2.169Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	584
2.170Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. . . . .	585

# Chapter 1

## Tabular Description of Immunogenicity Data

Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Characteristics	Vaccine (N = 899)	Placebo (N = 155)	Total (N = 1054)
<b>Age</b>			
Age < 65	436 (48.5%)	74 (47.7%)	510 (48.4%)
Age ≥ 65	463 (51.5%)	81 (52.3%)	544 (51.6%)
Mean (Range)	58.3 (18.0, 85.0)	61.6 (18.0, 85.0)	58.8 (18.0, 85.0)
<b>BMI</b>			
Mean ± SD	29.9 ± 6.9	29.8 ± 7.1	29.9 ± 6.9
<b>Risk for Severe Covid-19</b>			
At-risk	453 (50.4%)	79 (51.0%)	532 (50.5%)
Not at-risk	446 (49.6%)	76 (49.0%)	522 (49.5%)
<b>Age, Risk for Severe Covid-19</b>			
Age < 65 At-risk	214 (23.8%)	38 (24.5%)	252 (23.9%)
Age < 65 Not at-risk	222 (24.7%)	36 (23.2%)	258 (24.5%)
Age ≥ 65	463 (51.5%)	81 (52.3%)	544 (51.6%)
<b>Sex</b>			
Female	511 (56.8%)	88 (56.8%)	599 (56.8%)
Male	388 (43.2%)	67 (43.2%)	455 (43.2%)
<b>Hispanic or Latino ethnicity</b>			
Hispanic or Latino	115 (12.8%)	19 (12.3%)	134 (12.7%)
Not Hispanic or Latino	664 (73.9%)	120 (77.4%)	784 (74.4%)
Not reported and unknown	120 (13.3%)	16 (10.3%)	136 (12.9%)
<b>Race</b>			
White Non-Hispanic	337 (37.5%)	64 (41.3%)	401 (38.0%)
Black or African American	195 (21.7%)	38 (24.5%)	233 (22.1%)
Asian	53 (5.9%)	8 (5.2%)	61 (5.8%)
American Indian or Alaska Native	22 (2.4%)	2 (1.3%)	24 (2.3%)
Native Hawaiian or Other Pacific Islander	15 (1.7%)		15 (1.4%)
Multiracial	59 (6.6%)	8 (5.2%)	67 (6.4%)
Other	21 (2.3%)	3 (1.9%)	24 (2.3%)

*(continued)*

Characteristics	Vaccine (N = 899)	Placebo (N = 155)	Total (N = 1054)
Not reported and unknown	92 (10.2%)	20 (12.9%)	112 (10.6%)
Communities of Color	405 (45.1%)	65 (41.9%)	470 (44.6%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age  $\geq$  65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Characteristics	Vaccine (N = 278)	Placebo (N = 274)	Total (N = 552)
<b>Age</b>			
Age < 65	144 (51.8%)	150 (54.7%)	294 (53.3%)
Age ≥ 65	134 (48.2%)	124 (45.3%)	258 (46.7%)
Mean (Range)	58.0 (18.0, 85.0)	54.8 (18.0, 85.0)	56.4 (18.0, 85.0)
<b>BMI</b>			
Mean ± SD	30.1 ± 7.3	29.6 ± 7.0	29.9 ± 7.2
<b>Risk for Severe Covid-19</b>			
At-risk	130 (46.8%)	122 (44.5%)	252 (45.7%)
Not at-risk	148 (53.2%)	152 (55.5%)	300 (54.3%)
<b>Age, Risk for Severe Covid-19</b>			
Age < 65 At-risk	72 (25.9%)	75 (27.4%)	147 (26.6%)
Age < 65 Not at-risk	72 (25.9%)	75 (27.4%)	147 (26.6%)
Age ≥ 65	134 (48.2%)	124 (45.3%)	258 (46.7%)
<b>Sex</b>			
Female	151 (54.3%)	137 (50.0%)	288 (52.2%)
Male	127 (45.7%)	137 (50.0%)	264 (47.8%)
<b>Hispanic or Latino ethnicity</b>			
Hispanic or Latino	38 (13.7%)	28 (10.2%)	66 (12.0%)
Not Hispanic or Latino	211 (75.9%)	212 (77.4%)	423 (76.6%)
Not reported and unknown	29 (10.4%)	34 (12.4%)	63 (11.4%)
<b>Race</b>			
White Non-Hispanic	119 (42.8%)	121 (44.2%)	240 (43.5%)
Black or African American	58 (20.9%)	54 (19.7%)	112 (20.3%)
Asian	16 (5.8%)	15 (5.5%)	31 (5.6%)
American Indian or Alaska Native	6 (2.2%)	6 (2.2%)	12 (2.2%)
Native Hawaiian or Other Pacific Islander	5 (1.8%)	3 (1.1%)	8 (1.4%)
Multiracial	16 (5.8%)	15 (5.5%)	31 (5.6%)
Other	6 (2.2%)	11 (4.0%)	17 (3.1%)
Not reported and unknown	25 (9.0%)	28 (10.2%)	53 (9.6%)
Communities of Color	120 (43.2%)	111 (40.5%)	231 (41.8%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

Table 3a. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>All participants</b>								
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	899	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	899	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	899	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	155	95.2/13285 = 0.7% (0.2%, 2.8%)	47.6/13285 = 0.4% (0.0%, 2.5%)	0/13285 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0/13285 = 0.0% (0.0%, 0.0%)	0/13285 = 0.0% (0.0%, 0.0%)	0/13285 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0/13285 = 0.0% (0.0%, 0.0%)	0/13285 = 0.0% (0.0%, 0.0%)	0/13285 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	274	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	274	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	274	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	899	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	899	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	899	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	155	102.4/13285 = 0.8% (0.2%, 3.1%)	0/13285 = 0.0% (0.0%, 0.0%)	0/13285 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	155	27.4/13285 = 0.2% (0.0%, 1.5%)	27.4/13285 = 0.2% (0.0%, 1.5%)	0/13285 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	155	220.4/13285 = 1.7% (0.3%, 8.0%)	0/13285 = 0.0% (0.0%, 0.0%)	0/13285 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	274	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	274	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	274	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3b. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Age</b>								
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	436	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	144	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	144	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	144	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	74	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	150	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	150	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	150	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	436	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	144	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	144	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	144	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	74	54.8/10157 = 0.5% (0.1%, 3.9%)	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	74	172.8/10157 = 1.7% (0.2%, 11.6%)	0/10157 = 0.0% (0.0%, 0.0%)	0/10157 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	150	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	150	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	150	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	463	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	463	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	463	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	134	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	81	95.2/3128 = 3.0% (0.7%, 11.7%)	47.6/3128 = 1.5% (0.2%, 10.4%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	124	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	124	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	124	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	463	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	463	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	463	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	134	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	81	47.6/3128 = 1.5% (0.2%, 10.4%)	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	81	27.4/3128 = 0.9% (0.1%, 6.2%)	27.4/3128 = 0.9% (0.1%, 6.2%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	81	47.6/3128 = 1.5% (0.2%, 10.4%)	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age $\geq$ 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	124	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age $\geq$ 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	124	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age $\geq$ 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	124	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3c. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Risk for Severe Covid-19</b>								
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	453	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	453	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	453	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	130	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	130	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	130	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	47.6/3935.8 = 1.2% (0.2%, 8.3%)	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	122	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	122	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	122	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	453	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	453	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	453	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	130	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	130	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	130	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	102.4/3935.8 = 2.6% (0.6%, 10.2%)	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	27.4/3935.8 = 0.7% (0.1%, 4.9%)	27.4/3935.8 = 0.7% (0.1%, 4.9%)	0/3935.8 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	122	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	122	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	122	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	446	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	446	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	446	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	148	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	148	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	148	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	76	47.6/9349.2 = 0.5% (0.1%, 3.6%)	47.6/9349.2 = 0.5% (0.1%, 3.6%)	0/9349.2 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0/9349.2 = 0.0% (0.0%, 0.0%)	0/9349.2 = 0.0% (0.0%, 0.0%)	0/9349.2 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0/9349.2 = 0.0% (0.0%, 0.0%)	0/9349.2 = 0.0% (0.0%, 0.0%)	0/9349.2 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	152	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	152	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	152	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	446	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	446	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	446	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	148	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	148	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	148	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	76	0/9349.2 = 0.0% (0.0%, 0.0%)	0/9349.2 = 0.0% (0.0%, 0.0%)	0/9349.2 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0/9349.2 = 0.0% (0.0%, 0.0%)	0/9349.2 = 0.0% (0.0%, 0.0%)	0/9349.2 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	76	220.4/9349.2 = 2.4% (0.5%, 11.3%)	0/9349.2 = 0.0% (0.0%, 0.0%)	0/9349.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	152	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	152	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	152	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3d. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Age, Risk for Severe Covid-19</b>								
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	214	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	38	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	214	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	38	54.8/2348 = 2.3% (0.3%, 16.0%)	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	222	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	222	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	222	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	222	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	222	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	222	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	172.8/7809 = 2.2% (0.3%, 15.3%)	0/7809 = 0.0% (0.0%, 0.0%)	0/7809 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	239	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	239	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	239	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	58	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	41	47.6/1587.8 = 3.0% (0.4%, 19.6%)	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	47	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	47	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	47	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	239	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	239	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	239	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	58	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	41	47.6/1587.8 = 3.0% (0.4%, 19.6%)	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	41	27.4/1587.8 = 1.7% (0.2%, 12.0%)	27.4/1587.8 = 1.7% (0.2%, 12.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	47	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	47	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	47	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	224	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	224	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	224	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	76	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	47.6/1540.2 = 3.1% (0.4%, 20.2%)	47.6/1540.2 = 3.1% (0.4%, 20.2%)	0/1540.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/1540.2 = 0.0% (0.0%, 0.0%)	0/1540.2 = 0.0% (0.0%, 0.0%)	0/1540.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/1540.2 = 0.0% (0.0%, 0.0%)	0/1540.2 = 0.0% (0.0%, 0.0%)	0/1540.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	77	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	77	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	77	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	224	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	224	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	224	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	76	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	0/1540.2 = 0.0% (0.0%, 0.0%)	0/1540.2 = 0.0% (0.0%, 0.0%)	0/1540.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/1540.2 = 0.0% (0.0%, 0.0%)	0/1540.2 = 0.0% (0.0%, 0.0%)	0/1540.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	47.6/1540.2 = 3.1% (0.4%, 20.2%)	0/1540.2 = 0.0% (0.0%, 0.0%)	0/1540.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	77	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	77	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	77	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3e. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Sex</b>								
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	388	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	388	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	388	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	127	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	127	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	127	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	47.6/5535.6 = 0.9% (0.1%, 6.2%)	0/5535.6 = 0.0% (0.0%, 0.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0/5535.6 = 0.0% (0.0%, 0.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0/5535.6 = 0.0% (0.0%, 0.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	137	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	137	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	137	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	388	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	388	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	388	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	127	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	127	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	127	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	102.4/5535.6 = 1.8% (0.4%, 7.4%)	0/5535.6 = 0.0% (0.0%, 0.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	27.4/5535.6 = 0.5% (0.1%, 3.6%)	27.4/5535.6 = 0.5% (0.1%, 3.6%)	0/5535.6 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	172.8/5535.6 = 3.1% (0.4%, 20.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	137	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	137	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	137	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	511	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	511	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	511	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	151	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	88	47.6/7749.4 = 0.6% (0.1%, 4.4%)	47.6/7749.4 = 0.6% (0.1%, 4.4%)	0/7749.4 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	88	0/7749.4 = 0.0% (0.0%, 0.0%)	0/7749.4 = 0.0% (0.0%, 0.0%)	0/7749.4 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	88	0/7749.4 = 0.0% (0.0%, 0.0%)	0/7749.4 = 0.0% (0.0%, 0.0%)	0/7749.4 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	137	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	137	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	137	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	511	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	511	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	511	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	151	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	88	0/7749.4 = 0.0% (0.0%, 0.0%)	0/7749.4 = 0.0% (0.0%, 0.0%)	0/7749.4 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	88	0/7749.4 = 0.0% (0.0%, 0.0%)	0/7749.4 = 0.0% (0.0%, 0.0%)	0/7749.4 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	88	47.6/7749.4 = 0.6% (0.1%, 4.4%)	0/7749.4 = 0.0% (0.0%, 0.0%)	0/7749.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	137	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	137	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	137	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3f. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Age, sex</b>								
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	254	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	254	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	254	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	79	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	41	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	73	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	73	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	73	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	254	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	254	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	254	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	79	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	41	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	73	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	73	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	73	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	182	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	182	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	182	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	65	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	65	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	65	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	77	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	77	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	77	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	182	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	182	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	182	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	65	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	65	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	65	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	54.8/4240.6 = 1.3% (0.2%, 9.5%)	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	172.8/4240.6 = 4.1% (0.5%, 26.1%)	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	77	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	77	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	77	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	206	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	206	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	206	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	62	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	34	47.6/1295 = 3.7% (0.5%, 23.5%)	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	206	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	206	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	206	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	62	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	34	47.6/1295 = 3.7% (0.5%, 23.5%)	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	34	27.4/1295 = 2.1% (0.3%, 14.7%)	27.4/1295 = 2.1% (0.3%, 14.7%)	0/1295 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	257	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	257	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	257	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	47	47.6/1833 = 2.6% (0.3%, 17.2%)	47.6/1833 = 2.6% (0.3%, 17.2%)	0/1833 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	47	0/1833 = 0.0% (0.0%, 0.0%)	0/1833 = 0.0% (0.0%, 0.0%)	0/1833 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	47	0/1833 = 0.0% (0.0%, 0.0%)	0/1833 = 0.0% (0.0%, 0.0%)	0/1833 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	257	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	257	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	257	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	47	0/1833 = 0.0% (0.0%, 0.0%)	0/1833 = 0.0% (0.0%, 0.0%)	0/1833 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	47	0/1833 = 0.0% (0.0%, 0.0%)	0/1833 = 0.0% (0.0%, 0.0%)	0/1833 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	47	47.6/1833 = 2.6% (0.3%, 17.2%)	0/1833 = 0.0% (0.0%, 0.0%)	0/1833 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3g. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Hispanic or Latino ethnicity</b>								
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	115	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	115	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	115	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	38	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	19	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	28	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	28	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	28	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	115	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	115	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	115	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	38	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	19	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	19	172.8/1211.3 = 14.3% (1.7%, 61.9%)	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	28	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	28	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	28	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	664	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	664	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	664	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	211	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	211	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	211	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	120	95.2/10947.5 = 0.9% (0.2%, 3.4%)	47.6/10947.5 = 0.4% (0.1%, 3.1%)	0/10947.5 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	120	0/10947.5 = 0.0% (0.0%, 0.0%)	0/10947.5 = 0.0% (0.0%, 0.0%)	0/10947.5 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	120	0/10947.5 = 0.0% (0.0%, 0.0%)	0/10947.5 = 0.0% (0.0%, 0.0%)	0/10947.5 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	212	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	212	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	212	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	664	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	664	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	664	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	211	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	211	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	211	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	120	102.4/10947.5 = 0.9% (0.2%, 3.7%)	0/10947.5 = 0.0% (0.0%, 0.0%)	0/10947.5 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	120	0/10947.5 = 0.0% (0.0%, 0.0%)	0/10947.5 = 0.0% (0.0%, 0.0%)	0/10947.5 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	120	47.6/10947.5 = 0.4% (0.1%, 3.1%)	0/10947.5 = 0.0% (0.0%, 0.0%)	0/10947.5 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	212	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	212	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	212	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	120	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	120	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	120	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	29	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	16	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	16	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	16	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	34	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	34	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	34	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	120	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	120	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	120	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	29	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	16	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	16	27.4/1126.2 = 2.4% (0.2%, 20.4%)	27.4/1126.2 = 2.4% (0.2%, 20.4%)	0/1126.2 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	16	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	34	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	34	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	34	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.



Table 3h. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Race</b>								
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	64	95.2/6388.5 = 1.5% (0.4%, 5.9%)	47.6/6388.5 = 0.7% (0.1%, 5.3%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	64	47.6/6388.5 = 0.7% (0.1%, 5.3%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	64	47.6/6388.5 = 0.7% (0.1%, 5.3%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	195	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	58	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	38	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	54	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	54	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	54	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	195	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	58	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	38	54.8/2831.5 = 1.9% (0.3%, 13.4%)	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	38	27.4/2831.5 = 1.0% (0.1%, 7.1%)	27.4/2831.5 = 1.0% (0.1%, 7.1%)	0/2831.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	54	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	54	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	54	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	53	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	53	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	53	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	16	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	15	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	15	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	15	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	53	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	53	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	53	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	16	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	15	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	15	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	15	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	22	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	2	0/82.1 = 0.0%	0/82.1 = 0.0%	0/82.1 = 0.0%
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	2	0/82.1 = 0.0%	0/82.1 = 0.0%	0/82.1 = 0.0%
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	2	0/82.1 = 0.0%	0/82.1 = 0.0%	0/82.1 = 0.0%
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	6	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	6	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	6	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	22	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	2	0/82.1 = 0.0%	0/82.1 = 0.0%	0/82.1 = 0.0%
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	2	0/82.1 = 0.0%	0/82.1 = 0.0%	0/82.1 = 0.0%
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	2	0/82.1 = 0.0%	0/82.1 = 0.0%	0/82.1 = 0.0%
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	6	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	6	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	6	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	15	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	15	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	15	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	5	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	3	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	3	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	3	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	15	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	15	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	15	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	5	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	3	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	3	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	3	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	59	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	16	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	15	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	15	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	15	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	59	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	16	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	15	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	15	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	15	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	21	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	3	0/227.5 = 0.0%	0/227.5 = 0.0%	0/227.5 = 0.0%
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0/227.5 = 0.0%	0/227.5 = 0.0%	0/227.5 = 0.0%
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0/227.5 = 0.0%	0/227.5 = 0.0%	0/227.5 = 0.0%
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	11	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	11	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	11	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	21	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	3	0/227.5 = 0.0%	0/227.5 = 0.0%	0/227.5 = 0.0%
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0/227.5 = 0.0%	0/227.5 = 0.0%	0/227.5 = 0.0%
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	3	172.8/227.5 = 75.9%	0/227.5 = 0.0%	0/227.5 = 0.0%
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	11	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	11	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	11	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	92	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	92	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	92	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	25	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	20	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	20	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	20	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	28	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	28	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	28	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	92	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	92	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	92	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	25	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	20	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	20	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	20	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	28	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	28	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	28	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3i. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Underrepresented minority status</b>								
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	405	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	405	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	405	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	120	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	65	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	65	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	65	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	111	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	111	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	111	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	405	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	405	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	405	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	120	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	65	54.8/4344 = 1.3% (0.2%, 8.8%)	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	65	27.4/4344 = 0.6% (0.1%, 4.5%)	27.4/4344 = 0.6% (0.1%, 4.5%)	0/4344 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	65	172.8/4344 = 4.0% (0.5%, 24.9%)	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	111	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	111	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	111	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	64	95.2/6388.5 = 1.5% (0.4%, 5.9%)	47.6/6388.5 = 0.7% (0.1%, 5.3%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	64	47.6/6388.5 = 0.7% (0.1%, 5.3%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	64	47.6/6388.5 = 0.7% (0.1%, 5.3%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.




Table 3j. Percentage of responders, and participants with concentrations  $\geq 2 \times$  LLOD or  $\geq 4 \times$  LLOD for binding antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
<b>Age, Underrepresented minority status</b>								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	196	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	196	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	196	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	63	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	29	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	196	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	196	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	196	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	63	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	29	54.8/3359 = 1.6% (0.2%, 11.8%)	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	29	172.8/3359 = 5.1% (0.6%, 32.0%)	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	166	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	166	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	166	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	58	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	66	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	66	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	66	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	166	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	166	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	166	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	58	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	66	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	66	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	66	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	209	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	57	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	51	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	51	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	51	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	209	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	57	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	27.4/985 = 2.8% (0.4%, 18.7%)	27.4/985 = 2.8% (0.4%, 18.7%)	0/985 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	51	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	51	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	51	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	171	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	61	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	95.2/1476.3 = 6.5% (1.5%, 23.8%)	47.6/1476.3 = 3.2% (0.4%, 21.4%)	0/1476.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	55	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	55	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	55	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	171	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	61	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	47.6/1476.3 = 3.2% (0.4%, 21.4%)	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	47.6/1476.3 = 3.2% (0.4%, 21.4%)	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	55	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	55	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	55	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>All participants</b>								
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	899	13213.6/13221 = 99.9% (99.6%, 100.0%)	13213.6/13221 = 99.9% (99.6%, 100.0%)	13197.2/13221 = 99.8% (99.5%, 99.9%)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	278	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	155	275.8/13285 = 2.1% (0.3%, 11.7%)	275.8/13285 = 2.1% (0.3%, 11.7%)	27.4/13285 = 0.2% (0.0%, 1.5%)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	274	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)	1356.7/1377 = 98.5% (94.8%, 99.6%)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	899	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)	13221/13221 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	278	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)	1474/1474 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	155	343.7/13285 = 2.6% (0.6%, 10.8%)	343.7/13285 = 2.6% (0.6%, 10.8%)	0/13285 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	274	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)	1377/1377 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Age</b>								
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	436	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	144	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	74	248.4/10157 = 2.4% (0.3%, 16.2%)	248.4/10157 = 2.4% (0.3%, 16.2%)	0/10157 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	150	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)	1078/1096 = 98.4% (93.4%, 99.6%)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	436	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)	10401/10401 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	144	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)	1185/1185 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	74	248.4/10157 = 2.4% (0.3%, 16.2%)	248.4/10157 = 2.4% (0.3%, 16.2%)	0/10157 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	150	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)	1096/1096 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	463	2812.6/2820 = 99.7% (98.1%, 100.0%)	2812.6/2820 = 99.7% (98.1%, 100.0%)	2796.2/2820 = 99.2% (97.7%, 99.7%)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	134	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	81	27.4/3128 = 0.9% (0.1%, 6.2%)	27.4/3128 = 0.9% (0.1%, 6.2%)	27.4/3128 = 0.9% (0.1%, 6.2%)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	124	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	278.7/281 = 99.2% (94.2%, 99.9%)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	463	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)	2820/2820 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	134	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	81	95.2/3128 = 3.0% (0.7%, 11.7%)	95.2/3128 = 3.0% (0.7%, 11.7%)	0/3128 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	124	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Risk for Severe Covid-19</b>								
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	453	3659.2/3666.6 = 99.8% (98.6%, 100.0%)	3659.2/3666.6 = 99.8% (98.6%, 100.0%)	3642.9/3666.6 = 99.4% (98.2%, 99.8%)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	130	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)	0/3935.8 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	122	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)	313.8/321.7 = 97.5% (92.4%, 99.2%)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	453	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)	3666.6/3666.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	130	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)	351.4/351.4 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	47.6/3935.8 = 1.2% (0.2%, 8.3%)	47.6/3935.8 = 1.2% (0.2%, 8.3%)	0/3935.8 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	122	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)	321.7/321.7 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	446	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	148	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	76	275.8/9349.2 = 2.9% (0.5%, 16.4%)	275.8/9349.2 = 2.9% (0.5%, 16.4%)	27.4/9349.2 = 0.3% (0.0%, 2.1%)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	152	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1042.9/1055.3 = 98.8% (92.0%, 99.8%)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	446	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)	9554.4/9554.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	148	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)	1122.6/1122.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	76	296.1/9349.2 = 3.2% (0.6%, 15.9%)	296.1/9349.2 = 3.2% (0.6%, 15.9%)	0/9349.2 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	152	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)	1055.3/1055.3 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Age, Risk for Severe Covid-19</b>								
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	214	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	38	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)	209.4/215 = 97.4% (89.7%, 99.4%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	214	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)	2232/2232 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)	226/226 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	38	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)	0/2348 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)	215/215 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	222	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	248.4/7809 = 3.2% (0.4%, 21.1%)	248.4/7809 = 3.2% (0.4%, 21.1%)	0/7809 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)	868.6/881 = 98.6% (90.3%, 99.8%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	222	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)	8169/8169 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)	959/959 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	248.4/7809 = 3.2% (0.4%, 21.1%)	248.4/7809 = 3.2% (0.4%, 21.1%)	0/7809 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)	881/881 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	239	1427.2/1434.6 = 99.5% (96.4%, 99.9%)	1427.2/1434.6 = 99.5% (96.4%, 99.9%)	1410.9/1434.6 = 98.3% (95.5%, 99.4%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	58	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	41	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)	0/1587.8 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	47	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)	104.4/106.7 = 97.8% (85.3%, 99.7%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	239	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)	1434.6/1434.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	58	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)	125.4/125.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	41	47.6/1587.8 = 3.0% (0.4%, 19.6%)	47.6/1587.8 = 3.0% (0.4%, 19.6%)	0/1587.8 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	47	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)	106.7/106.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	224	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	76	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	27.4/1540.2 = 1.8% (0.2%, 12.4%)	27.4/1540.2 = 1.8% (0.2%, 12.4%)	27.4/1540.2 = 1.8% (0.2%, 12.4%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	77	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	224	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)	1385.4/1385.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	76	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)	163.6/163.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	47.6/1540.2 = 3.1% (0.4%, 20.2%)	47.6/1540.2 = 3.1% (0.4%, 20.2%)	0/1540.2 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	77	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)	174.3/174.3 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Sex</b>								
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	388	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	127	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	0/5535.6 = 0.0% (0.0%, 0.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)	0/5535.6 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	137	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	388	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)	5806.1/5806.1 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	127	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)	667.1/667.1 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	296.1/5535.6 = 5.3% (1.0%, 24.7%)	296.1/5535.6 = 5.3% (1.0%, 24.7%)	0/5535.6 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	137	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)	705.2/705.2 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	511	7407.5/7414.9 = 99.9% (99.3%, 100.0%)	7407.5/7414.9 = 99.9% (99.3%, 100.0%)	7391.1/7414.9 = 99.7% (99.1%, 99.9%)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	151	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	88	275.8/7749.4 = 3.6% (0.6%, 19.1%)	275.8/7749.4 = 3.6% (0.6%, 19.1%)	27.4/7749.4 = 0.4% (0.0%, 2.6%)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	137	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)	651.5/671.8 = 97.0% (89.6%, 99.2%)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	511	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)	7414.9/7414.9 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	151	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)	806.9/806.9 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	88	47.6/7749.4 = 0.6% (0.1%, 4.4%)	47.6/7749.4 = 0.6% (0.1%, 4.4%)	0/7749.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	137	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)	671.8/671.8 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Age, sex</b>								
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	254	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	79	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	41	248.4/5916.4 = 4.2% (0.5%, 26.3%)	248.4/5916.4 = 4.2% (0.5%, 26.3%)	0/5916.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	73	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)	508.8/526.7 = 96.6% (86.6%, 99.2%)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	254	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)	5849.6/5849.6 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	79	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)	651.8/651.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	41	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)	0/5916.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	73	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)	526.7/526.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	182	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	65	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)	0/4240.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	77	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	182	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)	4551.4/4551.4 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	65	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)	533.2/533.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	248.4/4240.6 = 5.9% (0.7%, 33.9%)	248.4/4240.6 = 5.9% (0.7%, 33.9%)	0/4240.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	77	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)	569.3/569.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	206	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	62	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	34	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)	0/1295 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	206	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)	1254.7/1254.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	62	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)	133.9/133.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	34	47.6/1295 = 3.7% (0.5%, 23.5%)	47.6/1295 = 3.7% (0.5%, 23.5%)	0/1295 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)	135.9/135.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	257	1557.9/1565.3 = 99.5% (96.7%, 99.9%)	1557.9/1565.3 = 99.5% (96.7%, 99.9%)	1541.6/1565.3 = 98.5% (95.9%, 99.4%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	47	27.4/1833 = 1.5% (0.2%, 10.4%)	27.4/1833 = 1.5% (0.2%, 10.4%)	27.4/1833 = 1.5% (0.2%, 10.4%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)	142.8/145.1 = 98.4% (89.1%, 99.8%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	257	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)	1565.3/1565.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)	155.1/155.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	47	47.6/1833 = 2.6% (0.3%, 17.2%)	47.6/1833 = 2.6% (0.3%, 17.2%)	0/1833 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)	145.1/145.1 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Hispanic or Latino ethnicity</b>								
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	115	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	38	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	19	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	28	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	115	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)	1183.5/1183.5 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	38	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)	163.2/163.2 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	19	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)	0/1211.3 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	28	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)	96.6/96.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	664	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10195.4/10211.7 = 99.8% (99.5%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	211	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	120	275.8/10947.5 = 2.5% (0.4%, 14.0%)	275.8/10947.5 = 2.5% (0.4%, 14.0%)	27.4/10947.5 = 0.2% (0.0%, 1.8%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	212	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1026.9/1047.2 = 98.1% (93.2%, 99.5%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	664	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)	10211.7/10211.7 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	211	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)	1137.4/1137.4 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	120	343.7/10947.5 = 3.1% (0.7%, 13.0%)	343.7/10947.5 = 3.1% (0.7%, 13.0%)	0/10947.5 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	212	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)	1047.2/1047.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	120	1818.4/1825.8 = 99.6% (97.1%, 99.9%)	1818.4/1825.8 = 99.6% (97.1%, 99.9%)	1818.4/1825.8 = 99.6% (97.1%, 99.9%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	29	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	16	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	34	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	120	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)	1825.8/1825.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	29	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)	173.4/173.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	16	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)	0/1126.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	34	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)	233.2/233.2 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Race</b>								
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5902.3/5909.8 = 99.9% (99.1%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	64	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	601.5/616.1 = 97.6% (87.9%, 99.6%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	64	343.7/6388.5 = 5.4% (1.2%, 21.4%)	343.7/6388.5 = 5.4% (1.2%, 21.4%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	195	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2264.8/2269.2 = 99.8% (98.6%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	58	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	38	27.4/2831.5 = 1.0% (0.1%, 7.1%)	27.4/2831.5 = 1.0% (0.1%, 7.1%)	27.4/2831.5 = 1.0% (0.1%, 7.1%)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	54	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	195	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)	2269.2/2269.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	58	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)	212.2/212.2 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	38	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)	0/2831.5 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	54	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)	298.7/298.7 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	53	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)	563.5/568 = 99.2% (94.3%, 99.9%)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	16	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	15	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)	48.4/50.7 = 95.4% (67.1%, 99.5%)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	53	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)	568/568 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	16	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)	69.5/69.5 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	15	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)	50.7/50.7 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	22	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	2	0/82.1 = 0.0%	0/82.1 = 0.0%	0/82.1 = 0.0%
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	6	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	22	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)	240.5/240.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)	26.3/26.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	2	0/82.1 = 0.0%	0/82.1 = 0.0%	0/82.1 = 0.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	6	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)	30.5/30.5 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	15	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	5	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	3	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	15	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)	121/121 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	5	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)	6.5/6.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	59	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	16	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	15	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	59	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)	567.8/567.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	16	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)	76/76 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	8	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)	0/446.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	15	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)	42.5/42.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	21	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	3	0/227.5 = 0.0%	0/227.5 = 0.0%	0/227.5 = 0.0%
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	11	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	21	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)	189.4/189.4 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)	27/27 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	3	0/227.5 = 0.0%	0/227.5 = 0.0%	0/227.5 = 0.0%
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	11	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)	41.7/41.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	92	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	25	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	20	248.4/1826.7 = 13.6% (1.6%, 59.9%)	248.4/1826.7 = 13.6% (1.6%, 59.9%)	0/1826.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	28	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)	167.8/171.1 = 98.1% (86.2%, 99.8%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	92	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)	1641.1/1641.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	25	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)	170.9/170.9 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	20	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)	0/1826.7 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	28	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)	171.1/171.1 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Underrepresented minority status</b>								
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	405	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)	4446.1/4455 = 99.8% (99.2%, 99.9%)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	120	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	65	27.4/4344 = 0.6% (0.1%, 4.5%)	27.4/4344 = 0.6% (0.1%, 4.5%)	27.4/4344 = 0.6% (0.1%, 4.5%)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	111	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)	483.7/486 = 99.5% (96.6%, 99.9%)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	405	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)	4455/4455 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	120	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)	490/490 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	65	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)	0/4344 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	111	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)	486/486 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5902.3/5909.8 = 99.9% (99.1%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	64	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)	0/6388.5 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	601.5/616.1 = 97.6% (87.9%, 99.6%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	337	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)	5909.8/5909.8 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	119	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)	715.6/715.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	64	343.7/6388.5 = 5.4% (1.2%, 21.4%)	343.7/6388.5 = 5.4% (1.2%, 21.4%)	0/6388.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	121	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)	616.1/616.1 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
<b>Age, Underrepresented minority status</b>								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	196	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	63	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	29	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	372.7/375 = 99.4% (95.5%, 99.9%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	196	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)	3521/3521 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	63	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)	383/383 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	29	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)	0/3359 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)	375/375 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	166	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	58	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)	0/4912.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	66	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)	475.7/488.1 = 97.5% (83.4%, 99.7%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	166	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)	4640.1/4640.1 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	58	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)	571.4/571.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	248.4/4912.2 = 5.1% (0.6%, 30.9%)	248.4/4912.2 = 5.1% (0.6%, 30.9%)	0/4912.2 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	66	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)	488.1/488.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	209	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)	925.1/934 = 99.0% (96.2%, 99.8%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	57	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	27.4/985 = 2.8% (0.4%, 18.7%)	27.4/985 = 2.8% (0.4%, 18.7%)	27.4/985 = 2.8% (0.4%, 18.7%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	51	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	209	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)	934/934 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	57	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)	107/107 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)	0/985 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	51	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)	111/111 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	171	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1262.3/1269.7 = 99.4% (95.9%, 99.9%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	61	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)	0/1476.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	55	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	125.8/128.1 = 98.2% (87.6%, 99.8%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	171	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)	1269.7/1269.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	61	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)	144.2/144.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	95.2/1476.3 = 6.5% (1.5%, 23.8%)	95.2/1476.3 = 6.5% (1.5%, 23.8%)	0/1476.3 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	55	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)	128.1/128.1 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>All participants</b>						
	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	899	0.02 (0.02, 0.02)
	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	899	0.27 (0.27, 0.27)
	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	899	0.09 (0.09, 0.09)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	899	5.00 (5.00, 5.00)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	899	5.00 (5.00, 5.00)
	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	278	0.02 (0.02, 0.02)
	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	278	0.27 (0.27, 0.27)
	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	278	0.09 (0.09, 0.09)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	278	5.00 (5.00, 5.00)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	278	5.00 (5.00, 5.00)
	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.03)
	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)
	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	155	5.20 (4.93, 5.48)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	155	5.32 (5.02, 5.63)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	274	0.02 (0.02, 0.02)
	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	274	0.27 (0.27, 0.28)
	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	274	0.09 (0.09, 0.09)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	274	5.00 (5.00, 5.00)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	274	5.00 (5.00, 5.00)
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	899	54.02 (45.95, 63.51)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	899	654.16 (574.81, 744.45)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	899	388.03 (347.63, 433.11)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	899	214.11 (198.95, 230.43)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	899	43.74 (40.91, 46.77)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	278	114.10 (86.34, 150.78)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	278	990.44 (772.01, 1270.66)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	278	662.31 (530.09, 827.52)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	278	380.36 (335.84, 430.79)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	278	76.35 (68.07, 85.64)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	155	5.14 (4.95, 5.33)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	155	5.20 (5.00, 5.40)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	274	22.94 (17.73, 29.69)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	274	298.16 (234.40, 379.27)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	274	155.95 (128.82, 188.81)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	274	96.18 (85.05, 108.77)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	274	24.82 (22.14, 27.81)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	899	878.77 (729.29, 1058.88)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	899	28797.32 (24648.34, 33644.68)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	899	19192.06 (16926.15, 21761.30)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	899	3868.22 (3766.31, 3972.89)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	899	969.06 (931.18, 1008.48)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	278	2526.16 (1771.45, 3602.41)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	278	89153.56 (71592.48, 111022.25)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	278	51099.69 (41691.19, 62631.42)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	278	4368.98 (4315.56, 4423.07)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	278	1280.94 (1268.63, 1293.36)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	155	5.22 (4.98, 5.47)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	155	5.02 (4.98, 5.05)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	274	322.49 (234.41, 443.66)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	274	11598.60 (8863.79, 15177.20)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	274	5752.35 (4635.25, 7138.66)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	274	2892.88 (2662.61, 3143.08)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	274	697.93 (640.72, 760.25)

Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Age</b>						
Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	436	0.02 (0.02, 0.02)
Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	0.27 (0.27, 0.27)
Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	0.09 (0.09, 0.09)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	436	5.00 (5.00, 5.00)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	436	5.00 (5.00, 5.00)
Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	144	0.02 (0.02, 0.02)
Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	144	0.27 (0.27, 0.27)
Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	144	0.09 (0.09, 0.09)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	144	5.00 (5.00, 5.00)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	144	5.00 (5.00, 5.00)
Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.03)
Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)
Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	74	5.20 (4.86, 5.56)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	74	5.42 (5.02, 5.84)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	150	0.02 (0.02, 0.02)
Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	150	0.27 (0.27, 0.28)
Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	150	0.09 (0.09, 0.09)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	150	5.00 (5.00, 5.00)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	150	5.00 (5.00, 5.00)
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	436	42.12 (34.51, 51.42)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	506.41 (432.08, 593.53)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	297.42 (260.00, 340.24)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	436	195.28 (178.46, 213.69)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	436	40.83 (37.60, 44.34)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	144	97.74 (69.73, 137.01)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	144	751.13 (555.65, 1015.38)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	144	506.46 (386.68, 663.35)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	144	352.52 (303.27, 409.77)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	144	73.22 (63.73, 84.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	74	5.11 (4.89, 5.35)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	74	5.20 (4.95, 5.46)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	150	17.67 (12.92, 24.18)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	150	230.33 (171.67, 309.04)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	150	117.76 (93.32, 148.59)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	150	85.93 (73.97, 99.82)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	150	22.72 (19.77, 26.10)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	436	679.74 (540.11, 855.46)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	21981.52 (18138.77, 26638.36)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	14740.85 (12625.30, 17210.89)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	436	3890.10 (3768.66, 4015.46)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	436	950.73 (905.07, 998.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	144	2030.31 (1316.69, 3130.69)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	144	73759.13 (56470.30, 96341.06)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	144	43080.81 (33568.40, 55288.80)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	144	4363.56 (4297.51, 4430.63)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	144	1281.61 (1267.10, 1296.29)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	74	5.25 (4.95, 5.58)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	74	5.00 (5.00, 5.00)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	150	226.08 (153.33, 333.35)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	150	8551.22 (6162.12, 11866.59)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	150	4036.58 (3112.40, 5235.19)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	150	2715.40 (2449.49, 3010.18)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	150	660.57 (594.65, 733.78)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	463	0.02 (0.02, 0.02)
Age $\geq$ 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	463	0.27 (0.27, 0.27)
Age $\geq$ 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	463	0.09 (0.09, 0.09)
Age $\geq$ 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	463	5.00 (5.00, 5.00)
Age $\geq$ 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	463	5.00 (5.00, 5.00)
Age $\geq$ 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	134	0.02 (0.02, 0.02)
Age $\geq$ 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	0.27 (0.27, 0.27)
Age $\geq$ 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	0.09 (0.09, 0.09)
Age $\geq$ 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	134	5.00 (5.00, 5.00)
Age $\geq$ 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	134	5.00 (5.00, 5.00)
Age $\geq$ 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.02)
Age $\geq$ 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.27 (0.27, 0.28)
Age $\geq$ 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)
Age $\geq$ 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	81	5.18 (4.94, 5.44)
Age $\geq$ 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	81	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	124	0.02 (0.02, 0.02)
Age ≥ 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	124	0.27 (0.27, 0.27)
Age ≥ 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	124	0.09 (0.09, 0.09)
Age ≥ 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	124	5.00 (5.00, 5.00)
Age ≥ 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	124	5.00 (5.00, 5.00)
Age ≥ 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	463	135.22 (112.92, 161.93)
Age ≥ 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	463	1681.67 (1444.09, 1958.34)
Age ≥ 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	463	1034.69 (905.25, 1182.64)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	463	300.67 (274.90, 328.85)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	463	56.40 (52.20, 60.94)
Age ≥ 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	134	215.14 (157.35, 294.15)
Age ≥ 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	3078.35 (2381.76, 3978.65)
Age ≥ 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	1989.81 (1606.86, 2464.03)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	134	519.49 (449.75, 600.04)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	134	90.63 (79.17, 103.75)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.03)
Age $\geq$ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.27 (0.27, 0.27)
Age $\geq$ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)
Age $\geq$ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	81	5.21 (4.90, 5.55)
Age $\geq$ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	81	5.19 (4.97, 5.42)
Age $\geq$ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	124	63.53 (47.73, 84.55)
Age $\geq$ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	124	816.01 (640.86, 1039.03)
Age $\geq$ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	124	466.50 (387.65, 561.39)
Age $\geq$ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	124	149.29 (130.52, 170.77)
Age $\geq$ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	124	35.02 (30.81, 39.81)
Age $\geq$ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	463	2265.90 (1840.03, 2790.34)
Age $\geq$ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	463	77977.39 (65963.24, 92179.73)
Age $\geq$ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	463	50792.16 (44281.28, 58260.36)
Age $\geq$ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	463	3788.56 (3623.56, 3961.06)
Age $\geq$ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	463	1039.78 (994.45, 1087.18)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	134	6188.40 (4440.93, 8623.49)
Age $\geq$ 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	193950.66 (157822.35, 238349.39)
Age $\geq$ 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	102895.16 (88557.76, 119553.76)
Age $\geq$ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	134	4391.29 (4368.90, 4413.79)
Age $\geq$ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	134	1278.15 (1258.33, 1298.29)
Age $\geq$ 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.03)
Age $\geq$ 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.27 (0.27, 0.28)
Age $\geq$ 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)
Age $\geq$ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	81	5.12 (4.95, 5.30)
Age $\geq$ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	81	5.08 (4.93, 5.23)
Age $\geq$ 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	124	1288.66 (915.52, 1813.87)
Age $\geq$ 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	124	38082.49 (28751.10, 50442.46)
Age $\geq$ 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	124	22900.37 (17987.61, 29154.91)
Age $\geq$ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	124	3703.20 (3519.25, 3896.77)
Age $\geq$ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	124	865.00 (796.62, 939.26)

Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Risk for Severe Covid-19</b>						
At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	453	0.02 (0.02, 0.02)
At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	453	0.27 (0.27, 0.27)
At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	453	0.09 (0.09, 0.09)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	453	5.00 (5.00, 5.00)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	453	5.00 (5.00, 5.00)
At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	130	0.02 (0.02, 0.02)
At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	130	0.27 (0.27, 0.28)
At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	130	0.09 (0.09, 0.09)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	130	5.00 (5.00, 5.00)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	130	5.00 (5.00, 5.00)
At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)
At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.28)
At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	79	5.19 (4.96, 5.44)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)
At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	122	0.28 (0.27, 0.29)
At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	122	5.00 (5.00, 5.00)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	453	59.16 (48.92, 71.53)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	453	706.64 (593.89, 840.81)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	453	427.84 (370.56, 493.98)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	453	208.58 (189.63, 229.42)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	453	42.83 (39.33, 46.64)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	130	115.77 (83.76, 160.00)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	130	1156.08 (879.41, 1519.79)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	130	727.15 (585.27, 903.44)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	130	377.53 (325.30, 438.14)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	130	77.79 (67.85, 89.18)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	5.12 (4.89, 5.36)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	79	5.18 (4.98, 5.38)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	122	21.13 (15.29, 29.20)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	122	257.09 (197.28, 335.03)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	122	160.84 (127.18, 203.40)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	122	89.95 (77.53, 104.37)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	122	23.87 (20.36, 27.98)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	453	906.59 (720.34, 1141.00)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	453	28328.44 (23519.92, 34120.02)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	453	19610.61 (16434.08, 23401.12)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	453	3523.35 (3346.50, 3709.55)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	453	926.51 (882.15, 973.09)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	130	2526.99 (1768.29, 3611.23)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	130	91621.85 (70437.56, 119177.38)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	130	54061.61 (43165.62, 67707.99)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	130	4393.54 (4375.15, 4412.02)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	130	1271.70 (1248.53, 1295.30)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.03)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.28)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	5.13 (4.95, 5.32)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	79	5.06 (4.94, 5.18)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	122	307.20 (207.85, 454.04)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	122	10327.84 (7549.43, 14128.78)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	122	6014.07 (4448.47, 8130.66)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	122	2718.16 (2455.97, 3008.34)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	122	682.53 (615.52, 756.84)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	446	0.02 (0.02, 0.02)
Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	446	0.27 (0.27, 0.27)
Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	446	0.09 (0.09, 0.09)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	446	5.00 (5.00, 5.00)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	446	5.00 (5.00, 5.00)
Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	148	0.02 (0.02, 0.02)
Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	148	0.27 (0.27, 0.27)
Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	148	0.09 (0.09, 0.09)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	148	5.00 (5.00, 5.00)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	148	5.00 (5.00, 5.00)
Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.03)
Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)
Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	76	5.20 (4.84, 5.59)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	76	5.45 (5.02, 5.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	152	0.02 (0.02, 0.02)
Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	152	0.27 (0.27, 0.27)
Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	152	0.09 (0.09, 0.09)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	152	5.00 (5.00, 5.00)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	152	5.00 (5.00, 5.00)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	446	52.17 (42.20, 64.51)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	446	635.07 (537.48, 750.37)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	446	373.75 (324.02, 431.11)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	446	216.27 (196.67, 237.84)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	446	44.10 (40.44, 48.10)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	148	113.58 (79.89, 161.47)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	148	943.63 (687.58, 1295.04)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	148	643.23 (483.57, 855.60)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	148	381.26 (325.94, 445.96)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	148	75.91 (65.68, 87.72)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	76	5.15 (4.90, 5.41)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	76	5.21 (4.94, 5.49)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	152	23.53 (17.04, 32.48)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	152	311.94 (230.08, 422.94)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	152	154.49 (121.47, 196.50)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	152	98.16 (84.13, 114.55)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	152	25.11 (21.81, 28.91)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	446	868.32 (681.00, 1107.17)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	446	28979.32 (23635.90, 35530.74)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	446	19033.81 (16203.87, 22358.00)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	446	4009.36 (3886.63, 4135.95)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	446	985.90 (936.10, 1038.36)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	148	2525.90 (1606.20, 3972.20)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	148	88394.64 (67041.37, 116549.11)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	148	50206.27 (38782.90, 64994.34)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	148	4361.32 (4291.66, 4432.12)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	148	1283.84 (1269.43, 1298.41)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	76	5.26 (4.93, 5.61)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	152	327.29 (219.32, 488.42)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	152	12016.26 (8561.45, 16865.18)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	152	5674.85 (4338.98, 7422.01)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	152	2948.35 (2657.33, 3271.25)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	152	702.69 (631.26, 782.22)

Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Age, Risk for Severe Covid-19</b>						
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	214	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	214	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	214	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.28 (0.27, 0.28)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.03)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	38	5.12 (4.89, 5.37)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.28 (0.27, 0.29)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	214	36.39 (28.23, 46.91)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	437.81 (344.38, 556.57)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	264.47 (219.21, 319.06)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	214	173.73 (153.25, 196.96)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	214	37.60 (33.49, 42.22)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	99.72 (64.74, 153.58)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	777.66 (541.96, 1115.87)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	468.31 (357.12, 614.13)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	340.95 (281.03, 413.65)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	72	71.82 (60.57, 85.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	38	5.09 (4.92, 5.26)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	12.24 (8.33, 17.97)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	149.77 (110.72, 202.59)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	86.71 (66.41, 113.22)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	69.41 (58.60, 82.21)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	75	19.25 (15.84, 23.39)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	214	560.63 (409.64, 767.29)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	17472.27 (13596.10, 22453.51)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	12580.73 (9832.00, 16097.92)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	214	3575.02 (3338.57, 3828.21)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	214	914.61 (858.56, 974.31)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	1902.80 (1205.14, 3004.33)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	67610.00 (47829.52, 95570.95)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	39349.13 (29030.17, 53336.03)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	4404.00 (4404.00, 4404.00)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	72	1275.97 (1248.80, 1303.74)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.03)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	38	5.13 (4.88, 5.39)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	142.10 (91.48, 220.73)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	4948.71 (3495.42, 7006.23)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	2931.01 (2088.69, 4113.03)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	2273.93 (1978.20, 2613.86)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	75	611.05 (532.94, 700.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	222	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	222	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	222	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	222	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	222	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.03)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.23 (4.79, 5.70)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.55 (5.03, 6.12)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	222	43.84 (34.34, 55.98)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	222	526.96 (435.27, 637.96)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	222	307.12 (260.83, 361.62)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	222	201.62 (180.72, 224.94)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	222	41.76 (37.79, 46.15)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	97.28 (64.91, 145.81)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	745.01 (518.42, 1070.66)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	515.90 (371.91, 715.64)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	355.30 (296.69, 425.49)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	72	73.56 (62.25, 86.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	5.15 (4.86, 5.46)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	36	5.23 (4.91, 5.58)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	19.33 (13.24, 28.22)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	255.84 (178.88, 365.91)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	126.89 (95.74, 168.17)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	90.52 (75.49, 108.56)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	75	23.66 (20.04, 27.93)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	222	716.48 (541.55, 947.90)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	222	23404.58 (18505.98, 29599.85)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	222	15393.07 (12788.38, 18528.27)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	222	3980.92 (3841.01, 4125.93)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	222	960.84 (904.68, 1020.49)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	2061.58 (1220.54, 3482.17)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	75287.86 (54682.18, 103658.30)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	44010.56 (32609.52, 59397.66)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	4354.09 (4272.80, 4436.92)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	72	1282.95 (1266.22, 1299.90)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.10)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	5.29 (4.90, 5.71)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	253.21 (158.15, 405.39)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	9772.30 (6562.44, 14552.17)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	4364.50 (3193.16, 5965.53)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	2835.57 (2506.26, 3208.15)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	75	673.25 (593.30, 763.96)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	239	0.02 (0.02, 0.02)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	239	0.27 (0.27, 0.27)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	239	0.09 (0.09, 0.09)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	239	5.00 (5.00, 5.00)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	239	5.00 (5.00, 5.00)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)
Age $\geq$ 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.28 (0.27, 0.29)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	41	5.30 (4.84, 5.81)
Age $\geq$ 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)
Age $\geq$ 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	239	126.00 (96.14, 165.12)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	239	1488.25 (1185.88, 1867.71)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	239	904.30 (734.70, 1113.04)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	239	277.19 (240.49, 319.49)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	239	52.45 (46.52, 59.13)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	58	151.49 (95.56, 240.15)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	2362.04 (1646.89, 3387.74)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	1606.84 (1190.41, 2168.95)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	58	453.62 (362.16, 568.16)
Age $\geq$ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	58	89.81 (71.63, 112.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.03)
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	41	5.30 (4.74, 5.93)
Age $\geq$ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	41	5.31 (4.90, 5.77)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	47	63.50 (38.43, 104.92)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	47	763.61 (506.19, 1151.95)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	47	558.42 (417.87, 746.23)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	47	151.67 (118.19, 194.63)
Age $\geq$ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	47	36.80 (28.80, 47.03)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	239	1914.94 (1394.03, 2630.48)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	239	60081.37 (46341.27, 77895.40)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	239	39122.16 (31191.96, 49068.51)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	239	3444.45 (3188.14, 3721.38)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	239	945.34 (874.68, 1021.70)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	58	4213.38 (2421.25, 7331.98)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	158431.51 (109869.90, 228456.95)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	95825.62 (72784.81, 126160.25)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	58	4374.76 (4323.89, 4426.24)
Age $\geq$ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	58	1264.03 (1221.93, 1307.59)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.03)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.28 (0.27, 0.28)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	41	5.13 (4.88, 5.41)
Age $\geq$ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	41	5.15 (4.86, 5.47)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	47	1452.28 (771.39, 2734.19)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	47	45474.93 (28432.89, 72731.60)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	47	25591.02 (16600.20, 39451.37)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	47	3894.22 (3653.98, 4150.25)
Age $\geq$ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	47	852.95 (748.49, 971.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	224	0.02 (0.02, 0.02)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	224	0.27 (0.27, 0.27)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	224	0.09 (0.09, 0.09)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	224	5.00 (5.00, 5.00)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	224	5.00 (5.00, 5.00)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5.00 (5.00, 5.00)
Age $\geq$ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.03)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	40	5.06 (4.94, 5.19)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)
Age $\geq$ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	224	145.49 (114.83, 184.34)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	224	1908.52 (1561.57, 2332.56)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	224	1189.57 (1009.03, 1402.40)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	224	327.08 (293.94, 363.95)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	224	60.81 (55.26, 66.92)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	76	281.53 (186.82, 424.24)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	3771.45 (2654.40, 5358.61)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	2344.17 (1749.97, 3140.14)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	76	576.39 (480.42, 691.54)
Age $\geq$ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	76	91.26 (77.48, 107.50)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	0.03 (0.02, 0.03)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	5.13 (4.88, 5.39)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	40	5.06 (4.94, 5.19)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	77	63.54 (45.04, 89.64)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	77	849.85 (631.19, 1144.26)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	77	417.85 (329.69, 529.60)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	77	147.86 (126.79, 172.43)
Age $\geq$ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	77	33.98 (29.49, 39.14)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	224	2697.29 (2068.92, 3516.52)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	224	102147.24 (83423.06, 125074.05)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	224	66558.70 (57689.44, 76791.54)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	224	4181.18 (4025.45, 4342.93)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	224	1147.54 (1104.96, 1191.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	76	8309.47 (5616.48, 12293.69)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	226487.29 (180806.57, 283709.21)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	108666.46 (92603.25, 127516.04)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	76	4404.00 (4404.00, 4404.00)
Age $\geq$ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	76	1289.09 (1277.63, 1300.64)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.10)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	5.11 (4.90, 5.34)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	77	1197.71 (810.06, 1770.88)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	77	34162.73 (24106.42, 48414.17)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	77	21394.59 (16094.94, 28439.27)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	77	3590.91 (3343.07, 3857.11)
Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	77	872.47 (784.15, 970.73)

Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Sex</b>						
Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	388	0.02 (0.02, 0.02)
Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	388	0.27 (0.27, 0.27)
Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	388	0.09 (0.09, 0.09)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	388	5.00 (5.00, 5.00)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	388	5.00 (5.00, 5.00)
Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)
Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.28)
Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	127	5.00 (5.00, 5.00)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	127	5.00 (5.00, 5.00)
Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	67	0.02 (0.02, 0.02)
Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0.27 (0.27, 0.28)
Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0.09 (0.09, 0.09)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	67	5.15 (4.98, 5.33)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	67	5.40 (4.87, 5.98)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	137	0.02 (0.02, 0.02)
Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	137	0.27 (0.27, 0.28)
Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	137	0.09 (0.09, 0.09)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	137	5.00 (5.00, 5.00)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	137	5.00 (5.00, 5.00)
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	388	57.82 (45.60, 73.33)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	388	681.55 (555.77, 835.80)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	388	420.65 (359.92, 491.63)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	388	217.28 (194.80, 242.36)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	388	47.25 (42.60, 52.41)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	127	103.53 (70.69, 151.62)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	127	936.15 (684.43, 1280.45)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	127	673.42 (504.28, 899.30)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	127	382.63 (318.90, 459.09)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	127	74.57 (62.54, 88.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	67	0.02 (0.02, 0.02)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0.27 (0.27, 0.27)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0.09 (0.09, 0.09)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	67	5.08 (4.92, 5.25)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	67	5.47 (5.00, 5.98)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	137	23.85 (17.23, 33.02)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	137	332.38 (240.94, 458.51)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	137	166.44 (126.58, 218.86)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	137	99.48 (85.42, 115.85)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	137	26.51 (23.14, 30.38)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	388	964.29 (726.31, 1280.25)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	388	29949.43 (23839.38, 37625.49)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	388	21361.84 (17840.87, 25577.69)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	388	3855.51 (3697.30, 4020.48)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	388	977.55 (919.07, 1039.74)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	127	2220.59 (1292.35, 3815.54)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	127	88480.82 (65501.35, 119522.04)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	127	58390.04 (43171.97, 78972.47)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	127	4399.17 (4390.79, 4407.57)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	127	1283.96 (1264.40, 1303.82)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	67	0.02 (0.02, 0.02)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0.27 (0.27, 0.28)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0.09 (0.09, 0.10)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	67	5.31 (4.87, 5.79)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	67	5.04 (4.96, 5.13)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	137	391.29 (254.31, 602.07)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	137	12275.65 (8418.55, 17899.95)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	137	6758.41 (5128.32, 8906.64)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	137	2696.77 (2381.21, 3054.15)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	137	703.13 (622.65, 794.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	511	0.02 (0.02, 0.02)
Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	511	0.27 (0.27, 0.27)
Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	511	0.09 (0.09, 0.09)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	511	5.00 (5.00, 5.00)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	511	5.00 (5.00, 5.00)
Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	151	0.02 (0.02, 0.02)
Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	0.27 (0.27, 0.27)
Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	0.09 (0.09, 0.09)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	151	5.00 (5.00, 5.00)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	151	5.00 (5.00, 5.00)
Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	88	0.02 (0.02, 0.03)
Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	88	0.27 (0.27, 0.27)
Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	88	0.09 (0.09, 0.09)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	88	5.23 (4.79, 5.70)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	88	5.26 (4.92, 5.63)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	137	0.02 (0.02, 0.02)
Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	137	0.27 (0.27, 0.27)
Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	137	0.09 (0.09, 0.09)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	137	5.00 (5.00, 5.00)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	137	5.00 (5.00, 5.00)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	511	51.22 (41.00, 63.99)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	511	633.48 (534.99, 750.10)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	511	364.25 (311.46, 426.00)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	511	211.66 (191.57, 233.87)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	511	41.18 (37.76, 44.92)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	151	123.64 (82.97, 184.24)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	1037.69 (709.82, 1517.01)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	653.26 (466.86, 914.08)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	151	378.50 (318.95, 449.17)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	151	77.85 (67.00, 90.46)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	88	0.02 (0.02, 0.02)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	88	0.27 (0.27, 0.27)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	88	0.09 (0.09, 0.09)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	88	5.18 (4.88, 5.49)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	88	5.01 (4.99, 5.04)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	137	22.03 (14.63, 33.16)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	137	266.03 (184.99, 382.56)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	137	145.66 (110.56, 191.88)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	137	92.84 (76.24, 113.04)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	137	23.15 (19.32, 27.74)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	511	817.13 (636.69, 1048.71)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	511	27926.21 (22536.53, 34604.84)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	511	17648.07 (14802.31, 21040.93)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	511	3878.20 (3746.51, 4014.51)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	511	962.46 (913.57, 1013.97)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	151	2810.33 (1757.86, 4492.97)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	89713.68 (65367.74, 123127.17)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	45764.31 (34756.65, 60258.18)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	151	4344.18 (4248.84, 4441.66)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	151	1278.44 (1263.07, 1294.00)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	88	0.02 (0.02, 0.02)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	88	0.27 (0.27, 0.27)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	88	0.09 (0.09, 0.09)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	88	5.16 (4.90, 5.43)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	88	5.00 (5.00, 5.00)
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	137	263.24 (162.81, 425.63)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	137	10928.07 (7403.08, 16131.49)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	137	4857.03 (3467.68, 6803.03)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	137	3114.10 (2797.61, 3466.39)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	137	692.52 (613.67, 781.50)

Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Age, sex</b>						
Age < 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	254	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	254	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	254	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	254	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	254	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	79	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.03)
Age < 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	41	5.30 (4.73, 5.93)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	41	5.34 (4.89, 5.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	254	39.74 (30.28, 52.15)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	254	482.04 (392.88, 591.45)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	254	278.55 (230.50, 336.60)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	254	192.98 (170.91, 217.91)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	254	38.03 (34.20, 42.27)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	79	109.33 (67.62, 176.78)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	803.57 (508.60, 1269.61)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	498.91 (333.71, 745.89)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	79	355.26 (289.31, 436.24)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	79	76.75 (64.08, 91.91)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	41	5.20 (4.82, 5.61)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	73	16.42 (9.95, 27.09)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	73	196.51 (126.31, 305.73)
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	73	109.22 (78.24, 152.47)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	73	81.03 (63.64, 103.18)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	73	20.73 (16.58, 25.92)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	254	622.55 (458.63, 845.07)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	254	21258.93 (16336.70, 27664.22)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	254	13227.30 (10680.44, 16381.49)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	254	3905.73 (3749.93, 4068.00)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	254	939.40 (880.98, 1001.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	79	2404.83 (1364.10, 4239.57)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	76819.60 (52441.36, 112530.46)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	38432.49 (27516.84, 53678.28)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	79	4335.06 (4218.09, 4455.26)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	79	1281.96 (1265.03, 1299.11)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	41	5.17 (4.84, 5.53)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	73	170.65 (95.02, 306.49)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	73	7893.10 (4907.89, 12694.06)
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	73	3185.58 (2135.76, 4751.43)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	73	2930.89 (2559.89, 3355.67)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	73	655.78 (564.52, 761.79)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	182	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	182	0.27 (0.27, 0.27)
Age < 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	182	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	182	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	182	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.28)
Age < 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	65	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	65	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age < 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.07 (4.94, 5.20)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.52 (4.83, 6.31)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.28)
Age < 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	182	45.41 (33.89, 60.84)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	182	539.55 (420.27, 692.68)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	182	323.57 (268.44, 390.03)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	182	198.28 (173.39, 226.74)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	182	44.75 (39.36, 50.87)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	65	85.24 (53.80, 135.06)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	65	691.67 (480.28, 996.09)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	65	515.85 (366.13, 726.80)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	65	349.20 (280.08, 435.39)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	65	69.14 (55.85, 85.59)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	5.00 (5.00, 5.00)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	33	5.49 (4.90, 6.15)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	77	18.92 (12.82, 27.93)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	77	266.79 (180.60, 394.10)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	77	126.26 (91.12, 174.93)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	77	90.72 (75.52, 108.99)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	77	24.72 (21.03, 29.07)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	182	761.02 (536.36, 1079.78)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	182	22946.38 (17354.29, 30340.43)
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	182	16943.13 (13595.81, 21114.56)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	182	3870.11 (3680.68, 4069.29)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	182	965.49 (894.55, 1042.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	65	1650.82 (852.61, 3196.31)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	65	70183.61 (48755.69, 101029.00)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	65	49532.33 (34193.02, 71753.00)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	65	4398.65 (4388.25, 4409.08)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	65	1281.20 (1256.83, 1306.04)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.10)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	5.37 (4.80, 6.00)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	77	293.28 (175.04, 491.41)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	77	9208.96 (5852.50, 14490.40)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	77	5025.27 (3631.02, 6954.87)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	77	2530.15 (2173.50, 2945.32)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	77	665.03 (573.85, 770.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	206	0.02 (0.02, 0.02)
Age $\geq$ 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	206	0.27 (0.27, 0.27)
Age $\geq$ 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	206	0.09 (0.09, 0.09)
Age $\geq$ 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	206	5.00 (5.00, 5.00)
Age $\geq$ 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	206	5.00 (5.00, 5.00)
Age $\geq$ 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)
Age $\geq$ 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)
Age $\geq$ 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)
Age $\geq$ 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)
Age $\geq$ 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	62	5.00 (5.00, 5.00)
Age $\geq$ 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.03)
Age $\geq$ 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.28 (0.27, 0.29)
Age $\geq$ 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)
Age $\geq$ 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.45 (4.87, 6.11)
Age $\geq$ 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)
Age ≥ 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)
Age ≥ 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)
Age ≥ 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Age ≥ 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	206	138.97 (108.57, 177.90)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	206	1590.67 (1268.06, 1995.36)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	206	1089.66 (896.83, 1323.95)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	206	302.83 (267.12, 343.31)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	206	57.56 (51.36, 64.50)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	62	224.57 (148.45, 339.73)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	3124.88 (2162.54, 4515.47)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	1946.81 (1427.86, 2654.37)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	62	550.65 (454.83, 666.66)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	62	100.80 (83.42, 121.80)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.03)
Age $\geq$ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)
Age $\geq$ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)
Age $\geq$ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	34	5.37 (4.68, 6.15)
Age $\geq$ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	34	5.39 (4.88, 5.95)
Age $\geq$ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	62.94 (44.41, 89.21)
Age $\geq$ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	834.58 (644.35, 1080.97)
Age $\geq$ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	529.53 (417.23, 672.06)
Age $\geq$ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	146.33 (124.77, 171.63)
Age $\geq$ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	60	35.54 (29.41, 42.96)
Age $\geq$ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	206	2276.02 (1685.32, 3073.74)
Age $\geq$ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	206	78706.94 (61541.70, 100659.92)
Age $\geq$ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	206	49515.60 (40474.72, 60575.96)
Age $\geq$ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	206	3802.99 (3557.91, 4064.95)
Age $\geq$ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	206	1022.56 (954.46, 1095.53)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	62	7232.41 (4696.34, 11138.00)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	222608.25 (170344.78, 290906.68)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	112431.46 (90214.53, 140119.70)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	62	4401.24 (4395.86, 4406.62)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	62	1295.00 (1295.00, 1295.00)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.03)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.28 (0.27, 0.29)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	34	5.14 (4.88, 5.41)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	34	5.19 (4.83, 5.58)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	1308.99 (813.79, 2105.50)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	40914.54 (27780.93, 60257.14)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	23378.08 (17176.06, 31819.57)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	3522.48 (3233.76, 3836.97)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	60	887.92 (791.57, 995.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	257	0.02 (0.02, 0.02)
Age $\geq$ 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	257	0.27 (0.27, 0.27)
Age $\geq$ 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	257	0.09 (0.09, 0.09)
Age $\geq$ 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	257	5.00 (5.00, 5.00)
Age $\geq$ 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	257	5.00 (5.00, 5.00)
Age $\geq$ 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)
Age $\geq$ 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)
Age $\geq$ 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)
Age $\geq$ 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.00 (5.00, 5.00)
Age $\geq$ 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)
Age $\geq$ 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)
Age $\geq$ 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)
Age $\geq$ 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)
Age $\geq$ 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)
Age $\geq$ 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
Age ≥ 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
Age ≥ 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
Age ≥ 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	64	5.00 (5.00, 5.00)
Age ≥ 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	257	132.29 (102.26, 171.13)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	257	1758.36 (1431.94, 2159.19)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	257	992.64 (826.53, 1192.13)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	257	298.95 (263.49, 339.18)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	257	55.49 (49.94, 61.65)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	207.32 (130.81, 328.58)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	3038.73 (2126.43, 4342.42)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	2027.69 (1509.65, 2723.51)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	494.00 (399.92, 610.22)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	72	82.68 (68.43, 99.91)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	47	0.03 (0.02, 0.03)
Age $\geq$ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)
Age $\geq$ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)
Age $\geq$ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	47	5.11 (4.90, 5.33)
Age $\geq$ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	47	5.05 (4.95, 5.16)
Age $\geq$ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	64.08 (41.10, 99.89)
Age $\geq$ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	798.99 (535.62, 1191.86)
Age $\geq$ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	414.27 (314.18, 546.25)
Age $\geq$ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	152.12 (123.06, 188.05)
Age $\geq$ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	64	34.54 (29.05, 41.07)
Age $\geq$ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	257	2257.83 (1693.64, 3009.96)
Age $\geq$ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	257	77397.53 (61633.51, 97193.53)
Age $\geq$ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	257	51839.07 (43007.61, 62484.04)
Age $\geq$ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	257	3777.02 (3557.81, 4009.75)
Age $\geq$ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	257	1053.79 (994.41, 1116.71)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	5409.15 (3304.70, 8853.73)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	172196.15 (126995.36, 233485.02)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	95315.70 (77743.47, 116859.74)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	4382.72 (4341.54, 4424.29)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	72	1263.79 (1227.88, 1300.74)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	47	5.12 (4.89, 5.35)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	1269.90 (779.82, 2067.95)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	35607.42 (23753.57, 53376.76)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	22461.69 (15552.67, 32439.93)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	3880.92 (3673.00, 4100.60)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	64	844.07 (750.43, 949.40)

Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Hispanic or Latino ethnicity</b>						
Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	115	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	115	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	115	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	115	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	115	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.03)
Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.28 (0.27, 0.29)
Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	19	5.24 (4.78, 5.74)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	28	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	28	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	28	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	28	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	28	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	115	63.21 (44.51, 89.77)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	115	539.45 (386.73, 752.46)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	115	366.44 (273.19, 491.52)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	115	248.23 (216.65, 284.42)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	115	41.62 (34.78, 49.81)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	38	136.74 (59.78, 312.77)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	1270.84 (806.27, 2003.08)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	1040.69 (625.19, 1732.34)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	38	393.53 (273.84, 565.53)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	38	78.34 (65.78, 93.31)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	19	5.95 (4.60, 7.69)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	28	23.92 (10.32, 55.44)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	28	496.64 (276.37, 892.46)
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	28	287.88 (179.44, 461.85)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	28	114.14 (88.90, 146.56)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	28	30.69 (24.78, 38.02)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	115	915.33 (578.36, 1448.63)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	115	27907.77 (17886.70, 43543.17)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	115	20620.30 (14504.89, 29314.04)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	115	4147.78 (4002.17, 4298.70)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	115	1034.99 (950.37, 1127.13)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	38	4382.06 (2340.31, 8205.09)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	119917.54 (68592.88, 209645.90)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	52252.53 (36597.87, 74603.43)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	38	4404.00 (4404.00, 4404.00)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	38	1276.07 (1239.72, 1313.49)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.10 (0.08, 0.13)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	19	5.25 (4.77, 5.79)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	28	581.71 (187.88, 1801.05)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	28	16833.03 (9066.10, 31253.89)
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	28	12188.18 (8469.64, 17539.33)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	28	3075.77 (2557.94, 3698.44)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	28	923.80 (804.97, 1060.18)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	664	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	664	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	664	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	664	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	664	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	211	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	211	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	211	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	211	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	211	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.03)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	120	5.21 (4.89, 5.55)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	120	5.39 (5.02, 5.78)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	212	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	212	0.27 (0.27, 0.28)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	212	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	212	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	212	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	664	54.20 (44.68, 65.75)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	664	686.21 (589.76, 798.44)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	664	384.98 (337.53, 439.10)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	664	214.68 (196.65, 234.35)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	664	44.41 (41.04, 48.06)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	211	112.19 (81.06, 155.28)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	211	1021.87 (764.35, 1366.13)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	211	695.86 (541.96, 893.47)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	211	382.63 (331.07, 442.23)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	211	77.42 (67.34, 89.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	120	5.17 (4.94, 5.41)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	120	5.14 (4.96, 5.33)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	212	22.96 (16.96, 31.07)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	212	318.94 (239.85, 424.12)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	212	165.46 (133.44, 205.17)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	212	97.56 (83.83, 113.53)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	212	24.68 (21.63, 28.16)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	664	880.11 (703.00, 1101.85)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	664	28854.69 (24011.94, 34674.13)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	664	19042.41 (16470.50, 22015.94)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	664	3831.04 (3707.28, 3958.92)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	664	957.59 (913.02, 1004.33)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	211	2473.81 (1618.17, 3781.88)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	211	89206.01 (69172.12, 115042.19)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	211	51544.02 (40654.47, 65350.41)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	211	4365.45 (4296.93, 4435.06)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	211	1290.15 (1284.90, 1295.42)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	120	5.24 (4.96, 5.54)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	120	5.02 (4.98, 5.07)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	212	336.43 (234.77, 482.13)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	212	12857.18 (9400.17, 17585.55)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	212	6068.65 (4737.21, 7774.30)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	212	2930.19 (2689.43, 3192.49)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	212	692.83 (629.31, 762.77)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	120	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	120	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	120	47.91 (32.03, 71.67)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	120	567.24 (399.68, 805.02)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	120	420.85 (323.84, 546.92)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	120	191.70 (159.49, 230.42)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	120	41.51 (35.34, 48.75)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	29	107.46 (53.66, 215.19)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	638.19 (286.81, 1420.05)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	313.04 (161.06, 608.43)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	29	354.30 (257.51, 487.47)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	29	68.05 (51.37, 90.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	34	22.49 (12.13, 41.70)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	34	178.34 (105.73, 300.82)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	34	92.74 (56.49, 152.27)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	34	84.06 (66.60, 106.10)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	34	23.28 (17.07, 31.75)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	120	848.58 (562.52, 1280.12)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	120	29063.70 (19868.80, 42513.83)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	120	19139.38 (13393.05, 27351.21)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	120	3902.36 (3689.26, 4127.77)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	120	992.54 (902.24, 1091.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	29	1725.81 (647.70, 4598.49)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	67190.42 (36051.18, 125226.21)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	47275.65 (23786.98, 93958.43)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	29	4359.38 (4301.65, 4417.89)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	29	1226.47 (1146.52, 1311.99)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	16	0.28 (0.27, 0.29)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	34	208.84 (87.18, 500.24)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	34	6258.60 (3314.40, 11818.13)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	34	3314.09 (1871.31, 5869.27)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	34	2662.64 (1993.60, 3556.20)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	34	642.20 (502.23, 821.17)

Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Race</b>						
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	337	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	337	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	337	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	119	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	119	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	119	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.03)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.34 (4.80, 5.94)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.51 (4.97, 6.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.28)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	121	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	121	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	337	59.21 (45.66, 76.78)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	720.77 (587.83, 883.78)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	402.33 (338.00, 478.91)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	337	224.04 (198.81, 252.46)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	337	46.46 (41.55, 51.95)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	119	120.20 (77.64, 186.10)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	1065.40 (713.58, 1590.69)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	710.20 (507.15, 994.54)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	119	391.38 (322.62, 474.79)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	119	78.13 (65.41, 93.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.03)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	64	5.07 (4.93, 5.22)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	64	5.23 (4.92, 5.55)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	121	20.17 (13.43, 30.30)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	121	307.28 (203.24, 464.59)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	121	163.54 (122.72, 217.93)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	121	95.17 (76.97, 117.67)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	121	24.57 (20.22, 29.85)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	337	1046.04 (764.11, 1431.99)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	30425.03 (23631.47, 39171.61)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	19667.85 (16047.10, 24105.54)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	337	3839.39 (3676.62, 4009.37)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	337	980.52 (920.61, 1044.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	119	2480.77 (1372.57, 4483.72)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	87192.72 (61818.93, 122981.26)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	50498.11 (37815.39, 67434.42)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	119	4398.86 (4389.76, 4407.99)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	119	1289.52 (1281.76, 1297.33)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	64	5.42 (4.94, 5.95)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	64	5.04 (4.96, 5.11)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	121	331.39 (196.04, 560.21)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	121	11323.25 (7351.20, 17441.53)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	121	6308.99 (4523.19, 8799.84)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	121	2851.13 (2536.03, 3205.37)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	121	664.80 (580.17, 761.78)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	195	0.02 (0.02, 0.02)
Black or African American	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	0.27 (0.27, 0.27)
Black or African American	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	0.09 (0.09, 0.09)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	195	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	195	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)
Black or African American	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)
Black or African American	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)
Black or African American	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)
Black or African American	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.28 (0.27, 0.28)
Black or African American	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	38	5.07 (4.97, 5.17)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)
Black or African American	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)
Black or African American	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	54	5.00 (5.00, 5.00)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	195	57.36 (42.08, 78.20)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	711.28 (556.63, 908.89)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	412.70 (331.57, 513.68)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	195	219.58 (190.48, 253.12)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	195	42.79 (37.64, 48.63)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	58	119.78 (78.99, 181.64)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	1240.21 (742.14, 2072.54)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	683.66 (506.50, 922.79)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	58	380.42 (310.15, 466.61)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	58	74.53 (60.43, 91.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	38	5.07 (4.93, 5.21)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	54	29.32 (18.68, 46.02)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	54	336.91 (224.16, 506.36)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	54	177.56 (125.81, 250.57)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	54	106.04 (89.35, 125.84)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	54	28.18 (23.41, 33.92)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	195	730.14 (505.61, 1054.39)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	31842.82 (23952.28, 42332.74)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	21072.84 (16551.63, 26829.05)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	195	3997.09 (3811.49, 4191.72)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	195	992.36 (915.48, 1075.71)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	58	3573.20 (1620.43, 7879.25)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	91390.25 (62755.80, 133090.15)
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	55587.10 (36233.78, 85277.50)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	58	4404.00 (4404.00, 4404.00)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	58	1295.00 (1295.00, 1295.00)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.03)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.28)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	54	435.84 (239.86, 791.92)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	54	19895.60 (11137.99, 35539.17)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	54	6794.49 (4649.49, 9929.06)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	54	3168.49 (2679.31, 3746.99)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	54	733.89 (642.60, 838.15)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	53	0.02 (0.02, 0.02)
Asian	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	53	0.27 (0.27, 0.27)
Asian	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	53	0.09 (0.09, 0.09)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	53	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	53	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)
Asian	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)
Asian	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)
Asian	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)
Asian	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	8	7.65 (4.44, 13.18)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)
Asian	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Asian	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	53	40.92 (22.62, 74.02)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	53	549.21 (310.34, 971.94)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	53	366.87 (234.75, 573.35)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	53	184.25 (145.24, 233.75)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	53	41.14 (33.45, 50.59)
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	16	105.82 (33.70, 332.25)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	763.02 (357.95, 1626.46)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	849.43 (399.96, 1804.00)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	16	368.24 (195.81, 692.53)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	16	67.73 (39.52, 116.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	8	5.23 (4.77, 5.72)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	15	18.56 (7.02, 49.08)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	15	304.61 (158.36, 585.91)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	15	131.53 (84.71, 204.23)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	15	80.47 (45.86, 141.22)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	15	22.29 (14.08, 35.29)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	53	735.81 (336.87, 1607.19)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	53	28753.40 (17040.35, 48517.68)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	53	15224.14 (10375.78, 22338.02)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	53	4004.83 (3716.00, 4316.10)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	53	971.39 (848.09, 1112.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	16	1571.09 (780.07, 3164.21)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	62112.57 (19546.97, 197369.27)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	36701.48 (14575.75, 92413.65)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	16	4404.00 (4404.00, 4404.00)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	16	1295.00 (1295.00, 1295.00)
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	15	350.71 (119.01, 1033.52)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	15	10934.13 (5178.17, 23088.33)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	15	3445.41 (1444.88, 8215.81)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	15	2773.87 (2358.23, 3262.77)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	15	564.04 (422.79, 752.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	2	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	2	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	2	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	22	42.79 (12.86, 142.35)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	521.17 (186.77, 1454.31)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	351.40 (216.84, 569.46)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	22	199.40 (130.99, 303.55)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	22	48.29 (32.91, 70.86)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	139.79 (8.66, 2255.75)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	827.36 (128.99, 5306.90)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	879.28 (181.79, 4252.89)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	380.25 (108.17, 1336.73)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	6	133.33 (46.80, 379.87)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	2	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	2	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	2	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	6	20.22 (7.01, 58.27)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	6	231.77 (97.36, 551.70)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	6	112.15 (56.88, 221.12)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	6	83.21 (61.14, 113.24)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	6	19.74 (11.41, 34.13)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	22	1279.72 (368.66, 4442.23)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	31820.09 (7995.82, 126630.97)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	21597.74 (11458.39, 40709.25)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	22	4082.28 (3741.43, 4454.18)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	22	1124.97 (964.22, 1312.51)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	2559.74 (173.75, 37711.94)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	116714.05 (12620.54, 1079364.68)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	61856.33 (15329.11, 249603.88)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	4297.02 (4141.44, 4458.45)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	6	1061.64 (788.06, 1430.18)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	2	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	2	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	2	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	6	464.84 (160.58, 1345.61)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	6	3254.58 (848.27, 12487.04)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	6	5100.49 (2075.45, 12534.62)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	6	2518.47 (1664.15, 3811.37)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	6	763.55 (419.60, 1389.43)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	5	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	15	97.26 (20.25, 467.15)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	15	1251.57 (405.80, 3860.09)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	15	482.29 (170.28, 1365.95)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	15	307.34 (154.68, 610.68)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	15	39.37 (19.57, 79.20)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	5	501.47 (186.20, 1350.56)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	3279.22 (1742.29, 6171.92)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	959.74 (671.76, 1371.17)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	5	919.67 (527.28, 1604.06)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	5	91.33 (67.08, 124.33)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	3	77.13 (45.27, 131.40)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	3	613.77 (413.57, 910.88)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	3	298.43 (121.92, 730.46)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	3	140.38 (101.36, 194.42)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	3	27.95 (20.60, 37.91)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	15	913.56 (281.17, 2968.28)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	15	30273.79 (12243.21, 74857.99)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	15	26664.51 (7632.61, 93152.47)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	15	4102.36 (3733.86, 4507.23)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	15	914.77 (722.73, 1157.84)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	5	13228.07 (2272.10, 77013.25)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	292207.65 (120365.67, 709382.55)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	85695.01 (53485.36, 137301.80)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	5	4404.00 (4404.00, 4404.00)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5	1295.00 (1295.00, 1295.00)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	3	475.64 (180.86, 1250.91)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	3	24451.32 (13080.76, 45705.82)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	3	21827.76 (14096.91, 33798.26)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3	3266.75 (2331.84, 4576.49)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	3	807.26 (377.37, 1726.87)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	59	0.02 (0.02, 0.03)
Multiracial	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	0.27 (0.27, 0.27)
Multiracial	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	0.09 (0.09, 0.09)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)
Multiracial	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)
Multiracial	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)
Multiracial	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	8	0.03 (0.02, 0.03)
Multiracial	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)
Multiracial	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	8	5.67 (4.44, 7.25)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)
Multiracial	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Multiracial	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	59	71.71 (38.25, 134.45)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	664.41 (358.50, 1231.35)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	410.99 (249.23, 677.74)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	59	226.68 (161.67, 317.82)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	59	40.12 (29.59, 54.40)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	16	139.44 (27.64, 703.30)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	1140.22 (638.37, 2036.60)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	1150.33 (464.78, 2847.07)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	16	374.67 (192.71, 728.45)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	16	72.14 (51.18, 101.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	8	5.47 (4.59, 6.52)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	15	45.44 (8.63, 239.35)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	15	913.43 (226.54, 3683.02)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	15	355.63 (140.47, 900.35)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	15	175.05 (76.86, 398.65)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	15	35.18 (18.40, 67.28)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	59	665.80 (275.10, 1611.37)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	32970.76 (17404.58, 62458.92)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	21768.56 (13741.44, 34484.78)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	59	3851.97 (3504.44, 4233.97)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	59	1076.44 (945.21, 1225.90)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	16	5998.27 (2815.49, 12779.06)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	205895.48 (114676.93, 369672.86)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	73849.03 (45467.31, 119947.28)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	16	4404.00 (4404.00, 4404.00)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	16	1295.00 (1295.00, 1295.00)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	8	5.72 (4.40, 7.42)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	15	913.66 (208.91, 3995.94)
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	15	18293.08 (5993.85, 55829.98)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	15	18248.11 (5192.32, 64131.94)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	15	3382.01 (2626.87, 4354.22)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	15	862.51 (638.10, 1165.85)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	21	0.02 (0.02, 0.02)
Other	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	0.27 (0.27, 0.27)
Other	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	0.09 (0.09, 0.09)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	21	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	21	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)
Other	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)
Other	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)
Other	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)
Other	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)
Other	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)
Other	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	21	33.17 (11.06, 99.42)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	316.08 (109.01, 916.45)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	236.45 (78.05, 716.35)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	21	164.58 (93.37, 290.08)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	21	32.97 (17.96, 60.52)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	53.45 (28.00, 102.02)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	952.68 (400.18, 2267.96)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	448.19 (325.90, 616.38)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	255.34 (175.87, 370.73)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	6	68.09 (54.76, 84.66)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	3	10.57 (6.87, 16.25)
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	11	33.46 (22.95, 48.79)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	11	893.55 (557.06, 1433.30)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	11	359.27 (186.94, 690.46)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	11	113.41 (91.90, 139.95)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	11	30.85 (24.98, 38.11)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	21	298.33 (68.31, 1302.84)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	15958.87 (3614.56, 70461.03)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	10116.77 (4537.67, 22555.44)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	21	3203.26 (2101.22, 4883.28)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	21	812.02 (510.33, 1292.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	911.80 (290.25, 2864.39)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	64621.25 (29833.95, 139971.58)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	40432.31 (11134.71, 146817.60)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	4404.00 (4404.00, 4404.00)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	6	1184.91 (990.55, 1417.42)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.18 (0.12, 0.26)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	11	577.49 (189.97, 1755.55)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	11	17608.45 (7784.44, 39830.42)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	11	11955.25 (8226.29, 17374.55)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	11	3153.07 (2343.09, 4243.04)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	11	1062.64 (936.06, 1206.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	92	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	92	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	92	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	92	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	92	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	20	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	20	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	20	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	20	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	20	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	28	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	28	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	28	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	28	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	28	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	92	45.24 (26.38, 77.59)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	92	653.51 (440.97, 968.50)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	92	375.82 (255.44, 552.94)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	92	200.81 (159.83, 252.29)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	92	43.25 (36.29, 51.54)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	25	61.38 (25.32, 148.79)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	578.32 (246.77, 1355.34)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	390.33 (156.67, 972.51)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	25	325.00 (221.44, 476.97)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	25	68.62 (42.88, 109.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	20	0.02 (0.02, 0.02)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	20	0.27 (0.27, 0.27)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	20	0.09 (0.09, 0.09)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	20	5.67 (4.52, 7.12)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	20	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	28	15.40 (6.05, 39.19)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	28	158.10 (87.00, 287.32)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	28	122.20 (62.05, 240.66)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	28	81.65 (58.60, 113.76)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	28	19.77 (15.10, 25.90)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	92	828.18 (503.59, 1362.00)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	92	26109.90 (15893.41, 42893.68)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	92	16940.60 (11592.94, 24755.06)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	92	3778.08 (3428.66, 4163.11)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	92	888.54 (770.29, 1024.95)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	25	1338.37 (465.35, 3849.21)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	81719.14 (40995.92, 162894.69)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	43323.30 (16546.07, 113435.29)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	25	4146.88 (3758.48, 4575.42)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	25	1257.94 (1207.02, 1311.00)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	20	0.02 (0.02, 0.02)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	20	0.27 (0.27, 0.27)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	20	0.09 (0.09, 0.09)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	20	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	20	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	28	141.31 (50.39, 396.29)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	28	6188.15 (3467.66, 11042.97)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	28	3384.44 (1872.97, 6115.64)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	28	2566.96 (1983.62, 3321.85)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	28	688.60 (521.20, 909.76)

Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Underrepresented minority status</b>						
Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	405	0.02 (0.02, 0.02)
Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	405	0.27 (0.27, 0.27)
Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	405	0.09 (0.09, 0.09)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	405	5.00 (5.00, 5.00)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	405	5.00 (5.00, 5.00)
Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)
Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)
Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5.00 (5.00, 5.00)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5.00 (5.00, 5.00)
Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)
Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.28)
Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	65	5.11 (4.97, 5.26)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	65	5.22 (4.79, 5.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	111	0.02 (0.02, 0.02)
Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	111	0.27 (0.27, 0.27)
Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	111	0.09 (0.09, 0.09)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	111	5.00 (5.00, 5.00)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	111	5.00 (5.00, 5.00)
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	405	53.98 (43.08, 67.63)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	405	613.00 (505.30, 743.66)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	405	371.80 (316.06, 437.37)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	405	215.96 (194.92, 239.26)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	405	41.69 (37.81, 45.97)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	120	124.79 (83.23, 187.09)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	1188.11 (867.30, 1627.58)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	815.95 (632.13, 1053.23)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	120	389.60 (321.08, 472.73)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	120	76.39 (65.91, 88.54)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.27)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	65	5.05 (4.96, 5.14)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	65	5.27 (4.87, 5.71)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	111	30.50 (21.44, 43.40)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	111	409.36 (295.30, 567.48)
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	111	194.97 (149.44, 254.37)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	111	109.46 (93.20, 128.56)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	111	27.84 (23.93, 32.38)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	405	744.66 (565.55, 980.50)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	405	28480.91 (22789.35, 35593.90)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	405	19177.21 (16106.10, 22833.93)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	405	3960.65 (3820.47, 4105.97)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	405	984.47 (930.22, 1041.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	120	3272.33 (2068.84, 5175.94)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	98855.57 (71157.44, 137335.23)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	51861.14 (39504.06, 68083.57)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	120	4398.18 (4386.82, 4409.58)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	120	1274.98 (1246.00, 1304.63)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.28)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.10)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	65	5.07 (4.93, 5.21)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	65	5.00 (5.00, 5.00)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	111	487.26 (317.22, 748.47)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	111	16697.08 (10951.84, 25456.21)
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	111	7572.41 (5551.38, 10329.23)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	111	3119.84 (2781.29, 3499.60)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	111	762.56 (683.89, 850.29)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	337	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	337	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	337	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	119	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	119	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	119	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.03)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.34 (4.80, 5.94)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.51 (4.97, 6.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.28)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	121	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	121	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	337	59.21 (45.66, 76.78)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	720.77 (587.83, 883.78)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	402.33 (338.00, 478.91)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	337	224.04 (198.81, 252.46)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	337	46.46 (41.55, 51.95)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	119	120.20 (77.64, 186.10)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	1065.40 (713.58, 1590.69)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	710.20 (507.15, 994.54)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	119	391.38 (322.62, 474.79)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	119	78.13 (65.41, 93.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.03)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	64	5.07 (4.93, 5.22)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	64	5.23 (4.92, 5.55)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	121	20.17 (13.43, 30.30)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	121	307.28 (203.24, 464.59)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	121	163.54 (122.72, 217.93)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	121	95.17 (76.97, 117.67)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	121	24.57 (20.22, 29.85)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	337	1046.04 (764.11, 1431.99)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	30425.03 (23631.47, 39171.61)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	19667.85 (16047.10, 24105.54)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	337	3839.39 (3676.62, 4009.37)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	337	980.52 (920.61, 1044.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	119	2480.77 (1372.57, 4483.72)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	87192.72 (61818.93, 122981.26)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	50498.11 (37815.39, 67434.42)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	119	4398.86 (4389.76, 4407.99)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	119	1289.52 (1281.76, 1297.33)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	64	5.42 (4.94, 5.95)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	64	5.04 (4.96, 5.11)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	121	331.39 (196.04, 560.21)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	121	11323.25 (7351.20, 17441.53)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	121	6308.99 (4523.19, 8799.84)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	121	2851.13 (2536.03, 3205.37)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	121	664.80 (580.17, 761.78)

Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
<b>Age, Underrepresented minority status</b>						
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	196	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	196	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	196	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	196	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	196	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	29	5.08 (4.92, 5.25)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	29	5.29 (4.74, 5.91)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	196	41.72 (31.62, 55.05)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	196	465.59 (367.04, 590.62)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	196	285.52 (233.95, 348.45)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	196	198.34 (175.01, 224.78)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	196	38.78 (34.40, 43.72)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	63	103.29 (62.37, 171.05)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	892.60 (604.83, 1317.31)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	616.73 (451.75, 841.97)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	63	356.86 (280.19, 454.49)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	63	72.26 (60.21, 86.72)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	29	5.32 (4.81, 5.89)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	60	23.20 (15.06, 35.74)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	60	317.58 (210.83, 478.39)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	60	155.25 (111.16, 216.83)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	60	97.70 (80.25, 118.95)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	60	25.88 (21.47, 31.21)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	196	551.62 (392.66, 774.92)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	196	21562.95 (16373.01, 28398.02)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	196	14854.74 (11983.97, 18413.22)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	196	3973.63 (3804.75, 4150.00)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	196	971.08 (905.90, 1040.95)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	63	2503.25 (1416.23, 4424.59)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	79697.87 (52812.10, 120270.73)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	41307.72 (29340.44, 58156.16)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	63	4396.56 (4382.03, 4411.14)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	63	1269.44 (1232.66, 1307.31)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.10)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	29	5.09 (4.92, 5.27)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	60	369.49 (217.38, 628.04)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	60	12276.41 (7224.62, 20860.63)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	60	5186.99 (3543.10, 7593.57)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	60	2938.35 (2536.26, 3404.18)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	60	710.85 (620.31, 814.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	166	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	166	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	166	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	166	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	166	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.28)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.03 (0.02, 0.03)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.36 (4.68, 6.14)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.68 (4.97, 6.49)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	66	0.28 (0.27, 0.28)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	166	47.98 (34.84, 66.08)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	166	557.44 (434.82, 714.65)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	166	300.21 (243.29, 370.43)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	166	206.48 (178.23, 239.20)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	166	43.63 (38.01, 50.09)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	58	105.74 (62.04, 180.22)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	823.68 (506.74, 1338.84)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	551.56 (366.20, 830.75)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	58	365.49 (289.02, 462.21)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	58	75.73 (61.01, 94.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	33	5.19 (4.82, 5.59)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	66	15.77 (9.58, 25.95)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	66	249.66 (149.87, 415.87)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	66	123.50 (87.19, 174.93)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	66	85.47 (65.77, 111.08)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	66	22.64 (17.81, 28.78)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	166	823.61 (558.43, 1214.72)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	166	23327.65 (17077.22, 31865.80)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	166	14736.44 (11484.90, 18908.53)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	166	3837.72 (3644.25, 4041.46)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	166	955.49 (883.55, 1033.29)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	58	2059.26 (994.08, 4265.82)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	72476.66 (47609.59, 110332.09)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	43571.89 (30552.22, 62139.83)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	58	4404.00 (4404.00, 4404.00)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	58	1295.00 (1295.00, 1295.00)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	5.47 (4.85, 6.17)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	66	237.24 (124.47, 452.19)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	66	8739.81 (5138.08, 14866.30)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	66	4700.63 (3140.44, 7035.93)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	66	2670.97 (2308.61, 3090.20)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	66	638.54 (539.77, 755.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	209	0.02 (0.02, 0.02)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	0.27 (0.27, 0.27)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	0.09 (0.09, 0.09)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	209	5.00 (5.00, 5.00)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	209	5.00 (5.00, 5.00)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)
Age $\geq$ 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.03)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.28 (0.26, 0.30)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.21 (4.92, 5.52)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	51	0.02 (0.02, 0.02)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	51	0.27 (0.27, 0.27)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	51	0.09 (0.09, 0.09)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)
Age $\geq$ 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	209	142.50 (111.73, 181.74)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	1728.91 (1416.31, 2110.50)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	1006.04 (843.06, 1200.52)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	209	297.63 (262.49, 337.47)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	209	54.78 (49.04, 61.20)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	57	245.54 (164.92, 365.56)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	3306.86 (2456.37, 4451.82)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	2222.37 (1678.90, 2941.77)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	57	533.41 (447.78, 635.41)
Age $\geq$ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	57	93.20 (78.76, 110.29)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	5.20 (4.81, 5.63)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	36	5.10 (4.91, 5.30)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	51	76.86 (48.35, 122.19)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	51	965.09 (707.47, 1316.51)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	51	420.90 (332.51, 532.78)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	51	160.70 (129.30, 199.73)
Age $\geq$ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	51	35.58 (29.52, 42.90)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	209	2308.03 (1759.79, 3027.06)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	81305.19 (65362.65, 101136.27)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	50226.61 (41911.60, 60191.27)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	209	3912.11 (3712.74, 4122.17)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	209	1036.61 (969.60, 1108.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	57	8537.62 (5399.20, 13500.34)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	213733.98 (164102.55, 278376.03)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	117092.61 (100398.77, 136562.23)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	57	4404.00 (4404.00, 4404.00)
Age $\geq$ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	57	1295.00 (1295.00, 1295.00)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.28 (0.27, 0.29)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	5.00 (5.00, 5.00)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	51	1240.86 (730.63, 2107.41)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	51	47194.06 (31924.84, 69766.35)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	51	27187.35 (19327.74, 38243.05)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	51	3820.05 (3587.39, 4067.80)
Age $\geq$ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	51	966.74 (862.78, 1083.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	171	0.02 (0.02, 0.02)
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	0.27 (0.27, 0.27)
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	0.09 (0.09, 0.09)
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	171	5.00 (5.00, 5.00)
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	171	5.00 (5.00, 5.00)
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	61	0.02 (0.02, 0.02)
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	0.27 (0.27, 0.27)
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	0.09 (0.09, 0.09)
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)
Age ≥ 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5.00 (5.00, 5.00)
Age ≥ 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.02 (0.02, 0.02)
Age ≥ 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)
Age ≥ 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.09)
Age ≥ 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.25 (4.78, 5.77)
Age ≥ 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	55	5.00 (5.00, 5.00)
Age $\geq$ 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	55	5.00 (5.00, 5.00)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	171	127.70 (95.38, 170.98)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	1843.38 (1438.70, 2361.89)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	1172.98 (947.44, 1452.22)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	171	301.90 (263.07, 346.45)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	171	58.44 (51.62, 66.17)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	61	199.80 (124.50, 320.63)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	2954.11 (1911.61, 4565.12)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	1934.06 (1397.99, 2675.69)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	61	513.27 (409.68, 643.06)
Age $\geq$ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	61	88.39 (71.66, 109.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	0.03 (0.02, 0.03)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.09)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	5.32 (4.71, 6.00)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	31	5.34 (4.88, 5.83)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	55	51.56 (33.71, 78.88)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	55	677.97 (457.85, 1003.93)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	55	476.71 (350.51, 648.35)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	55	143.32 (118.11, 173.90)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	55	33.56 (27.62, 40.77)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	171	2505.91 (1801.29, 3486.15)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	80316.62 (61529.72, 104839.74)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	56479.52 (45561.67, 70013.59)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	171	3845.51 (3584.99, 4124.95)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	171	1077.72 (1010.35, 1149.59)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	61	5189.23 (3093.99, 8703.35)
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	181405.13 (130182.84, 252781.57)
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	90612.57 (70108.72, 117112.92)
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	61	4378.56 (4334.07, 4423.50)
Age $\geq$ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	61	1268.02 (1230.99, 1306.17)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	0.02 (0.02, 0.03)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.10)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	5.27 (4.91, 5.65)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	31	5.17 (4.85, 5.51)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	55	1184.28 (725.51, 1933.14)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	55	30376.55 (19660.22, 46934.12)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	55	19362.40 (13429.80, 27915.71)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	55	3656.25 (3380.78, 3954.16)
Age $\geq$ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	55	775.16 (678.37, 885.76)

Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>All participants</b>								
	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	899	0.02 (0.02, 0.02)	54.02 (45.95, 63.51)	2247.14 (1912.17, 2640.79)
	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	899	0.27 (0.27, 0.27)	654.16 (574.81, 744.45)	2404.99 (2113.29, 2736.96)
	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	899	0.09 (0.09, 0.09)	388.03 (347.63, 433.11)	4310.03 (3861.39, 4810.78)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	899	5.00 (5.00, 5.00)	214.11 (198.95, 230.43)	42.82 (39.79, 46.09)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	899	5.00 (5.00, 5.00)	43.74 (40.91, 46.77)	8.75 (8.18, 9.35)
	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	278	0.02 (0.02, 0.02)	114.10 (86.34, 150.78)	4753.99 (3597.43, 6282.38)
	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	278	0.27 (0.27, 0.27)	990.44 (772.01, 1270.66)	3634.92 (2833.73, 4662.63)
	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	278	0.09 (0.09, 0.09)	662.31 (530.09, 827.52)	7359.01 (5889.85, 9194.62)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	278	5.00 (5.00, 5.00)	380.36 (335.84, 430.79)	76.07 (67.17, 86.16)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	278	5.00 (5.00, 5.00)	76.35 (68.07, 85.64)	15.27 (13.61, 17.13)
	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.99 (0.95, 1.02)
	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (0.99, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	155	5.20 (4.93, 5.48)	5.14 (4.95, 5.33)	0.99 (0.93, 1.05)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	155	5.32 (5.02, 5.63)	5.20 (5.00, 5.40)	0.98 (0.91, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	274	0.02 (0.02, 0.02)	22.94 (17.73, 29.69)	956.03 (738.85, 1237.05)
	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	274	0.27 (0.27, 0.28)	298.16 (234.40, 379.27)	1091.76 (858.16, 1388.95)
	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	274	0.09 (0.09, 0.09)	155.95 (128.82, 188.81)	1732.82 (1431.29, 2097.88)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	274	5.00 (5.00, 5.00)	96.18 (85.05, 108.77)	19.24 (17.01, 21.75)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	274	5.00 (5.00, 5.00)	24.82 (22.14, 27.81)	4.96 (4.43, 5.56)
	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	899	0.02 (0.02, 0.02)	878.77 (729.29, 1058.88)	36553.78 (30345.07, 44032.81)
	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	899	0.27 (0.27, 0.27)	28797.32 (24648.34, 33644.68)	105872.50 (90618.91, 123693.67)
	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	899	0.09 (0.09, 0.09)	19192.06 (16926.15, 21761.30)	213177.61 (188009.47, 241714.93)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	899	5.00 (5.00, 5.00)	3868.22 (3766.31, 3972.89)	773.64 (753.26, 794.58)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	899	5.00 (5.00, 5.00)	969.06 (931.18, 1008.48)	193.81 (186.24, 201.70)
	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	278	0.02 (0.02, 0.02)	2526.16 (1771.45, 3602.41)	105256.66 (73810.38, 150100.34)
	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	278	0.27 (0.27, 0.27)	89153.56 (71592.48, 111022.25)	327195.59 (262771.43, 407414.75)
	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	278	0.09 (0.09, 0.09)	51099.69 (41691.19, 62631.42)	567774.36 (463235.44, 695904.71)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	278	5.00 (5.00, 5.00)	4368.98 (4315.56, 4423.07)	873.80 (863.11, 884.61)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	278	5.00 (5.00, 5.00)	1280.94 (1268.63, 1293.36)	256.19 (253.73, 258.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.95, 1.02)
	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (0.99, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.04)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	155	5.20 (4.93, 5.48)	5.22 (4.98, 5.47)	1.00 (0.96, 1.05)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	155	5.32 (5.02, 5.63)	5.02 (4.98, 5.05)	0.94 (0.89, 1.00)
	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	274	0.02 (0.02, 0.02)	322.49 (234.41, 443.66)	13436.93 (9767.06, 18485.73)
	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	274	0.27 (0.27, 0.28)	11598.60 (8863.79, 15177.20)	42469.75 (32464.83, 55557.97)
	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	274	0.09 (0.09, 0.09)	5752.35 (4635.25, 7138.66)	63914.98 (51502.82, 79318.47)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	274	5.00 (5.00, 5.00)	2892.88 (2662.61, 3143.08)	578.58 (532.52, 628.62)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	274	5.00 (5.00, 5.00)	697.93 (640.72, 760.25)	139.59 (128.14, 152.05)

Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Age</b>								
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	436	0.02 (0.02, 0.02)	42.12 (34.51, 51.42)	1751.43 (1435.37, 2137.09)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	0.27 (0.27, 0.27)	506.41 (432.08, 593.53)	1861.81 (1588.55, 2182.08)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	0.09 (0.09, 0.09)	297.42 (260.00, 340.24)	3304.69 (2888.84, 3780.39)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	436	5.00 (5.00, 5.00)	195.28 (178.46, 213.69)	39.06 (35.69, 42.74)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	436	5.00 (5.00, 5.00)	40.83 (37.60, 44.34)	8.17 (7.52, 8.87)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	144	0.02 (0.02, 0.02)	97.74 (69.73, 137.01)	4072.68 (2905.58, 5708.59)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	144	0.27 (0.27, 0.27)	751.13 (555.65, 1015.38)	2755.50 (2038.80, 3724.12)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	144	0.09 (0.09, 0.09)	506.46 (386.68, 663.35)	5627.36 (4296.42, 7370.60)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	144	5.00 (5.00, 5.00)	352.52 (303.27, 409.77)	70.50 (60.65, 81.95)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	144	5.00 (5.00, 5.00)	73.22 (63.73, 84.14)	14.64 (12.75, 16.83)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.93, 1.02)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	74	5.20 (4.86, 5.56)	5.11 (4.89, 5.35)	0.98 (0.91, 1.07)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	74	5.42 (5.02, 5.84)	5.20 (4.95, 5.46)	0.96 (0.87, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	150	0.02 (0.02, 0.02)	17.67 (12.92, 24.18)	736.34 (538.19, 1007.46)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	150	0.27 (0.27, 0.28)	230.33 (171.67, 309.04)	842.50 (627.82, 1130.60)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	150	0.09 (0.09, 0.09)	117.76 (93.32, 148.59)	1308.43 (1036.94, 1651.01)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	150	5.00 (5.00, 5.00)	85.93 (73.97, 99.82)	17.19 (14.79, 19.96)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	150	5.00 (5.00, 5.00)	22.72 (19.77, 26.10)	4.54 (3.95, 5.22)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	436	0.02 (0.02, 0.02)	679.74 (540.11, 855.46)	28261.89 (22465.34, 35554.07)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	0.27 (0.27, 0.27)	21981.52 (18138.77, 26638.36)	80814.40 (66686.65, 97935.16)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	0.09 (0.09, 0.09)	14740.85 (12625.30, 17210.89)	163787.22 (140281.07, 191232.17)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	436	5.00 (5.00, 5.00)	3890.10 (3768.66, 4015.46)	778.02 (753.73, 803.09)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	436	5.00 (5.00, 5.00)	950.73 (905.07, 998.69)	190.15 (181.01, 199.74)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	144	0.02 (0.02, 0.02)	2030.31 (1316.69, 3130.69)	84596.20 (54862.16, 130445.43)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	144	0.27 (0.27, 0.27)	73759.13 (56470.30, 96341.06)	270581.80 (207185.08, 353377.33)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	144	0.09 (0.09, 0.09)	43080.81 (33568.40, 55288.80)	478675.71 (372982.20, 614320.02)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	144	5.00 (5.00, 5.00)	4363.56 (4297.51, 4430.63)	872.71 (859.50, 886.13)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	144	5.00 (5.00, 5.00)	1281.61 (1267.10, 1296.29)	256.32 (253.42, 259.26)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.94, 1.02)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.02 (0.99, 1.05)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	74	5.20 (4.86, 5.56)	5.25 (4.95, 5.58)	1.01 (0.96, 1.07)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	74	5.42 (5.02, 5.84)	5.00 (5.00, 5.00)	0.92 (0.86, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	150	0.02 (0.02, 0.02)	226.08 (153.33, 333.35)	9420.01 (6388.76, 13889.47)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	150	0.27 (0.27, 0.28)	8551.22 (6162.12, 11866.59)	31278.91 (22548.39, 43389.81)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	150	0.09 (0.09, 0.09)	4036.58 (3112.40, 5235.19)	44850.91 (34582.19, 58168.79)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	150	5.00 (5.00, 5.00)	2715.40 (2449.49, 3010.18)	543.08 (489.90, 602.04)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	150	5.00 (5.00, 5.00)	660.57 (594.65, 733.78)	132.11 (118.93, 146.76)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	463	0.02 (0.02, 0.02)	135.22 (112.92, 161.93)	5634.31 (4705.01, 6747.15)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	463	0.27 (0.27, 0.27)	1681.67 (1444.09, 1958.34)	6182.62 (5309.17, 7199.77)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	463	0.09 (0.09, 0.09)	1034.69 (905.25, 1182.64)	11479.51 (10043.86, 13120.37)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	463	5.00 (5.00, 5.00)	300.67 (274.90, 328.85)	60.13 (54.98, 65.77)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	463	5.00 (5.00, 5.00)	56.40 (52.20, 60.94)	11.28 (10.44, 12.19)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	134	0.02 (0.02, 0.02)	215.14 (157.35, 294.15)	8964.16 (6556.28, 12256.37)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	0.27 (0.27, 0.27)	3078.35 (2381.76, 3978.65)	11317.45 (8756.48, 14627.40)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	0.09 (0.09, 0.09)	1989.81 (1606.86, 2464.03)	22109.00 (17853.96, 27378.13)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	134	5.00 (5.00, 5.00)	519.49 (449.75, 600.04)	103.90 (89.95, 120.01)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	134	5.00 (5.00, 5.00)	90.63 (79.17, 103.75)	18.13 (15.83, 20.75)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	1.03 (0.97, 1.09)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	0.99 (0.97, 1.01)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	81	5.18 (4.94, 5.44)	5.21 (4.90, 5.55)	1.01 (0.97, 1.04)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	81	5.00 (5.00, 5.00)	5.19 (4.97, 5.42)	1.04 (0.99, 1.08)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	124	0.02 (0.02, 0.02)	63.53 (47.73, 84.55)	2646.91 (1988.73, 3522.91)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	124	0.27 (0.27, 0.27)	816.01 (640.86, 1039.03)	3000.03 (2356.09, 3819.97)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	124	0.09 (0.09, 0.09)	466.50 (387.65, 561.39)	5183.30 (4307.18, 6237.63)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	124	5.00 (5.00, 5.00)	149.29 (130.52, 170.77)	29.86 (26.10, 34.15)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	124	5.00 (5.00, 5.00)	35.02 (30.81, 39.81)	7.00 (6.16, 7.96)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	463	0.02 (0.02, 0.02)	2265.90 (1840.03, 2790.34)	94412.54 (76667.94, 116264.08)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	463	0.27 (0.27, 0.27)	77977.39 (65963.24, 92179.73)	286681.59 (242511.92, 338896.07)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	463	0.09 (0.09, 0.09)	50792.16 (44281.28, 58260.36)	563520.86 (491309.79, 646345.26)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	463	5.00 (5.00, 5.00)	3788.56 (3623.56, 3961.06)	757.71 (724.71, 792.21)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	463	5.00 (5.00, 5.00)	1039.78 (994.45, 1087.18)	207.96 (198.89, 217.44)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	134	0.02 (0.02, 0.02)	6188.40 (4440.93, 8623.49)	257849.95 (185038.66, 359311.93)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	134	0.27 (0.27, 0.27)	193950.66 (157822.35, 238349.39)	713053.91 (580229.23, 876284.51)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	134	0.09 (0.09, 0.09)	102895.16 (88557.76, 119553.76)	1143279.52 (983975.16, 1328375.07)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	134	5.00 (5.00, 5.00)	4391.29 (4368.90, 4413.79)	878.26 (873.78, 882.76)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	134	5.00 (5.00, 5.00)	1278.15 (1258.33, 1298.29)	255.63 (251.67, 259.66)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	1.01 (0.97, 1.04)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.27 (0.27, 0.28)	0.27 (0.27, 0.28)	1.00 (0.97, 1.02)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.03)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	81	5.18 (4.94, 5.44)	5.12 (4.95, 5.30)	0.99 (0.93, 1.05)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	81	5.00 (5.00, 5.00)	5.08 (4.93, 5.23)	1.02 (0.99, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	124	0.02 (0.02, 0.02)	1288.66 (915.52, 1813.87)	53693.99 (38146.55, 75578.12)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	124	0.27 (0.27, 0.27)	38082.49 (28751.10, 50442.46)	140009.17 (105702.59, 185450.21)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	124	0.09 (0.09, 0.09)	22900.37 (17987.61, 29154.91)	254448.59 (199862.31, 323943.46)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	124	5.00 (5.00, 5.00)	3703.20 (3519.25, 3896.77)	740.64 (703.85, 779.35)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	124	5.00 (5.00, 5.00)	865.00 (796.62, 939.26)	173.00 (159.32, 187.85)

Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Risk for Severe Covid-19</b>								
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	453	0.02 (0.02, 0.02)	59.16 (48.92, 71.53)	2464.81 (2038.38, 2980.44)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	453	0.27 (0.27, 0.27)	706.64 (593.89, 840.81)	2597.95 (2183.40, 3091.20)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	453	0.09 (0.09, 0.09)	427.84 (370.56, 493.98)	4748.40 (4112.85, 5482.16)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	453	5.00 (5.00, 5.00)	208.58 (189.63, 229.42)	41.72 (37.93, 45.88)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	453	5.00 (5.00, 5.00)	42.83 (39.33, 46.64)	8.57 (7.87, 9.33)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	130	0.02 (0.02, 0.02)	115.77 (83.76, 160.00)	4823.63 (3490.15, 6666.58)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	130	0.27 (0.27, 0.28)	1156.08 (879.41, 1519.79)	4219.11 (3217.18, 5533.06)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	130	0.09 (0.09, 0.09)	727.15 (585.27, 903.44)	8079.48 (6502.95, 10038.21)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	130	5.00 (5.00, 5.00)	377.53 (325.30, 438.14)	75.51 (65.06, 87.63)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	130	5.00 (5.00, 5.00)	77.79 (67.85, 89.18)	15.56 (13.57, 17.84)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.97, 1.03)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	0.99 (0.98, 1.01)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5.19 (4.96, 5.44)	5.12 (4.89, 5.36)	0.99 (0.95, 1.02)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)	5.18 (4.98, 5.38)	1.04 (1.00, 1.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)	21.13 (15.29, 29.20)	880.44 (637.05, 1216.81)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	122	0.28 (0.27, 0.29)	257.09 (197.28, 335.03)	928.94 (711.03, 1213.64)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)	160.84 (127.18, 203.40)	1787.08 (1413.12, 2260.02)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	122	5.00 (5.00, 5.00)	89.95 (77.53, 104.37)	17.99 (15.51, 20.87)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)	23.87 (20.36, 27.98)	4.77 (4.07, 5.60)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	453	0.02 (0.02, 0.02)	906.59 (720.34, 1141.00)	37774.61 (30014.24, 47541.48)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	453	0.27 (0.27, 0.27)	28328.44 (23519.92, 34120.02)	104148.66 (86470.31, 125441.24)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	453	0.09 (0.09, 0.09)	19610.61 (16434.08, 23401.12)	217647.19 (182399.66, 259706.06)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	453	5.00 (5.00, 5.00)	3523.35 (3346.50, 3709.55)	704.67 (669.30, 741.91)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	453	5.00 (5.00, 5.00)	926.51 (882.15, 973.09)	185.30 (176.43, 194.62)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	130	0.02 (0.02, 0.02)	2526.99 (1768.29, 3611.23)	105291.40 (73678.67, 150467.94)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	130	0.27 (0.27, 0.28)	91621.85 (70437.56, 119177.38)	334373.98 (257416.04, 434339.52)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	130	0.09 (0.09, 0.09)	54061.61 (43165.62, 67707.99)	600684.56 (479618.05, 752311.01)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	130	5.00 (5.00, 5.00)	4393.54 (4375.15, 4412.02)	878.71 (875.03, 882.40)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	130	5.00 (5.00, 5.00)	1271.70 (1248.53, 1295.30)	254.34 (249.71, 259.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	1.01 (0.97, 1.05)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.28)	0.27 (0.27, 0.28)	1.00 (0.98, 1.02)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5.19 (4.96, 5.44)	5.13 (4.95, 5.32)	0.99 (0.95, 1.03)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)	5.06 (4.94, 5.18)	1.01 (0.99, 1.04)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)	307.20 (207.85, 454.04)	12800.17 (8660.56, 18918.43)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	122	0.28 (0.27, 0.29)	10327.84 (7549.43, 14128.78)	37318.16 (27392.81, 50839.81)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)	6014.07 (4448.47, 8130.66)	66822.96 (49427.44, 90340.67)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	122	5.00 (5.00, 5.00)	2718.16 (2455.97, 3008.34)	543.63 (491.19, 601.67)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)	682.53 (615.52, 756.84)	136.51 (123.10, 151.37)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	446	0.02 (0.02, 0.02)	52.17 (42.20, 64.51)	2168.81 (1754.96, 2680.25)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	446	0.27 (0.27, 0.27)	635.07 (537.48, 750.37)	2334.81 (1976.04, 2758.71)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	446	0.09 (0.09, 0.09)	373.75 (324.02, 431.11)	4152.75 (3600.18, 4790.13)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	446	5.00 (5.00, 5.00)	216.27 (196.67, 237.84)	43.25 (39.33, 47.57)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	446	5.00 (5.00, 5.00)	44.10 (40.44, 48.10)	8.82 (8.09, 9.62)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	148	0.02 (0.02, 0.02)	113.58 (79.89, 161.47)	4732.40 (3328.81, 6727.82)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	148	0.27 (0.27, 0.27)	943.63 (687.58, 1295.04)	3469.23 (2527.85, 4761.19)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	148	0.09 (0.09, 0.09)	643.23 (483.57, 855.60)	7146.95 (5372.96, 9506.66)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	148	5.00 (5.00, 5.00)	381.26 (325.94, 445.96)	76.25 (65.19, 89.19)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	148	5.00 (5.00, 5.00)	75.91 (65.68, 87.72)	15.18 (13.14, 17.54)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.93, 1.03)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	76	5.20 (4.84, 5.59)	5.15 (4.90, 5.41)	0.99 (0.91, 1.08)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	76	5.45 (5.02, 5.92)	5.21 (4.94, 5.49)	0.95 (0.86, 1.06)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	152	0.02 (0.02, 0.02)	23.53 (17.04, 32.48)	980.34 (710.14, 1353.36)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	152	0.27 (0.27, 0.27)	311.94 (230.08, 422.94)	1146.85 (845.88, 1554.92)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	152	0.09 (0.09, 0.09)	154.49 (121.47, 196.50)	1716.61 (1349.66, 2183.32)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	152	5.00 (5.00, 5.00)	98.16 (84.13, 114.55)	19.63 (16.83, 22.91)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	152	5.00 (5.00, 5.00)	25.11 (21.81, 28.91)	5.02 (4.36, 5.78)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	446	0.02 (0.02, 0.02)	868.32 (681.00, 1107.17)	36095.80 (28321.20, 46004.66)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	446	0.27 (0.27, 0.27)	28979.32 (23635.90, 35530.74)	106541.60 (86896.67, 130627.71)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	446	0.09 (0.09, 0.09)	19033.81 (16203.87, 22358.00)	211486.81 (180042.96, 248422.22)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	446	5.00 (5.00, 5.00)	4009.36 (3886.63, 4135.95)	801.87 (777.33, 827.19)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	446	5.00 (5.00, 5.00)	985.90 (936.10, 1038.36)	197.18 (187.22, 207.67)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	148	0.02 (0.02, 0.02)	2525.90 (1606.20, 3972.20)	105245.78 (66925.19, 165508.31)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	148	0.27 (0.27, 0.27)	88394.64 (67041.37, 116549.11)	324980.28 (246475.62, 428489.38)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	148	0.09 (0.09, 0.09)	50206.27 (38782.90, 64994.34)	557847.40 (430921.13, 722159.35)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	148	5.00 (5.00, 5.00)	4361.32 (4291.66, 4432.12)	872.26 (858.33, 886.42)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	148	5.00 (5.00, 5.00)	1283.84 (1269.43, 1298.41)	256.77 (253.89, 259.68)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.93, 1.02)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.02 (0.99, 1.05)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	76	5.20 (4.84, 5.59)	5.26 (4.93, 5.61)	1.01 (0.95, 1.08)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	76	5.45 (5.02, 5.92)	5.00 (5.00, 5.00)	0.92 (0.84, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	152	0.02 (0.02, 0.02)	327.29 (219.32, 488.42)	13637.28 (9138.41, 20350.97)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	152	0.27 (0.27, 0.27)	12016.26 (8561.45, 16865.18)	44177.41 (31475.91, 62004.36)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	152	0.09 (0.09, 0.09)	5674.85 (4338.98, 7422.01)	63053.90 (48210.89, 82466.74)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	152	5.00 (5.00, 5.00)	2948.35 (2657.33, 3271.25)	589.67 (531.47, 654.25)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	152	5.00 (5.00, 5.00)	702.69 (631.26, 782.22)	140.54 (126.25, 156.44)

Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Age, Risk for Severe Covid-19</b>								
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	214	0.02 (0.02, 0.02)	36.39 (28.23, 46.91)	1516.09 (1176.09, 1954.39)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	0.27 (0.27, 0.27)	437.81 (344.38, 556.57)	1609.58 (1266.11, 2046.22)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	0.09 (0.09, 0.09)	264.47 (219.21, 319.06)	2938.51 (2435.71, 3545.09)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	214	5.00 (5.00, 5.00)	173.73 (153.25, 196.96)	34.75 (30.65, 39.39)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	214	5.00 (5.00, 5.00)	37.60 (33.49, 42.22)	7.52 (6.70, 8.44)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	99.72 (64.74, 153.58)	4154.93 (2697.68, 6399.35)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.28 (0.27, 0.28)	777.66 (541.96, 1115.87)	2826.50 (1979.19, 4036.55)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	468.31 (357.12, 614.13)	5203.45 (3967.96, 6823.65)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.00 (5.00, 5.00)	340.95 (281.03, 413.65)	68.19 (56.21, 82.73)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)	71.82 (60.57, 85.16)	14.36 (12.11, 17.03)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.95, 1.02)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	38	5.12 (4.89, 5.37)	5.00 (5.00, 5.00)	0.98 (0.93, 1.02)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)	5.09 (4.92, 5.26)	1.02 (0.98, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	12.24 (8.33, 17.97)	509.96 (347.24, 748.92)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.28 (0.27, 0.29)	149.77 (110.72, 202.59)	536.53 (395.19, 728.43)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	86.71 (66.41, 113.22)	963.48 (737.90, 1258.03)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	69.41 (58.60, 82.21)	13.88 (11.72, 16.44)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)	19.25 (15.84, 23.39)	3.85 (3.17, 4.68)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	214	0.02 (0.02, 0.02)	560.63 (409.64, 767.29)	23359.70 (17068.19, 31970.31)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	214	0.27 (0.27, 0.27)	17472.27 (13596.10, 22453.51)	64236.27 (49985.66, 82549.65)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	214	0.09 (0.09, 0.09)	12580.73 (9832.00, 16097.92)	139785.89 (109244.43, 178865.82)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	214	5.00 (5.00, 5.00)	3575.02 (3338.57, 3828.21)	715.00 (667.71, 765.64)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	214	5.00 (5.00, 5.00)	914.61 (858.56, 974.31)	182.92 (171.71, 194.86)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	1902.80 (1205.14, 3004.33)	79283.26 (50214.18, 125180.48)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.28 (0.27, 0.28)	67610.00 (47829.52, 95570.95)	245736.58 (174325.41, 346400.84)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	39349.13 (29030.17, 53336.03)	437212.58 (322557.48, 592622.57)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)	1275.97 (1248.80, 1303.74)	255.19 (249.76, 260.75)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	1.00 (0.95, 1.05)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	38	5.12 (4.89, 5.37)	5.13 (4.88, 5.39)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	142.10 (91.48, 220.73)	5920.80 (3811.68, 9196.95)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.28 (0.27, 0.29)	4948.71 (3495.42, 7006.23)	17728.41 (12648.16, 24849.17)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	2931.01 (2088.69, 4113.03)	32566.78 (23207.62, 45700.29)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	2273.93 (1978.20, 2613.86)	454.79 (395.64, 522.77)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)	611.05 (532.94, 700.61)	122.21 (106.59, 140.12)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	222	0.02 (0.02, 0.02)	43.84 (34.34, 55.98)	1821.87 (1427.85, 2324.61)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	222	0.27 (0.27, 0.27)	526.96 (435.27, 637.96)	1937.36 (1600.27, 2345.45)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	222	0.09 (0.09, 0.09)	307.12 (260.83, 361.62)	3412.45 (2898.12, 4018.05)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	222	5.00 (5.00, 5.00)	201.62 (180.72, 224.94)	40.32 (36.14, 44.99)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	222	5.00 (5.00, 5.00)	41.76 (37.79, 46.15)	8.35 (7.56, 9.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	97.28 (64.91, 145.81)	4053.54 (2704.59, 6075.29)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)	745.01 (518.42, 1070.66)	2739.02 (1905.94, 3936.24)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	515.90 (371.91, 715.64)	5732.18 (4132.28, 7951.53)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.00 (5.00, 5.00)	355.30 (296.69, 425.49)	71.06 (59.34, 85.10)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)	73.56 (62.25, 86.92)	14.71 (12.45, 17.38)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.92, 1.03)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.23 (4.79, 5.70)	5.15 (4.86, 5.46)	0.99 (0.89, 1.10)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.55 (5.03, 6.12)	5.23 (4.91, 5.58)	0.94 (0.84, 1.07)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	19.33 (13.24, 28.22)	805.41 (551.72, 1175.76)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)	255.84 (178.88, 365.91)	940.59 (657.65, 1345.25)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	126.89 (95.74, 168.17)	1409.89 (1063.79, 1868.59)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	90.52 (75.49, 108.56)	18.10 (15.10, 21.71)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)	23.66 (20.04, 27.93)	4.73 (4.01, 5.59)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	222	0.02 (0.02, 0.02)	716.48 (541.55, 947.90)	29771.89 (22514.90, 39367.96)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	222	0.27 (0.27, 0.27)	23404.58 (18505.98, 29599.85)	86046.24 (68036.70, 108822.97)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	222	0.09 (0.09, 0.09)	15393.07 (12788.38, 18528.27)	171034.08 (142093.10, 205869.66)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	222	5.00 (5.00, 5.00)	3980.92 (3841.01, 4125.93)	796.18 (768.20, 825.19)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	222	5.00 (5.00, 5.00)	960.84 (904.68, 1020.49)	192.17 (180.94, 204.10)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	2061.58 (1220.54, 3482.17)	85899.24 (50855.76, 145090.35)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)	75287.86 (54682.18, 103658.30)	276793.59 (201037.42, 381096.68)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	44010.56 (32609.52, 59397.66)	489006.23 (362328.05, 659974.01)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.00 (5.00, 5.00)	4354.09 (4272.80, 4436.92)	870.82 (854.56, 887.38)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)	1282.95 (1266.22, 1299.90)	256.59 (253.24, 259.98)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.92, 1.03)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.02 (0.98, 1.06)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.23 (4.79, 5.70)	5.29 (4.90, 5.71)	1.01 (0.94, 1.09)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.55 (5.03, 6.12)	5.00 (5.00, 5.00)	0.90 (0.82, 0.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	253.21 (158.15, 405.39)	10550.36 (6589.75, 16891.38)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)	9772.30 (6562.44, 14552.17)	35927.56 (24126.62, 53500.64)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	4364.50 (3193.16, 5965.53)	48494.45 (35479.54, 66283.62)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	2835.57 (2506.26, 3208.15)	567.11 (501.25, 641.63)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)	673.25 (593.30, 763.96)	134.65 (118.66, 152.79)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	239	0.02 (0.02, 0.02)	126.00 (96.14, 165.12)	5249.82 (4005.85, 6880.07)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	239	0.27 (0.27, 0.27)	1488.25 (1185.88, 1867.71)	5471.50 (4359.84, 6866.60)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	239	0.09 (0.09, 0.09)	904.30 (734.70, 1113.04)	10018.52 (8140.61, 12329.64)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	239	5.00 (5.00, 5.00)	277.19 (240.49, 319.49)	55.44 (48.10, 63.90)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	239	5.00 (5.00, 5.00)	52.45 (46.52, 59.13)	10.49 (9.30, 11.83)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	151.49 (95.56, 240.15)	6311.92 (3981.49, 10006.38)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	2362.04 (1646.89, 3387.74)	8683.96 (6054.73, 12454.93)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	1606.84 (1190.41, 2168.95)	17853.78 (13226.74, 24099.48)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	453.62 (362.16, 568.16)	90.72 (72.43, 113.63)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	89.81 (71.63, 112.61)	17.96 (14.33, 22.52)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	1.03 (0.98, 1.08)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	0.98 (0.94, 1.02)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	41	5.30 (4.84, 5.81)	5.30 (4.74, 5.93)	1.00 (0.96, 1.04)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)	5.31 (4.90, 5.77)	1.06 (0.98, 1.15)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)	63.50 (38.43, 104.92)	2645.70 (1601.19, 4371.58)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)	763.61 (506.19, 1151.95)	2807.39 (1860.98, 4235.09)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)	558.42 (417.87, 746.23)	6204.66 (4643.04, 8291.50)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)	151.67 (118.19, 194.63)	30.33 (23.64, 38.93)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)	36.80 (28.80, 47.03)	7.36 (5.76, 9.41)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	239	0.02 (0.02, 0.02)	1914.94 (1394.03, 2630.48)	79788.98 (58084.78, 109603.25)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	239	0.27 (0.27, 0.27)	60081.37 (46341.27, 77895.40)	220887.40 (170372.31, 286380.14)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	239	0.09 (0.09, 0.09)	39122.16 (31191.96, 49068.51)	433425.07 (345622.93, 543532.49)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	239	5.00 (5.00, 5.00)	3444.45 (3188.14, 3721.38)	688.89 (637.63, 744.28)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	239	5.00 (5.00, 5.00)	945.34 (874.68, 1021.70)	189.07 (174.94, 204.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	4213.38 (2421.25, 7331.98)	175557.63 (100885.60, 305499.30)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	158431.51 (109869.90, 228456.95)	582468.79 (403933.47, 839915.28)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	95825.62 (72784.81, 126160.25)	1064729.11 (808720.08, 1401780.54)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	4374.76 (4323.89, 4426.24)	874.95 (864.78, 885.25)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	1264.03 (1221.93, 1307.59)	252.81 (244.39, 261.52)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	1.03 (0.97, 1.09)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.28 (0.27, 0.29)	0.28 (0.27, 0.28)	0.99 (0.95, 1.04)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	41	5.30 (4.84, 5.81)	5.13 (4.88, 5.41)	0.97 (0.87, 1.08)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)	5.15 (4.86, 5.47)	1.03 (0.97, 1.09)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)	1452.28 (771.39, 2734.19)	60511.73 (32141.17, 113924.60)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)	45474.93 (28432.89, 72731.60)	167187.26 (104532.69, 267395.58)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)	25591.02 (16600.20, 39451.37)	284344.71 (184446.62, 438348.58)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)	3894.22 (3653.98, 4150.25)	778.84 (730.80, 830.05)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)	852.95 (748.49, 971.99)	170.59 (149.70, 194.40)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	224	0.02 (0.02, 0.02)	145.49 (114.83, 184.34)	6062.19 (4784.62, 7680.88)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	224	0.27 (0.27, 0.27)	1908.52 (1561.57, 2332.56)	7016.61 (5741.05, 8575.58)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	224	0.09 (0.09, 0.09)	1189.57 (1009.03, 1402.40)	13217.42 (11211.47, 15582.27)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	224	5.00 (5.00, 5.00)	327.08 (293.94, 363.95)	65.42 (58.79, 72.79)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	224	5.00 (5.00, 5.00)	60.81 (55.26, 66.92)	12.16 (11.05, 13.38)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)	281.53 (186.82, 424.24)	11730.37 (7784.37, 17676.66)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)	3771.45 (2654.40, 5358.61)	13865.64 (9758.81, 19700.77)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	2344.17 (1749.97, 3140.14)	26046.35 (19444.06, 34890.47)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5.00 (5.00, 5.00)	576.39 (480.42, 691.54)	115.28 (96.08, 138.31)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)	91.26 (77.48, 107.50)	18.25 (15.50, 21.50)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.03)	0.03 (0.02, 0.03)	1.03 (0.93, 1.15)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5.06 (4.94, 5.19)	5.13 (4.88, 5.39)	1.01 (0.96, 1.07)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)	5.06 (4.94, 5.19)	1.01 (0.99, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)	63.54 (45.04, 89.64)	2647.65 (1876.87, 3734.96)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)	849.85 (631.19, 1144.26)	3124.45 (2320.55, 4206.85)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)	417.85 (329.69, 529.60)	4642.82 (3663.20, 5884.41)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)	147.86 (126.79, 172.43)	29.57 (25.36, 34.49)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)	33.98 (29.49, 39.14)	6.80 (5.90, 7.83)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	224	0.02 (0.02, 0.02)	2697.29 (2068.92, 3516.52)	112387.28 (86204.99, 146521.69)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	224	0.27 (0.27, 0.27)	102147.24 (83423.06, 125074.05)	375541.34 (306702.42, 459831.05)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	224	0.09 (0.09, 0.09)	66558.70 (57689.44, 76791.54)	739541.14 (640993.79, 853239.32)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	224	5.00 (5.00, 5.00)	4181.18 (4025.45, 4342.93)	836.24 (805.09, 868.59)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	224	5.00 (5.00, 5.00)	1147.54 (1104.96, 1191.76)	229.51 (220.99, 238.35)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)	8309.47 (5616.48, 12293.69)	346227.97 (234020.16, 512237.07)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)	226487.29 (180806.57, 283709.21)	832673.85 (664730.05, 1043048.58)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	108666.46 (92603.25, 127516.04)	1207405.12 (1028924.96, 1416844.93)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)	1289.09 (1277.63, 1300.64)	257.82 (255.53, 260.13)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.95, 1.02)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.02 (0.98, 1.07)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5.06 (4.94, 5.19)	5.11 (4.90, 5.34)	1.01 (0.96, 1.06)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)	1197.71 (810.06, 1770.88)	49904.62 (33752.38, 73786.52)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)	34162.73 (24106.42, 48414.17)	125598.28 (88626.54, 177993.28)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)	21394.59 (16094.94, 28439.27)	237717.64 (178832.69, 315991.87)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)	3590.91 (3343.07, 3857.11)	718.18 (668.61, 771.42)
Age $\geq$ 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)	872.47 (784.15, 970.73)	174.49 (156.83, 194.15)



Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Sex</b>								
Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	388	0.02 (0.02, 0.02)	57.82 (45.60, 73.33)	2409.31 (1899.94, 3055.24)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	388	0.27 (0.27, 0.27)	681.55 (555.77, 835.80)	2505.70 (2043.27, 3072.79)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	388	0.09 (0.09, 0.09)	420.65 (359.92, 491.63)	4670.53 (3996.36, 5458.44)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	388	5.00 (5.00, 5.00)	217.28 (194.80, 242.36)	43.46 (38.96, 48.47)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	388	5.00 (5.00, 5.00)	47.25 (42.60, 52.41)	9.45 (8.52, 10.48)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)	103.53 (70.69, 151.62)	4313.83 (2945.59, 6317.64)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.28)	936.15 (684.43, 1280.45)	3428.39 (2508.25, 4686.08)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)	673.42 (504.28, 899.30)	7482.49 (5603.10, 9992.26)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	127	5.00 (5.00, 5.00)	382.63 (318.90, 459.09)	76.53 (63.78, 91.82)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	127	5.00 (5.00, 5.00)	74.57 (62.54, 88.93)	14.91 (12.51, 17.79)
Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.97, 1.02)
Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	0.99 (0.98, 1.01)
Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5.15 (4.98, 5.33)	5.08 (4.92, 5.25)	0.99 (0.96, 1.01)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5.40 (4.87, 5.98)	5.47 (5.00, 5.98)	1.01 (0.88, 1.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	137	0.02 (0.02, 0.02)	23.85 (17.23, 33.02)	993.87 (718.02, 1375.68)
Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	137	0.27 (0.27, 0.28)	332.38 (240.94, 458.51)	1212.37 (878.39, 1673.32)
Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	137	0.09 (0.09, 0.09)	166.44 (126.58, 218.86)	1849.35 (1406.45, 2431.73)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	137	5.00 (5.00, 5.00)	99.48 (85.42, 115.85)	19.90 (17.08, 23.17)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	137	5.00 (5.00, 5.00)	26.51 (23.14, 30.38)	5.30 (4.63, 6.08)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	388	0.02 (0.02, 0.02)	964.29 (726.31, 1280.25)	40178.74 (30262.81, 53343.74)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	388	0.27 (0.27, 0.27)	29949.43 (23839.38, 37625.49)	110108.20 (87644.78, 138329.02)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	388	0.09 (0.09, 0.09)	21361.84 (17840.87, 25577.69)	237182.83 (198093.31, 283985.83)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	388	5.00 (5.00, 5.00)	3855.51 (3697.30, 4020.48)	771.10 (739.46, 804.10)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	388	5.00 (5.00, 5.00)	977.55 (919.07, 1039.74)	195.51 (183.81, 207.95)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)	2220.59 (1292.35, 3815.54)	92524.55 (53847.95, 158980.84)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.28)	88480.82 (65501.35, 119522.04)	324037.93 (239972.25, 437553.02)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)	58390.04 (43171.97, 78972.47)	648778.23 (479688.50, 877471.93)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	127	5.00 (5.00, 5.00)	4399.17 (4390.79, 4407.57)	879.83 (878.16, 881.51)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	127	5.00 (5.00, 5.00)	1283.96 (1264.40, 1303.82)	256.79 (252.88, 260.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	67	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.98, 1.03)
Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	67	0.27 (0.27, 0.28)	0.27 (0.27, 0.28)	1.00 (0.98, 1.01)
Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	67	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.03 (0.97, 1.08)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	67	5.15 (4.98, 5.33)	5.31 (4.87, 5.79)	1.03 (0.94, 1.13)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	67	5.40 (4.87, 5.98)	5.04 (4.96, 5.13)	0.93 (0.84, 1.04)
Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	137	0.02 (0.02, 0.02)	391.29 (254.31, 602.07)	16303.89 (10596.20, 25086.05)
Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	137	0.27 (0.27, 0.28)	12275.65 (8418.55, 17899.95)	44775.94 (30727.32, 65247.64)
Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	137	0.09 (0.09, 0.09)	6758.41 (5128.32, 8906.64)	75093.44 (56981.32, 98962.70)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	137	5.00 (5.00, 5.00)	2696.77 (2381.21, 3054.15)	539.35 (476.24, 610.83)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	137	5.00 (5.00, 5.00)	703.13 (622.65, 794.01)	140.63 (124.53, 158.80)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	511	0.02 (0.02, 0.02)	51.22 (41.00, 63.99)	2127.82 (1704.65, 2656.03)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	511	0.27 (0.27, 0.27)	633.48 (534.99, 750.10)	2328.97 (1966.88, 2757.72)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	511	0.09 (0.09, 0.09)	364.25 (311.46, 426.00)	4047.27 (3460.68, 4733.30)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	511	5.00 (5.00, 5.00)	211.66 (191.57, 233.87)	42.33 (38.31, 46.77)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	511	5.00 (5.00, 5.00)	41.18 (37.76, 44.92)	8.24 (7.55, 8.98)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	151	0.02 (0.02, 0.02)	123.64 (82.97, 184.24)	5151.66 (3457.25, 7676.51)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	0.27 (0.27, 0.27)	1037.69 (709.82, 1517.01)	3815.05 (2609.65, 5577.24)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	0.09 (0.09, 0.09)	653.26 (466.86, 914.08)	7258.45 (5187.33, 10156.49)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	151	5.00 (5.00, 5.00)	378.50 (318.95, 449.17)	75.70 (63.79, 89.83)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	151	5.00 (5.00, 5.00)	77.85 (67.00, 90.46)	15.57 (13.40, 18.09)
Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	88	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.92, 1.04)
Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	88	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	88	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	88	5.23 (4.79, 5.70)	5.18 (4.88, 5.49)	0.99 (0.89, 1.10)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	88	5.26 (4.92, 5.63)	5.01 (4.99, 5.04)	0.95 (0.89, 1.02)
Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	137	0.02 (0.02, 0.02)	22.03 (14.63, 33.16)	917.87 (609.67, 1381.85)
Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	137	0.27 (0.27, 0.27)	266.03 (184.99, 382.56)	978.05 (680.12, 1406.48)
Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	137	0.09 (0.09, 0.09)	145.66 (110.56, 191.88)	1618.39 (1228.50, 2132.03)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	137	5.00 (5.00, 5.00)	92.84 (76.24, 113.04)	18.57 (15.25, 22.61)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	137	5.00 (5.00, 5.00)	23.15 (19.32, 27.74)	4.63 (3.86, 5.55)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	511	0.02 (0.02, 0.02)	817.13 (636.69, 1048.71)	33945.16 (26467.32, 43535.74)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	511	0.27 (0.27, 0.27)	27926.21 (22536.53, 34604.84)	102669.89 (82854.90, 127223.69)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	511	0.09 (0.09, 0.09)	17648.07 (14802.31, 21040.93)	196089.70 (164470.13, 233788.17)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	511	5.00 (5.00, 5.00)	3878.20 (3746.51, 4014.51)	775.64 (749.30, 802.90)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	511	5.00 (5.00, 5.00)	962.46 (913.57, 1013.97)	192.49 (182.71, 202.79)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	151	0.02 (0.02, 0.02)	2810.33 (1757.86, 4492.97)	117097.29 (73243.97, 187206.88)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	0.27 (0.27, 0.27)	89713.68 (65367.74, 123127.17)	329829.72 (240322.58, 452673.43)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	0.09 (0.09, 0.09)	45764.31 (34756.65, 60258.18)	508492.33 (386184.95, 669535.28)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	151	5.00 (5.00, 5.00)	4344.18 (4248.84, 4441.66)	868.84 (849.77, 888.33)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	151	5.00 (5.00, 5.00)	1278.44 (1263.07, 1294.00)	255.69 (252.61, 258.80)
Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	88	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.92, 1.03)
Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	88	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	88	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	88	5.23 (4.79, 5.70)	5.16 (4.90, 5.43)	0.99 (0.95, 1.02)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	88	5.26 (4.92, 5.63)	5.00 (5.00, 5.00)	0.95 (0.89, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	137	0.02 (0.02, 0.02)	263.24 (162.81, 425.63)	10968.29 (6783.56, 17734.54)
Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	137	0.27 (0.27, 0.27)	10928.07 (7403.08, 16131.49)	40176.72 (27217.20, 59306.95)
Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	137	0.09 (0.09, 0.09)	4857.03 (3467.68, 6803.03)	53966.96 (38529.74, 75589.21)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	137	5.00 (5.00, 5.00)	3114.10 (2797.61, 3466.39)	622.82 (559.52, 693.28)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	137	5.00 (5.00, 5.00)	692.52 (613.67, 781.50)	138.50 (122.73, 156.30)




Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Age, sex</b>								
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	254	0.02 (0.02, 0.02)	39.74 (30.28, 52.15)	1649.35 (1258.11, 2162.26)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	254	0.27 (0.27, 0.27)	482.04 (392.88, 591.45)	1772.22 (1444.40, 2174.43)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	254	0.09 (0.09, 0.09)	278.55 (230.50, 336.60)	3094.95 (2561.15, 3740.00)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	254	5.00 (5.00, 5.00)	192.98 (170.91, 217.91)	38.60 (34.18, 43.58)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	254	5.00 (5.00, 5.00)	38.03 (34.20, 42.27)	7.61 (6.84, 8.45)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)	109.33 (67.62, 176.78)	4555.40 (2817.33, 7365.71)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)	803.57 (508.60, 1269.61)	2954.31 (1869.86, 4667.69)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)	498.91 (333.71, 745.89)	5543.44 (3707.86, 8287.71)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	79	5.00 (5.00, 5.00)	355.26 (289.31, 436.24)	71.05 (57.86, 87.25)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)	76.75 (64.08, 91.91)	15.35 (12.82, 18.38)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.96 (0.89, 1.04)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	41	5.30 (4.73, 5.93)	5.20 (4.82, 5.61)	0.98 (0.85, 1.13)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	41	5.34 (4.89, 5.83)	5.00 (5.00, 5.00)	0.94 (0.86, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	16.42 (9.95, 27.09)	684.01 (414.57, 1128.54)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	196.51 (126.31, 305.73)	722.45 (464.36, 1123.99)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	109.22 (78.24, 152.47)	1213.53 (869.28, 1694.09)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	81.03 (63.64, 103.18)	16.21 (12.73, 20.64)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	20.73 (16.58, 25.92)	4.15 (3.32, 5.18)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	254	0.02 (0.02, 0.02)	622.55 (458.63, 845.07)	25841.10 (19053.87, 35046.03)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	254	0.27 (0.27, 0.27)	21258.93 (16336.70, 27664.22)	78157.83 (60061.41, 101706.67)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	254	0.09 (0.09, 0.09)	13227.30 (10680.44, 16381.49)	146969.99 (118671.53, 182016.52)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	254	5.00 (5.00, 5.00)	3905.73 (3749.93, 4068.00)	781.15 (749.99, 813.60)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	254	5.00 (5.00, 5.00)	939.40 (880.98, 1001.69)	187.88 (176.20, 200.34)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)	2404.83 (1364.10, 4239.57)	100201.23 (56837.56, 176648.78)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)	76819.60 (52441.36, 112530.46)	282424.99 (192799.12, 413714.94)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)	38432.49 (27516.84, 53678.28)	427027.70 (305742.63, 596425.35)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	79	5.00 (5.00, 5.00)	4335.06 (4218.09, 4455.26)	867.01 (843.62, 891.05)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)	1281.96 (1265.03, 1299.11)	256.39 (253.01, 259.82)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.96 (0.89, 1.04)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	41	5.30 (4.73, 5.93)	5.17 (4.84, 5.53)	0.98 (0.93, 1.02)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	41	5.34 (4.89, 5.83)	5.00 (5.00, 5.00)	0.94 (0.86, 1.02)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	170.65 (95.02, 306.49)	7110.56 (3959.17, 12770.36)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	7893.10 (4907.89, 12694.06)	29018.74 (18043.70, 46669.33)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	3185.58 (2135.76, 4751.43)	35395.31 (23730.67, 52793.62)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	2930.89 (2559.89, 3355.67)	586.18 (511.98, 671.13)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	655.78 (564.52, 761.79)	131.16 (112.90, 152.36)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	182	0.02 (0.02, 0.02)	45.41 (33.89, 60.84)	1891.96 (1412.11, 2534.87)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	182	0.27 (0.27, 0.27)	539.55 (420.27, 692.68)	1983.64 (1545.11, 2546.63)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	182	0.09 (0.09, 0.09)	323.57 (268.44, 390.03)	3595.25 (2982.66, 4333.66)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	182	5.00 (5.00, 5.00)	198.28 (173.39, 226.74)	39.66 (34.68, 45.35)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	182	5.00 (5.00, 5.00)	44.75 (39.36, 50.87)	8.95 (7.87, 10.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)	85.24 (53.80, 135.06)	3551.61 (2241.46, 5627.54)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.28)	691.67 (480.28, 996.09)	2530.58 (1758.72, 3641.20)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)	515.85 (366.13, 726.80)	5731.66 (4068.07, 8075.55)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	65	5.00 (5.00, 5.00)	349.20 (280.08, 435.39)	69.84 (56.02, 87.08)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	65	5.00 (5.00, 5.00)	69.14 (55.85, 85.59)	13.83 (11.17, 17.12)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.07 (4.94, 5.20)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.52 (4.83, 6.31)	5.49 (4.90, 6.15)	0.99 (0.82, 1.20)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)	18.92 (12.82, 27.93)	788.33 (533.96, 1163.89)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.28)	266.79 (180.60, 394.10)	971.29 (657.04, 1435.83)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)	126.26 (91.12, 174.93)	1402.85 (1012.50, 1943.69)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)	90.72 (75.52, 108.99)	18.14 (15.10, 21.80)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)	24.72 (21.03, 29.07)	4.94 (4.21, 5.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	182	0.02 (0.02, 0.02)	761.02 (536.36, 1079.78)	31709.06 (22348.19, 44990.87)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	182	0.27 (0.27, 0.27)	22946.38 (17354.29, 30340.43)	84361.70 (63802.52, 111545.69)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	182	0.09 (0.09, 0.09)	16943.13 (13595.81, 21114.56)	188256.99 (151064.59, 234606.24)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	182	5.00 (5.00, 5.00)	3870.11 (3680.68, 4069.29)	774.02 (736.14, 813.86)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	182	5.00 (5.00, 5.00)	965.49 (894.55, 1042.06)	193.10 (178.91, 208.41)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)	1650.82 (852.61, 3196.31)	68784.35 (35525.60, 133179.64)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.28)	70183.61 (48755.69, 101029.00)	256778.98 (178458.71, 369471.70)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)	49532.33 (34193.02, 71753.00)	550359.22 (379922.42, 797255.60)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	65	5.00 (5.00, 5.00)	4398.65 (4388.25, 4409.08)	879.73 (877.65, 881.82)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	65	5.00 (5.00, 5.00)	1281.20 (1256.83, 1306.04)	256.24 (251.37, 261.21)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.97, 1.03)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.04 (0.97, 1.11)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.07 (4.94, 5.20)	5.37 (4.80, 6.00)	1.06 (0.95, 1.18)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.52 (4.83, 6.31)	5.00 (5.00, 5.00)	0.91 (0.79, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)	293.28 (175.04, 491.41)	12220.12 (7293.15, 20475.58)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.28)	9208.96 (5852.50, 14490.40)	33526.78 (21323.58, 52713.71)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)	5025.27 (3631.02, 6954.87)	55836.31 (40344.72, 77276.38)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)	2530.15 (2173.50, 2945.32)	506.03 (434.70, 589.06)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)	665.03 (573.85, 770.68)	133.01 (114.77, 154.14)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	206	0.02 (0.02, 0.02)	138.97 (108.57, 177.90)	5790.62 (4523.67, 7412.40)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	206	0.27 (0.27, 0.27)	1590.67 (1268.06, 1995.36)	5848.06 (4662.00, 7335.87)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	206	0.09 (0.09, 0.09)	1089.66 (896.83, 1323.95)	12067.05 (9932.84, 14659.82)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	206	5.00 (5.00, 5.00)	302.83 (267.12, 343.31)	60.57 (53.42, 68.66)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	206	5.00 (5.00, 5.00)	57.56 (51.36, 64.50)	11.51 (10.27, 12.90)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)	224.57 (148.45, 339.73)	9357.06 (6185.22, 14155.45)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)	3124.88 (2162.54, 4515.47)	11488.54 (7950.52, 16600.98)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)	1946.81 (1427.86, 2654.37)	21631.25 (15865.14, 29493.02)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	550.65 (454.83, 666.66)	110.13 (90.97, 133.33)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	62	5.00 (5.00, 5.00)	100.80 (83.42, 121.80)	20.16 (16.68, 24.36)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	1.01 (0.94, 1.09)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	0.98 (0.93, 1.02)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.45 (4.87, 6.11)	5.37 (4.68, 6.15)	0.98 (0.93, 1.04)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	5.39 (4.88, 5.95)	1.08 (0.98, 1.19)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	62.94 (44.41, 89.21)	2622.64 (1850.47, 3717.02)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	834.58 (644.35, 1080.97)	3068.30 (2368.93, 3974.14)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	529.53 (417.23, 672.06)	5883.67 (4635.85, 7467.35)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	146.33 (124.77, 171.63)	29.27 (24.95, 34.33)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	35.54 (29.41, 42.96)	7.11 (5.88, 8.59)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	206	0.02 (0.02, 0.02)	2276.02 (1685.32, 3073.74)	94834.00 (70221.87, 128072.46)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	206	0.27 (0.27, 0.27)	78706.94 (61541.70, 100659.92)	289363.74 (226256.24, 370073.23)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	206	0.09 (0.09, 0.09)	49515.60 (40474.72, 60575.96)	548342.18 (448299.57, 670710.32)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	206	5.00 (5.00, 5.00)	3802.99 (3557.91, 4064.95)	760.60 (711.58, 812.99)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	206	5.00 (5.00, 5.00)	1022.56 (954.46, 1095.53)	204.51 (190.89, 219.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)	7232.41 (4696.34, 11138.00)	301350.53 (195680.71, 464083.25)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)	222608.25 (170344.78, 290906.68)	818412.69 (626267.57, 1069509.83)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)	112431.46 (90214.53, 140119.70)	1249238.43 (1002383.70, 1556885.51)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	4401.24 (4395.86, 4406.62)	880.25 (879.17, 881.32)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	62	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	1.02 (0.94, 1.10)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.28 (0.27, 0.29)	0.28 (0.27, 0.29)	0.99 (0.94, 1.05)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.45 (4.87, 6.11)	5.14 (4.88, 5.41)	0.94 (0.83, 1.07)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	5.19 (4.83, 5.58)	1.04 (0.97, 1.12)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	1308.99 (813.79, 2105.50)	54541.10 (33908.12, 87729.20)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	40914.54 (27780.93, 60257.14)	150421.09 (102135.78, 221533.59)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	23378.08 (17176.06, 31819.57)	259756.49 (190845.11, 353550.78)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	3522.48 (3233.76, 3836.97)	704.50 (646.75, 767.39)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	887.92 (791.57, 995.99)	177.58 (158.31, 199.20)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	257	0.02 (0.02, 0.02)	132.29 (102.26, 171.13)	5512.08 (4261.01, 7130.46)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	257	0.27 (0.27, 0.27)	1758.36 (1431.94, 2159.19)	6464.55 (5264.47, 7938.19)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	257	0.09 (0.09, 0.09)	992.64 (826.53, 1192.13)	11029.31 (9183.66, 13245.87)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	257	5.00 (5.00, 5.00)	298.95 (263.49, 339.18)	59.79 (52.70, 67.84)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	257	5.00 (5.00, 5.00)	55.49 (49.94, 61.65)	11.10 (9.99, 12.33)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	207.32 (130.81, 328.58)	8638.28 (5450.31, 13690.93)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)	3038.73 (2126.43, 4342.42)	11171.79 (7817.77, 15964.78)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	2027.69 (1509.65, 2723.51)	22529.92 (16773.89, 30261.17)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.00 (5.00, 5.00)	494.00 (399.92, 610.22)	98.80 (79.98, 122.04)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)	82.68 (68.43, 99.91)	16.54 (13.69, 19.98)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)	0.03 (0.02, 0.03)	1.04 (0.96, 1.13)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)	5.11 (4.90, 5.33)	1.02 (0.98, 1.07)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)	5.05 (4.95, 5.16)	1.01 (0.99, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	64.08 (41.10, 99.89)	2669.84 (1712.59, 4162.16)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	798.99 (535.62, 1191.86)	2937.46 (1969.19, 4381.82)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	414.27 (314.18, 546.25)	4603.00 (3490.88, 6069.42)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5.00 (5.00, 5.00)	152.12 (123.06, 188.05)	30.42 (24.61, 37.61)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	34.54 (29.05, 41.07)	6.91 (5.81, 8.21)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	257	0.02 (0.02, 0.02)	2257.83 (1693.64, 3009.96)	94076.08 (70568.24, 125414.90)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	257	0.27 (0.27, 0.27)	77397.53 (61633.51, 97193.53)	284549.76 (226593.77, 357329.16)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	257	0.09 (0.09, 0.09)	51839.07 (43007.61, 62484.04)	575989.67 (477862.31, 694267.13)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	257	5.00 (5.00, 5.00)	3777.02 (3557.81, 4009.75)	755.40 (711.56, 801.95)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	257	5.00 (5.00, 5.00)	1053.79 (994.41, 1116.71)	210.76 (198.88, 223.34)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	5409.15 (3304.70, 8853.73)	225381.44 (137695.91, 368905.60)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)	172196.15 (126995.36, 233485.02)	633074.07 (466894.69, 858400.81)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	95315.70 (77743.47, 116859.74)	1059063.29 (863816.39, 1298441.50)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.00 (5.00, 5.00)	4382.72 (4341.54, 4424.29)	876.54 (868.31, 884.86)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)	1263.79 (1227.88, 1300.74)	252.76 (245.58, 260.15)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.02 (0.98, 1.05)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)	5.12 (4.89, 5.35)	1.02 (0.98, 1.07)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	1269.90 (779.82, 2067.95)	52912.31 (32492.67, 86164.44)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	35607.42 (23753.57, 53376.76)	130909.65 (87329.31, 196238.09)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	22461.69 (15552.67, 32439.93)	249574.37 (172807.46, 360443.72)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5.00 (5.00, 5.00)	3880.92 (3673.00, 4100.60)	776.18 (734.60, 820.12)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	844.07 (750.43, 949.40)	168.81 (150.09, 189.88)

Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Hispanic or Latino ethnicity</b>								
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	115	0.02 (0.02, 0.02)	63.21 (44.51, 89.77)	2633.61 (1854.40, 3740.23)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	115	0.27 (0.27, 0.27)	539.45 (386.73, 752.46)	1983.26 (1421.81, 2766.41)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	115	0.09 (0.09, 0.09)	366.44 (273.19, 491.52)	4071.51 (3035.40, 5461.29)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	115	5.00 (5.00, 5.00)	248.23 (216.65, 284.42)	49.65 (43.33, 56.88)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	115	5.00 (5.00, 5.00)	41.62 (34.78, 49.81)	8.32 (6.96, 9.96)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)	136.74 (59.78, 312.77)	5697.64 (2491.02, 13032.07)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)	1270.84 (806.27, 2003.08)	4672.19 (2964.23, 7364.27)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	1040.69 (625.19, 1732.34)	11563.24 (6946.53, 19248.24)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)	393.53 (273.84, 565.53)	78.71 (54.77, 113.11)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)	78.34 (65.78, 93.31)	15.67 (13.16, 18.66)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.91, 1.03)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	0.97 (0.93, 1.03)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	19	5.24 (4.78, 5.74)	5.00 (5.00, 5.00)	0.95 (0.87, 1.05)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)	5.95 (4.60, 7.69)	1.19 (0.92, 1.54)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	28	0.02 (0.02, 0.02)	23.92 (10.32, 55.44)	996.58 (429.98, 2309.83)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	28	0.27 (0.27, 0.27)	496.64 (276.37, 892.46)	1825.87 (1016.06, 3281.09)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	28	0.09 (0.09, 0.09)	287.88 (179.44, 461.85)	3198.65 (1993.78, 5131.64)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	28	5.00 (5.00, 5.00)	114.14 (88.90, 146.56)	22.83 (17.78, 29.31)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	28	5.00 (5.00, 5.00)	30.69 (24.78, 38.02)	6.14 (4.96, 7.60)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	115	0.02 (0.02, 0.02)	915.33 (578.36, 1448.63)	38138.82 (24098.37, 60359.67)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	115	0.27 (0.27, 0.27)	27907.77 (17886.70, 43543.17)	102602.10 (65759.93, 160085.20)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	115	0.09 (0.09, 0.09)	20620.30 (14504.89, 29314.04)	229114.46 (161165.41, 325711.54)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	115	5.00 (5.00, 5.00)	4147.78 (4002.17, 4298.70)	829.56 (800.43, 859.74)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	115	5.00 (5.00, 5.00)	1034.99 (950.37, 1127.13)	207.00 (190.07, 225.43)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)	4382.06 (2340.31, 8205.09)	182585.76 (97512.80, 341878.80)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)	119917.54 (68592.88, 209645.90)	440873.30 (252179.71, 770756.98)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	52252.53 (36597.87, 74603.43)	580583.64 (406643.03, 828926.96)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)	1276.07 (1239.72, 1313.49)	255.21 (247.94, 262.70)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.91, 1.03)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	0.97 (0.93, 1.03)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)	0.10 (0.08, 0.13)	1.13 (0.90, 1.42)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	19	5.24 (4.78, 5.74)	5.25 (4.77, 5.79)	1.00 (1.00, 1.01)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	28	0.02 (0.02, 0.02)	581.71 (187.88, 1801.05)	24237.96 (7828.48, 75043.75)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	28	0.27 (0.27, 0.27)	16833.03 (9066.10, 31253.89)	61886.16 (33331.27, 114904.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	28	0.09 (0.09, 0.09)	12188.18 (8469.64, 17539.33)	135424.28 (94107.11, 194881.50)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	28	5.00 (5.00, 5.00)	3075.77 (2557.94, 3698.44)	615.15 (511.59, 739.69)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	28	5.00 (5.00, 5.00)	923.80 (804.97, 1060.18)	184.76 (160.99, 212.04)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	664	0.02 (0.02, 0.02)	54.20 (44.68, 65.75)	2253.36 (1858.30, 2732.39)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	664	0.27 (0.27, 0.27)	686.21 (589.76, 798.44)	2522.84 (2168.23, 2935.43)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	664	0.09 (0.09, 0.09)	384.98 (337.53, 439.10)	4275.78 (3748.79, 4876.84)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	664	5.00 (5.00, 5.00)	214.68 (196.65, 234.35)	42.94 (39.33, 46.87)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	664	5.00 (5.00, 5.00)	44.41 (41.04, 48.06)	8.88 (8.21, 9.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	211	0.02 (0.02, 0.02)	112.19 (81.06, 155.28)	4674.60 (3377.41, 6470.02)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	211	0.27 (0.27, 0.27)	1021.87 (764.35, 1366.13)	3748.32 (2804.40, 5009.96)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	211	0.09 (0.09, 0.09)	695.86 (541.96, 893.47)	7731.80 (6021.75, 9927.47)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	211	5.00 (5.00, 5.00)	382.63 (331.07, 442.23)	76.53 (66.21, 88.45)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	211	5.00 (5.00, 5.00)	77.42 (67.34, 89.00)	15.48 (13.47, 17.80)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.99 (0.95, 1.03)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	120	5.21 (4.89, 5.55)	5.17 (4.94, 5.41)	0.99 (0.92, 1.07)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	120	5.39 (5.02, 5.78)	5.14 (4.96, 5.33)	0.95 (0.88, 1.03)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	212	0.02 (0.02, 0.02)	22.96 (16.96, 31.07)	956.60 (706.85, 1294.57)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	212	0.27 (0.27, 0.28)	318.94 (239.85, 424.12)	1166.36 (876.94, 1551.31)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	212	0.09 (0.09, 0.09)	165.46 (133.44, 205.17)	1838.47 (1482.66, 2279.67)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	212	5.00 (5.00, 5.00)	97.56 (83.83, 113.53)	19.51 (16.77, 22.71)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	212	5.00 (5.00, 5.00)	24.68 (21.63, 28.16)	4.94 (4.33, 5.63)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	664	0.02 (0.02, 0.02)	880.11 (703.00, 1101.85)	36591.41 (29239.60, 45791.70)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	664	0.27 (0.27, 0.27)	28854.69 (24011.94, 34674.13)	106083.42 (88279.20, 127478.40)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	664	0.09 (0.09, 0.09)	19042.41 (16470.50, 22015.94)	211495.73 (182931.88, 244519.68)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	664	5.00 (5.00, 5.00)	3831.04 (3707.28, 3958.92)	766.21 (741.46, 791.78)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	664	5.00 (5.00, 5.00)	957.59 (913.02, 1004.33)	191.52 (182.60, 200.87)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	211	0.02 (0.02, 0.02)	2473.81 (1618.17, 3781.88)	103075.47 (67423.96, 157578.30)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	211	0.27 (0.27, 0.27)	89206.01 (69172.12, 115042.19)	327218.06 (253770.04, 421923.94)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	211	0.09 (0.09, 0.09)	51544.02 (40654.47, 65350.41)	572711.34 (451716.28, 726115.68)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	211	5.00 (5.00, 5.00)	4365.45 (4296.93, 4435.06)	873.09 (859.39, 887.01)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	211	5.00 (5.00, 5.00)	1290.15 (1284.90, 1295.42)	258.03 (256.98, 259.08)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.99 (0.94, 1.03)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	120	5.21 (4.89, 5.55)	5.24 (4.96, 5.54)	1.01 (0.95, 1.06)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	120	5.39 (5.02, 5.78)	5.02 (4.98, 5.07)	0.93 (0.87, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	212	0.02 (0.02, 0.02)	336.43 (234.77, 482.13)	14018.08 (9781.88, 20088.82)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	212	0.27 (0.27, 0.28)	12857.18 (9400.17, 17585.55)	47018.26 (34389.91, 64283.89)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	212	0.09 (0.09, 0.09)	6068.65 (4737.21, 7774.30)	67429.39 (52635.63, 86381.09)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	212	5.00 (5.00, 5.00)	2930.19 (2689.43, 3192.49)	586.04 (537.89, 638.50)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	212	5.00 (5.00, 5.00)	692.83 (629.31, 762.77)	138.57 (125.86, 152.55)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)	47.91 (32.03, 71.67)	1996.40 (1334.68, 2986.20)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	567.24 (399.68, 805.02)	2085.42 (1469.43, 2959.65)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	420.85 (323.84, 546.92)	4676.12 (3598.24, 6076.87)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	120	5.00 (5.00, 5.00)	191.70 (159.49, 230.42)	38.34 (31.90, 46.08)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	120	5.00 (5.00, 5.00)	41.51 (35.34, 48.75)	8.30 (7.07, 9.75)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	107.46 (53.66, 215.19)	4477.43 (2235.83, 8966.42)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	638.19 (286.81, 1420.05)	2346.30 (1054.47, 5220.77)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	313.04 (161.06, 608.43)	3478.19 (1789.52, 6760.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)	354.30 (257.51, 487.47)	70.86 (51.50, 97.49)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)	68.05 (51.37, 90.14)	13.61 (10.27, 18.03)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)	22.49 (12.13, 41.70)	937.23 (505.60, 1737.34)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)	178.34 (105.73, 300.82)	655.67 (388.71, 1105.95)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)	92.74 (56.49, 152.27)	1030.49 (627.65, 1691.89)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	84.06 (66.60, 106.10)	16.81 (13.32, 21.22)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	23.28 (17.07, 31.75)	4.66 (3.41, 6.35)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)	848.58 (562.52, 1280.12)	35357.61 (23438.23, 53338.52)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	29063.70 (19868.80, 42513.83)	106851.84 (73047.05, 156300.85)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	19139.38 (13393.05, 27351.21)	212659.81 (148811.63, 303902.30)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	120	5.00 (5.00, 5.00)	3902.36 (3689.26, 4127.77)	780.47 (737.85, 825.55)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	120	5.00 (5.00, 5.00)	992.54 (902.24, 1091.88)	198.51 (180.45, 218.38)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	1725.81 (647.70, 4598.49)	71908.93 (26987.43, 191603.84)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	67190.42 (36051.18, 125226.21)	247023.59 (132541.09, 460390.46)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	47275.65 (23786.98, 93958.43)	525284.96 (264299.72, 1043982.51)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)	4359.38 (4301.65, 4417.89)	871.88 (860.33, 883.58)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)	1226.47 (1146.52, 1311.99)	245.29 (229.30, 262.40)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)	0.28 (0.27, 0.29)	1.02 (0.98, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)	208.84 (87.18, 500.24)	8701.47 (3632.61, 20843.29)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)	6258.60 (3314.40, 11818.13)	23009.55 (12185.31, 43448.99)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)	3314.09 (1871.31, 5869.27)	36823.26 (20792.32, 65214.10)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	2662.64 (1993.60, 3556.20)	532.53 (398.72, 711.24)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	642.20 (502.23, 821.17)	128.44 (100.45, 164.23)

Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Race</b>								
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	337	0.02 (0.02, 0.02)	59.21 (45.66, 76.78)	2467.16 (1902.68, 3199.11)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	0.27 (0.27, 0.27)	720.77 (587.83, 883.78)	2649.89 (2161.14, 3249.18)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	0.09 (0.09, 0.09)	402.33 (338.00, 478.91)	4470.35 (3755.56, 5321.18)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	337	5.00 (5.00, 5.00)	224.04 (198.81, 252.46)	44.81 (39.76, 50.49)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	337	5.00 (5.00, 5.00)	46.46 (41.55, 51.95)	9.29 (8.31, 10.39)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	119	0.02 (0.02, 0.02)	120.20 (77.64, 186.10)	5008.51 (3235.14, 7753.97)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	0.27 (0.27, 0.27)	1065.40 (713.58, 1590.69)	3902.79 (2615.12, 5824.51)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	0.09 (0.09, 0.09)	710.20 (507.15, 994.54)	7891.11 (5635.04, 11050.44)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	119	5.00 (5.00, 5.00)	391.38 (322.62, 474.79)	78.28 (64.52, 94.96)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	119	5.00 (5.00, 5.00)	78.13 (65.41, 93.32)	15.63 (13.08, 18.66)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	0.98 (0.91, 1.06)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.34 (4.80, 5.94)	5.07 (4.93, 5.22)	0.95 (0.86, 1.06)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.51 (4.97, 6.11)	5.23 (4.92, 5.55)	0.95 (0.84, 1.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)	20.17 (13.43, 30.30)	840.46 (559.51, 1262.48)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.28)	307.28 (203.24, 464.59)	1119.54 (740.11, 1693.48)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)	163.54 (122.72, 217.93)	1817.06 (1363.53, 2421.42)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	121	5.00 (5.00, 5.00)	95.17 (76.97, 117.67)	19.03 (15.39, 23.53)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	121	5.00 (5.00, 5.00)	24.57 (20.22, 29.85)	4.91 (4.04, 5.97)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	337	0.02 (0.02, 0.02)	1046.04 (764.11, 1431.99)	43584.99 (31838.06, 59666.04)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	0.27 (0.27, 0.27)	30425.03 (23631.47, 39171.61)	111856.74 (86880.39, 144013.29)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	0.09 (0.09, 0.09)	19667.85 (16047.10, 24105.54)	218531.61 (178301.15, 267839.36)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	337	5.00 (5.00, 5.00)	3839.39 (3676.62, 4009.37)	767.88 (735.32, 801.87)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	337	5.00 (5.00, 5.00)	980.52 (920.61, 1044.34)	196.10 (184.12, 208.87)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	119	0.02 (0.02, 0.02)	2480.77 (1372.57, 4483.72)	103365.35 (57190.35, 186821.65)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	0.27 (0.27, 0.27)	87192.72 (61818.93, 122981.26)	319404.47 (226521.94, 450372.35)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	0.09 (0.09, 0.09)	50498.11 (37815.39, 67434.42)	561090.08 (420171.00, 749271.33)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	119	5.00 (5.00, 5.00)	4398.86 (4389.76, 4407.99)	879.77 (877.95, 881.60)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	119	5.00 (5.00, 5.00)	1289.52 (1281.76, 1297.33)	257.90 (256.35, 259.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.91, 1.04)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (1.00, 1.02)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.34 (4.80, 5.94)	5.42 (4.94, 5.95)	1.02 (0.93, 1.11)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.51 (4.97, 6.11)	5.04 (4.96, 5.11)	0.91 (0.82, 1.01)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)	331.39 (196.04, 560.21)	13808.07 (8168.26, 23341.90)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.28)	11323.25 (7351.20, 17441.53)	41254.91 (26805.19, 63493.97)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)	6308.99 (4523.19, 8799.84)	70099.86 (50257.64, 97775.99)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	121	5.00 (5.00, 5.00)	2851.13 (2536.03, 3205.37)	570.23 (507.21, 641.07)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	121	5.00 (5.00, 5.00)	664.80 (580.17, 761.78)	132.96 (116.03, 152.36)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	195	0.02 (0.02, 0.02)	57.36 (42.08, 78.20)	2390.14 (1753.20, 3258.49)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	0.27 (0.27, 0.27)	711.28 (556.63, 908.89)	2615.00 (2046.44, 3341.52)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	0.09 (0.09, 0.09)	412.70 (331.57, 513.68)	4577.07 (3677.65, 5696.47)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	195	5.00 (5.00, 5.00)	219.58 (190.48, 253.12)	43.92 (38.10, 50.62)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	195	5.00 (5.00, 5.00)	42.79 (37.64, 48.63)	8.56 (7.53, 9.73)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	119.78 (78.99, 181.64)	4990.94 (3291.33, 7568.22)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	1240.21 (742.14, 2072.54)	4559.60 (2728.47, 7619.62)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	683.66 (506.50, 922.79)	7596.27 (5627.80, 10253.26)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	380.42 (310.15, 466.61)	76.08 (62.03, 93.32)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	74.53 (60.43, 91.92)	14.91 (12.09, 18.38)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.28 (0.27, 0.28)	0.27 (0.27, 0.27)	0.99 (0.97, 1.01)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	38	5.07 (4.97, 5.17)	5.07 (4.93, 5.21)	1.00 (0.97, 1.03)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	29.32 (18.68, 46.02)	1221.57 (778.15, 1917.65)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)	336.91 (224.16, 506.36)	1238.64 (824.14, 1861.62)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	177.56 (125.81, 250.57)	1972.84 (1397.94, 2784.16)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	106.04 (89.35, 125.84)	21.21 (17.87, 25.17)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	54	5.00 (5.00, 5.00)	28.18 (23.41, 33.92)	5.64 (4.68, 6.78)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	195	0.02 (0.02, 0.02)	730.14 (505.61, 1054.39)	30422.52 (21066.98, 43932.72)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	195	0.27 (0.27, 0.27)	31842.82 (23952.28, 42332.74)	117069.21 (88059.85, 155635.06)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	195	0.09 (0.09, 0.09)	21072.84 (16551.63, 26829.05)	233711.46 (183584.52, 297525.34)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	195	5.00 (5.00, 5.00)	3997.09 (3811.49, 4191.72)	799.42 (762.30, 838.34)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	195	5.00 (5.00, 5.00)	992.36 (915.48, 1075.71)	198.47 (183.10, 215.14)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	3573.20 (1620.43, 7879.25)	148883.26 (67517.81, 328301.89)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	91390.25 (62755.80, 133090.15)	335993.58 (230719.85, 489302.02)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	55587.10 (36233.78, 85277.50)	617634.48 (402597.55, 947527.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	1.01 (0.97, 1.04)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.28 (0.27, 0.28)	0.27 (0.27, 0.28)	1.00 (0.97, 1.02)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	38	5.07 (4.97, 5.17)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	435.84 (239.86, 791.92)	18159.81 (9994.30, 32996.68)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)	19895.60 (11137.99, 35539.17)	73145.58 (40948.48, 130658.70)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	6794.49 (4649.49, 9929.06)	75494.31 (51661.01, 110322.87)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	3168.49 (2679.31, 3746.99)	633.70 (535.86, 749.40)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	54	5.00 (5.00, 5.00)	733.89 (642.60, 838.15)	146.78 (128.52, 167.63)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	53	0.02 (0.02, 0.02)	40.92 (22.62, 74.02)	1704.91 (942.44, 3084.27)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	53	0.27 (0.27, 0.27)	549.21 (310.34, 971.94)	2019.16 (1140.96, 3573.30)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	53	0.09 (0.09, 0.09)	366.87 (234.75, 573.35)	4076.30 (2608.29, 6370.54)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	53	5.00 (5.00, 5.00)	184.25 (145.24, 233.75)	36.85 (29.05, 46.75)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	53	5.00 (5.00, 5.00)	41.14 (33.45, 50.59)	8.23 (6.69, 10.12)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)	105.82 (33.70, 332.25)	4409.09 (1404.24, 13843.84)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)	763.02 (357.95, 1626.46)	2805.22 (1316.01, 5979.64)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)	849.43 (399.96, 1804.00)	9438.12 (4444.04, 20044.39)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)	368.24 (195.81, 692.53)	73.65 (39.16, 138.51)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)	67.73 (39.52, 116.08)	13.55 (7.90, 23.22)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	8	7.65 (4.44, 13.18)	5.23 (4.77, 5.72)	0.68 (0.38, 1.22)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	18.56 (7.02, 49.08)	773.30 (292.43, 2044.90)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	304.61 (158.36, 585.91)	1119.89 (582.22, 2154.08)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	131.53 (84.71, 204.23)	1461.45 (941.24, 2269.17)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	80.47 (45.86, 141.22)	16.09 (9.17, 28.24)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	22.29 (14.08, 35.29)	4.46 (2.82, 7.06)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	53	0.02 (0.02, 0.02)	735.81 (336.87, 1607.19)	30658.83 (14036.42, 66966.07)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	53	0.27 (0.27, 0.27)	28753.40 (17040.35, 48517.68)	105711.03 (62648.34, 178373.81)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	53	0.09 (0.09, 0.09)	15224.14 (10375.78, 22338.02)	169157.10 (115286.47, 248200.18)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	53	5.00 (5.00, 5.00)	4004.83 (3716.00, 4316.10)	800.97 (743.20, 863.22)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	53	5.00 (5.00, 5.00)	971.39 (848.09, 1112.61)	194.28 (169.62, 222.52)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)	1571.09 (780.07, 3164.21)	65462.00 (32503.09, 131842.03)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)	62112.57 (19546.97, 197369.27)	228355.05 (71863.87, 725622.30)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)	36701.48 (14575.75, 92413.65)	407794.19 (161952.80, 1026818.30)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	8	7.65 (4.44, 13.18)	5.00 (5.00, 5.00)	0.65 (0.38, 1.13)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	350.71 (119.01, 1033.52)	14613.00 (4958.71, 43063.53)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	10934.13 (5178.17, 23088.33)	40199.03 (19037.39, 84883.58)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	3445.41 (1444.88, 8215.81)	38282.37 (16054.24, 91286.75)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	2773.87 (2358.23, 3262.77)	554.77 (471.65, 652.55)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	564.04 (422.79, 752.47)	112.81 (84.56, 150.49)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	42.79 (12.86, 142.35)	1782.75 (535.85, 5931.16)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	521.17 (186.77, 1454.31)	1916.06 (686.64, 5346.73)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	351.40 (216.84, 569.46)	3904.43 (2409.32, 6327.33)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	199.40 (130.99, 303.55)	39.88 (26.20, 60.71)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	48.29 (32.91, 70.86)	9.66 (6.58, 14.17)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)	139.79 (8.66, 2255.75)	5824.38 (360.93, 93989.57)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)	827.36 (128.99, 5306.90)	3041.77 (474.22, 19510.65)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)	879.28 (181.79, 4252.89)	9769.82 (2019.91, 47254.35)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	380.25 (108.17, 1336.73)	76.05 (21.63, 267.35)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	133.33 (46.80, 379.87)	26.67 (9.36, 75.97)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	2	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	2	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	2	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)	20.22 (7.01, 58.27)	842.38 (292.29, 2427.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)	231.77 (97.36, 551.70)	852.08 (357.95, 2028.31)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)	112.15 (56.88, 221.12)	1246.07 (631.97, 2456.92)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	83.21 (61.14, 113.24)	16.64 (12.23, 22.65)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	19.74 (11.41, 34.13)	3.95 (2.28, 6.83)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	1279.72 (368.66, 4442.23)	53321.82 (15361.01, 185093.09)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	31820.09 (7995.82, 126630.97)	116985.63 (29396.39, 465555.02)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	21597.74 (11458.39, 40709.25)	239974.89 (127315.42, 452325.03)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	4082.28 (3741.43, 4454.18)	816.46 (748.29, 890.84)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	1124.97 (964.22, 1312.51)	224.99 (192.84, 262.50)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)	2559.74 (173.75, 37711.94)	106656.04 (7239.41, 1571330.79)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)	116714.05 (12620.54, 1079364.68)	429095.77 (46399.06, 3968252.50)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)	61856.33 (15329.11, 249603.88)	687292.57 (170323.46, 2773376.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	4297.02 (4141.44, 4458.45)	859.40 (828.29, 891.69)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	1061.64 (788.06, 1430.18)	212.33 (157.61, 286.04)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	2	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	2	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	2	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	2	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	2	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)	464.84 (160.58, 1345.61)	19368.19 (6690.70, 56066.91)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)	3254.58 (848.27, 12487.04)	11965.38 (3118.62, 45908.22)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)	5100.49 (2075.45, 12534.62)	56672.13 (23060.60, 139273.51)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	2518.47 (1664.15, 3811.37)	503.69 (332.83, 762.27)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	763.55 (419.60, 1389.43)	152.71 (83.92, 277.89)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	97.26 (20.25, 467.15)	4052.41 (843.69, 19464.63)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	1251.57 (405.80, 3860.09)	4601.37 (1491.92, 14191.52)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	482.29 (170.28, 1365.95)	5358.72 (1892.04, 15177.23)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	307.34 (154.68, 610.68)	61.47 (30.94, 122.14)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	39.37 (19.57, 79.20)	7.87 (3.91, 15.84)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	5	0.02 (0.02, 0.02)	501.47 (186.20, 1350.56)	20894.67 (7758.33, 56273.34)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	0.27 (0.27, 0.27)	3279.22 (1742.29, 6171.92)	12055.94 (6405.47, 22690.88)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	0.09 (0.09, 0.09)	959.74 (671.76, 1371.17)	10663.79 (7464.05, 15235.21)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	919.67 (527.28, 1604.06)	183.93 (105.46, 320.81)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	91.33 (67.08, 124.33)	18.27 (13.42, 24.87)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)	77.13 (45.27, 131.40)	3213.66 (1886.31, 5475.05)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)	613.77 (413.57, 910.88)	2256.49 (1520.46, 3348.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)	298.43 (121.92, 730.46)	3315.89 (1354.72, 8116.18)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	140.38 (101.36, 194.42)	28.08 (20.27, 38.88)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	27.95 (20.60, 37.91)	5.59 (4.12, 7.58)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	913.56 (281.17, 2968.28)	38065.14 (11715.50, 123678.44)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	30273.79 (12243.21, 74857.99)	111300.70 (45011.82, 275213.20)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	26664.51 (7632.61, 93152.47)	296272.36 (84806.75, 1035027.47)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	4102.36 (3733.86, 4507.23)	820.47 (746.77, 901.45)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	914.77 (722.73, 1157.84)	182.95 (144.55, 231.57)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	5	0.02 (0.02, 0.02)	13228.07 (2272.10, 77013.25)	551169.79 (94670.92, 3208885.24)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	5	0.27 (0.27, 0.27)	292207.65 (120365.67, 709382.55)	1074292.82 (442520.86, 2608024.10)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	5	0.09 (0.09, 0.09)	85695.01 (53485.36, 137301.80)	952166.83 (594281.73, 1525575.53)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)	475.64 (180.86, 1250.91)	19818.31 (7535.64, 52121.08)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)	24451.32 (13080.76, 45705.82)	89894.54 (48091.03, 168036.11)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)	21827.76 (14096.91, 33798.26)	242530.67 (156632.36, 375536.24)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	3266.75 (2331.84, 4576.49)	653.35 (466.37, 915.30)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	807.26 (377.37, 1726.87)	161.45 (75.47, 345.37)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	59	0.02 (0.02, 0.03)	71.71 (38.25, 134.45)	2873.03 (1599.58, 5160.29)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	0.27 (0.27, 0.27)	664.41 (358.50, 1231.35)	2442.68 (1318.01, 4527.03)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	0.09 (0.09, 0.09)	410.99 (249.23, 677.74)	4566.52 (2769.18, 7530.42)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)	226.68 (161.67, 317.82)	45.34 (32.33, 63.56)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)	40.12 (29.59, 54.40)	8.02 (5.92, 10.88)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)	139.44 (27.64, 703.30)	5809.88 (1151.87, 29304.27)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)	1140.22 (638.37, 2036.60)	4191.99 (2346.94, 7487.51)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)	1150.33 (464.78, 2847.07)	12781.46 (5164.22, 31634.12)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)	374.67 (192.71, 728.45)	74.93 (38.54, 145.69)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)	72.14 (51.18, 101.68)	14.43 (10.24, 20.34)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	8	0.03 (0.02, 0.03)	0.02 (0.02, 0.02)	0.91 (0.77, 1.09)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	8	5.67 (4.44, 7.25)	5.00 (5.00, 5.00)	0.88 (0.69, 1.13)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	5.47 (4.59, 6.52)	1.09 (0.92, 1.30)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	45.44 (8.63, 239.35)	1893.54 (359.52, 9972.88)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	913.43 (226.54, 3683.02)	3358.21 (832.88, 13540.50)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	355.63 (140.47, 900.35)	3951.49 (1560.82, 10003.84)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	175.05 (76.86, 398.65)	35.01 (15.37, 79.73)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	35.18 (18.40, 67.28)	7.04 (3.68, 13.46)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	59	0.02 (0.02, 0.03)	665.80 (275.10, 1611.37)	26674.58 (11422.72, 62291.07)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	59	0.27 (0.27, 0.27)	32970.76 (17404.58, 62458.92)	121216.05 (63987.43, 229628.37)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	59	0.09 (0.09, 0.09)	21768.56 (13741.44, 34484.78)	241872.93 (152682.62, 383164.21)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)	3851.97 (3504.44, 4233.97)	770.39 (700.89, 846.79)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)	1076.44 (945.21, 1225.90)	215.29 (189.04, 245.18)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)	5998.27 (2815.49, 12779.06)	249927.96 (117311.91, 532460.73)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	16	0.27 (0.27, 0.27)	205895.48 (114676.93, 369672.86)	756968.69 (421606.37, 1359091.40)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)	73849.03 (45467.31, 119947.28)	820544.83 (505192.30, 1332747.59)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	8	0.03 (0.02, 0.03)	0.02 (0.02, 0.02)	0.91 (0.77, 1.09)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	8	5.67 (4.44, 7.25)	5.72 (4.40, 7.42)	1.01 (0.99, 1.02)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	913.66 (208.91, 3995.94)	38069.29 (8704.46, 166497.61)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	18293.08 (5993.85, 55829.98)	67253.97 (22036.23, 205257.29)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	18248.11 (5192.32, 64131.94)	202756.81 (57692.46, 712577.12)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	3382.01 (2626.87, 4354.22)	676.40 (525.37, 870.84)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	862.51 (638.10, 1165.85)	172.50 (127.62, 233.17)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	21	0.02 (0.02, 0.02)	33.17 (11.06, 99.42)	1381.91 (460.98, 4142.63)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	0.27 (0.27, 0.27)	316.08 (109.01, 916.45)	1162.04 (400.78, 3369.32)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	0.09 (0.09, 0.09)	236.45 (78.05, 716.35)	2627.28 (867.21, 7959.50)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	21	5.00 (5.00, 5.00)	164.58 (93.37, 290.08)	32.92 (18.67, 58.02)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	21	5.00 (5.00, 5.00)	32.97 (17.96, 60.52)	6.59 (3.59, 12.10)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)	53.45 (28.00, 102.02)	2227.08 (1166.83, 4250.75)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)	952.68 (400.18, 2267.96)	3502.50 (1471.26, 8338.08)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)	448.19 (325.90, 616.38)	4979.94 (3621.12, 6848.65)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	255.34 (175.87, 370.73)	51.07 (35.17, 74.15)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	68.09 (54.76, 84.66)	13.62 (10.95, 16.93)
Other	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	10.57 (6.87, 16.25)	2.11 (1.37, 3.25)
Other	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)	33.46 (22.95, 48.79)	1394.13 (956.05, 2032.95)
Other	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)	893.55 (557.06, 1433.30)	3285.11 (2048.00, 5269.49)
Other	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)	359.27 (186.94, 690.46)	3991.91 (2077.14, 7671.76)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	113.41 (91.90, 139.95)	22.68 (18.38, 27.99)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	30.85 (24.98, 38.11)	6.17 (5.00, 7.62)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	21	0.02 (0.02, 0.02)	298.33 (68.31, 1302.84)	12430.25 (2846.30, 54284.89)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	0.27 (0.27, 0.27)	15958.87 (3614.56, 70461.03)	58672.32 (13288.82, 259047.92)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	0.09 (0.09, 0.09)	10116.77 (4537.67, 22555.44)	112408.55 (50418.50, 250615.96)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	21	5.00 (5.00, 5.00)	3203.26 (2101.22, 4883.28)	640.65 (420.24, 976.66)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	21	5.00 (5.00, 5.00)	812.02 (510.33, 1292.06)	162.40 (102.07, 258.41)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)	911.80 (290.25, 2864.39)	37991.86 (12093.72, 119349.64)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)	64621.25 (29833.95, 139971.58)	237578.11 (109683.65, 514601.39)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)	40432.31 (11134.71, 146817.60)	449247.85 (123719.00, 1631306.64)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	1184.91 (990.55, 1417.42)	236.98 (198.11, 283.48)
Other	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)	0.18 (0.12, 0.26)	1.96 (1.33, 2.88)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)	577.49 (189.97, 1755.55)	24062.07 (7915.26, 73147.78)
Other	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)	17608.45 (7784.44, 39830.42)	64736.95 (28619.26, 146435.37)
Other	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)	11955.25 (8226.29, 17374.55)	132836.16 (91403.23, 193050.56)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	3153.07 (2343.09, 4243.04)	630.61 (468.62, 848.61)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	1062.64 (936.06, 1206.34)	212.53 (187.21, 241.27)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	92	0.02 (0.02, 0.02)	45.24 (26.38, 77.59)	1884.99 (1099.08, 3232.87)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	92	0.27 (0.27, 0.27)	653.51 (440.97, 968.50)	2402.62 (1621.21, 3560.66)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	92	0.09 (0.09, 0.09)	375.82 (255.44, 552.94)	4175.81 (2838.21, 6143.79)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	92	5.00 (5.00, 5.00)	200.81 (159.83, 252.29)	40.16 (31.97, 50.46)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	92	5.00 (5.00, 5.00)	43.25 (36.29, 51.54)	8.65 (7.26, 10.31)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	61.38 (25.32, 148.79)	2557.49 (1055.03, 6199.61)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	578.32 (246.77, 1355.34)	2126.19 (907.24, 4982.87)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	390.33 (156.67, 972.51)	4337.02 (1740.73, 10805.65)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)	325.00 (221.44, 476.97)	65.00 (44.29, 95.39)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)	68.62 (42.88, 109.81)	13.72 (8.58, 21.96)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	20	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	20	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	20	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	20	5.00 (5.00, 5.00)	5.67 (4.52, 7.12)	1.13 (0.90, 1.42)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	20	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	28	0.02 (0.02, 0.02)	15.40 (6.05, 39.19)	641.84 (252.26, 1633.04)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	28	0.27 (0.27, 0.27)	158.10 (87.00, 287.32)	581.26 (319.84, 1056.34)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	28	0.09 (0.09, 0.09)	122.20 (62.05, 240.66)	1357.77 (689.43, 2674.04)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	28	5.00 (5.00, 5.00)	81.65 (58.60, 113.76)	16.33 (11.72, 22.75)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	28	5.00 (5.00, 5.00)	19.77 (15.10, 25.90)	3.95 (3.02, 5.18)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	92	0.02 (0.02, 0.02)	828.18 (503.59, 1362.00)	34507.67 (20982.82, 56750.21)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	92	0.27 (0.27, 0.27)	26109.90 (15893.41, 42893.68)	95992.28 (58431.67, 157697.35)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	92	0.09 (0.09, 0.09)	16940.60 (11592.94, 24755.06)	188228.93 (128810.49, 275056.26)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	92	5.00 (5.00, 5.00)	3778.08 (3428.66, 4163.11)	755.62 (685.73, 832.62)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	92	5.00 (5.00, 5.00)	888.54 (770.29, 1024.95)	177.71 (154.06, 204.99)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	1338.37 (465.35, 3849.21)	55765.61 (19389.78, 160383.64)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	81719.14 (40995.92, 162894.69)	300438.02 (150720.30, 598877.53)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	43323.30 (16546.07, 113435.29)	481369.97 (183845.21, 1260392.07)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)	4146.88 (3758.48, 4575.42)	829.38 (751.70, 915.08)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)	1257.94 (1207.02, 1311.00)	251.59 (241.40, 262.20)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	20	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	20	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	20	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	20	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	20	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	28	0.02 (0.02, 0.02)	141.31 (50.39, 396.29)	5888.00 (2099.60, 16511.97)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	28	0.27 (0.27, 0.27)	6188.15 (3467.66, 11042.97)	22750.57 (12748.75, 40599.14)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	28	0.09 (0.09, 0.09)	3384.44 (1872.97, 6115.64)	37604.85 (20810.78, 67951.54)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	28	5.00 (5.00, 5.00)	2566.96 (1983.62, 3321.85)	513.39 (396.72, 664.37)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	28	5.00 (5.00, 5.00)	688.60 (521.20, 909.76)	137.72 (104.24, 181.95)

MOCK

Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Underrepresented minority status</b>								
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	405	0.02 (0.02, 0.02)	53.98 (43.08, 67.63)	2237.77 (1789.80, 2797.87)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	405	0.27 (0.27, 0.27)	613.00 (505.30, 743.66)	2253.67 (1857.71, 2734.04)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	405	0.09 (0.09, 0.09)	371.80 (316.06, 437.37)	4127.20 (3508.50, 4854.99)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	405	5.00 (5.00, 5.00)	215.96 (194.92, 239.26)	43.19 (38.98, 47.85)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	405	5.00 (5.00, 5.00)	41.69 (37.81, 45.97)	8.34 (7.56, 9.19)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)	124.79 (83.23, 187.09)	5199.46 (3467.99, 7795.41)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	1188.11 (867.30, 1627.58)	4368.05 (3188.61, 5983.76)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	815.95 (632.13, 1053.23)	9066.15 (7023.69, 11702.55)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5.00 (5.00, 5.00)	389.60 (321.08, 472.73)	77.92 (64.22, 94.55)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5.00 (5.00, 5.00)	76.39 (65.91, 88.54)	15.28 (13.18, 17.71)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.96, 1.01)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	0.99 (0.98, 1.01)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	65	5.11 (4.97, 5.26)	5.05 (4.96, 5.14)	0.99 (0.95, 1.02)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	65	5.22 (4.79, 5.69)	5.27 (4.87, 5.71)	1.01 (0.89, 1.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	111	0.02 (0.02, 0.02)	30.50 (21.44, 43.40)	1270.83 (893.14, 1808.26)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	111	0.27 (0.27, 0.27)	409.36 (295.30, 567.48)	1505.01 (1085.66, 2086.34)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	111	0.09 (0.09, 0.09)	194.97 (149.44, 254.37)	2166.31 (1660.42, 2826.34)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	111	5.00 (5.00, 5.00)	109.46 (93.20, 128.56)	21.89 (18.64, 25.71)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	111	5.00 (5.00, 5.00)	27.84 (23.93, 32.38)	5.57 (4.79, 6.48)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	405	0.02 (0.02, 0.02)	744.66 (565.55, 980.50)	30872.70 (23488.85, 40577.71)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	405	0.27 (0.27, 0.27)	28480.91 (22789.35, 35593.90)	104709.21 (83784.39, 130859.93)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	405	0.09 (0.09, 0.09)	19177.21 (16106.10, 22833.93)	212880.19 (178792.37, 253467.06)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	405	5.00 (5.00, 5.00)	3960.65 (3820.47, 4105.97)	792.13 (764.09, 821.19)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	405	5.00 (5.00, 5.00)	984.47 (930.22, 1041.88)	196.89 (186.04, 208.38)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)	3272.33 (2068.84, 5175.94)	136347.22 (86201.51, 215664.02)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	98855.57 (71157.44, 137335.23)	363439.58 (261608.23, 504908.93)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	51861.14 (39504.06, 68083.57)	576234.87 (438934.05, 756484.08)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5.00 (5.00, 5.00)	4398.18 (4386.82, 4409.58)	879.64 (877.36, 881.92)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5.00 (5.00, 5.00)	1274.98 (1246.00, 1304.63)	255.00 (249.20, 260.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.02)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.28)	0.27 (0.27, 0.28)	1.00 (0.98, 1.02)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.04 (0.97, 1.11)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	65	5.11 (4.97, 5.26)	5.07 (4.93, 5.21)	0.99 (0.98, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	65	5.22 (4.79, 5.69)	5.00 (5.00, 5.00)	0.96 (0.88, 1.04)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	111	0.02 (0.02, 0.02)	487.26 (317.22, 748.47)	20302.67 (13217.38, 31186.07)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	111	0.27 (0.27, 0.27)	16697.08 (10951.84, 25456.21)	61386.31 (40264.11, 93589.01)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	111	0.09 (0.09, 0.09)	7572.41 (5551.38, 10329.23)	84137.93 (61681.96, 114769.22)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	111	5.00 (5.00, 5.00)	3119.84 (2781.29, 3499.60)	623.97 (556.26, 699.92)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	111	5.00 (5.00, 5.00)	762.56 (683.89, 850.29)	152.51 (136.78, 170.06)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	337	0.02 (0.02, 0.02)	59.21 (45.66, 76.78)	2467.16 (1902.68, 3199.11)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	0.27 (0.27, 0.27)	720.77 (587.83, 883.78)	2649.89 (2161.14, 3249.18)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	0.09 (0.09, 0.09)	402.33 (338.00, 478.91)	4470.35 (3755.56, 5321.18)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	337	5.00 (5.00, 5.00)	224.04 (198.81, 252.46)	44.81 (39.76, 50.49)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	337	5.00 (5.00, 5.00)	46.46 (41.55, 51.95)	9.29 (8.31, 10.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	119	0.02 (0.02, 0.02)	120.20 (77.64, 186.10)	5008.51 (3235.14, 7753.97)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	0.27 (0.27, 0.27)	1065.40 (713.58, 1590.69)	3902.79 (2615.12, 5824.51)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	0.09 (0.09, 0.09)	710.20 (507.15, 994.54)	7891.11 (5635.04, 11050.44)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	119	5.00 (5.00, 5.00)	391.38 (322.62, 474.79)	78.28 (64.52, 94.96)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	119	5.00 (5.00, 5.00)	78.13 (65.41, 93.32)	15.63 (13.08, 18.66)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	0.98 (0.91, 1.06)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.34 (4.80, 5.94)	5.07 (4.93, 5.22)	0.95 (0.86, 1.06)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.51 (4.97, 6.11)	5.23 (4.92, 5.55)	0.95 (0.84, 1.07)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)	20.17 (13.43, 30.30)	840.46 (559.51, 1262.48)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.28)	307.28 (203.24, 464.59)	1119.54 (740.11, 1693.48)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)	163.54 (122.72, 217.93)	1817.06 (1363.53, 2421.42)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	121	5.00 (5.00, 5.00)	95.17 (76.97, 117.67)	19.03 (15.39, 23.53)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	121	5.00 (5.00, 5.00)	24.57 (20.22, 29.85)	4.91 (4.04, 5.97)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	337	0.02 (0.02, 0.02)	1046.04 (764.11, 1431.99)	43584.99 (31838.06, 59666.04)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	337	0.27 (0.27, 0.27)	30425.03 (23631.47, 39171.61)	111856.74 (86880.39, 144013.29)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	337	0.09 (0.09, 0.09)	19667.85 (16047.10, 24105.54)	218531.61 (178301.15, 267839.36)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	337	5.00 (5.00, 5.00)	3839.39 (3676.62, 4009.37)	767.88 (735.32, 801.87)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	337	5.00 (5.00, 5.00)	980.52 (920.61, 1044.34)	196.10 (184.12, 208.87)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	119	0.02 (0.02, 0.02)	2480.77 (1372.57, 4483.72)	103365.35 (57190.35, 186821.65)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	119	0.27 (0.27, 0.27)	87192.72 (61818.93, 122981.26)	319404.47 (226521.94, 450372.35)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	119	0.09 (0.09, 0.09)	50498.11 (37815.39, 67434.42)	561090.08 (420171.00, 749271.33)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	119	5.00 (5.00, 5.00)	4398.86 (4389.76, 4407.99)	879.77 (877.95, 881.60)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	119	5.00 (5.00, 5.00)	1289.52 (1281.76, 1297.33)	257.90 (256.35, 259.47)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.91, 1.04)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (1.00, 1.02)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.34 (4.80, 5.94)	5.42 (4.94, 5.95)	1.02 (0.93, 1.11)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.51 (4.97, 6.11)	5.04 (4.96, 5.11)	0.91 (0.82, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)	331.39 (196.04, 560.21)	13808.07 (8168.26, 23341.90)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.28)	11323.25 (7351.20, 17441.53)	41254.91 (26805.19, 63493.97)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)	6308.99 (4523.19, 8799.84)	70099.86 (50257.64, 97775.99)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	121	5.00 (5.00, 5.00)	2851.13 (2536.03, 3205.37)	570.23 (507.21, 641.07)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	121	5.00 (5.00, 5.00)	664.80 (580.17, 761.78)	132.96 (116.03, 152.36)




Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
<b>Age, Underrepresented minority status</b>								
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	196	0.02 (0.02, 0.02)	41.72 (31.62, 55.05)	1727.43 (1312.71, 2273.16)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	196	0.27 (0.27, 0.27)	465.59 (367.04, 590.62)	1711.75 (1349.40, 2171.39)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	196	0.09 (0.09, 0.09)	285.52 (233.95, 348.45)	3172.39 (2599.45, 3871.61)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	196	5.00 (5.00, 5.00)	198.34 (175.01, 224.78)	39.67 (35.00, 44.96)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	196	5.00 (5.00, 5.00)	38.78 (34.40, 43.72)	7.76 (6.88, 8.74)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)	103.29 (62.37, 171.05)	4303.66 (2598.77, 7126.99)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)	892.60 (604.83, 1317.31)	3281.63 (2223.62, 4843.05)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)	616.73 (451.75, 841.97)	6852.57 (5019.44, 9355.18)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)	356.86 (280.19, 454.49)	71.37 (56.04, 90.90)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)	72.26 (60.21, 86.72)	14.45 (12.04, 17.34)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	29	5.08 (4.92, 5.25)	5.00 (5.00, 5.00)	0.98 (0.95, 1.02)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	29	5.29 (4.74, 5.91)	5.32 (4.81, 5.89)	1.01 (0.86, 1.18)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	23.20 (15.06, 35.74)	966.67 (627.48, 1489.19)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	317.58 (210.83, 478.39)	1167.59 (775.12, 1758.78)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	155.25 (111.16, 216.83)	1725.02 (1235.11, 2409.25)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	97.70 (80.25, 118.95)	19.54 (16.05, 23.79)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	25.88 (21.47, 31.21)	5.18 (4.29, 6.24)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	196	0.02 (0.02, 0.02)	551.62 (392.66, 774.92)	22839.05 (16295.35, 32010.49)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	196	0.27 (0.27, 0.27)	21562.95 (16373.01, 28398.02)	79275.56 (60194.88, 104404.47)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	196	0.09 (0.09, 0.09)	14854.74 (11983.97, 18413.22)	165052.72 (133155.23, 204591.28)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	196	5.00 (5.00, 5.00)	3973.63 (3804.75, 4150.00)	794.73 (760.95, 830.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	196	5.00 (5.00, 5.00)	971.08 (905.90, 1040.95)	194.22 (181.18, 208.19)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)	2503.25 (1416.23, 4424.59)	104302.10 (59009.77, 184358.07)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)	79697.87 (52812.10, 120270.73)	293006.86 (194162.13, 442171.80)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)	41307.72 (29340.44, 58156.16)	458974.63 (326004.93, 646179.53)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)	4396.56 (4382.03, 4411.14)	879.31 (876.41, 882.23)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)	1269.44 (1232.66, 1307.31)	253.89 (246.53, 261.46)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.97, 1.04)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.05 (0.96, 1.14)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	29	5.08 (4.92, 5.25)	5.09 (4.92, 5.27)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	29	5.29 (4.74, 5.91)	5.00 (5.00, 5.00)	0.95 (0.85, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	369.49 (217.38, 628.04)	15395.33 (9057.31, 26168.49)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	12276.41 (7224.62, 20860.63)	45133.85 (26561.12, 76693.48)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	5186.99 (3543.10, 7593.57)	57633.18 (39367.83, 84373.05)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	2938.35 (2536.26, 3404.18)	587.67 (507.25, 680.84)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	710.85 (620.31, 814.60)	142.17 (124.06, 162.92)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	166	0.02 (0.02, 0.02)	47.98 (34.84, 66.08)	1999.20 (1451.65, 2753.28)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	166	0.27 (0.27, 0.27)	557.44 (434.82, 714.65)	2049.43 (1598.61, 2627.38)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	166	0.09 (0.09, 0.09)	300.21 (243.29, 370.43)	3335.64 (2703.26, 4115.94)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	166	5.00 (5.00, 5.00)	206.48 (178.23, 239.20)	41.30 (35.65, 47.84)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	166	5.00 (5.00, 5.00)	43.63 (38.01, 50.09)	8.73 (7.60, 10.02)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	105.74 (62.04, 180.22)	4405.82 (2584.98, 7509.25)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.28)	823.68 (506.74, 1338.84)	3014.54 (1855.60, 4897.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	551.56 (366.20, 830.75)	6128.50 (4068.94, 9230.54)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	365.49 (289.02, 462.21)	73.10 (57.80, 92.44)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	75.73 (61.01, 94.00)	15.15 (12.20, 18.80)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.03 (0.02, 0.03)	0.02 (0.02, 0.02)	0.96 (0.87, 1.04)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.36 (4.68, 6.14)	5.00 (5.00, 5.00)	0.93 (0.81, 1.07)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.68 (4.97, 6.49)	5.19 (4.82, 5.59)	0.91 (0.78, 1.07)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	15.77 (9.58, 25.95)	656.97 (399.24, 1081.06)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	66	0.28 (0.27, 0.28)	249.66 (149.87, 415.87)	907.44 (544.39, 1512.60)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	123.50 (87.19, 174.93)	1372.24 (968.79, 1943.71)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	85.47 (65.77, 111.08)	17.09 (13.15, 22.22)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	22.64 (17.81, 28.78)	4.53 (3.56, 5.76)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	166	0.02 (0.02, 0.02)	823.61 (558.43, 1214.72)	34317.28 (23268.10, 50613.31)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	166	0.27 (0.27, 0.27)	23327.65 (17077.22, 31865.80)	85763.43 (62783.89, 117153.69)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	166	0.09 (0.09, 0.09)	14736.44 (11484.90, 18908.53)	163738.18 (127609.99, 210094.77)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	166	5.00 (5.00, 5.00)	3837.72 (3644.25, 4041.46)	767.54 (728.85, 808.29)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	166	5.00 (5.00, 5.00)	955.49 (883.55, 1033.29)	191.10 (176.71, 206.66)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	2059.26 (994.08, 4265.82)	85802.65 (41419.99, 177742.54)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.28)	72476.66 (47609.59, 110332.09)	265254.45 (174306.97, 403655.25)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	43571.89 (30552.22, 62139.83)	484132.13 (339469.11, 690442.57)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.03 (0.02, 0.03)	0.02 (0.02, 0.02)	0.96 (0.87, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.36 (4.68, 6.14)	5.47 (4.85, 6.17)	1.02 (0.91, 1.14)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.68 (4.97, 6.49)	5.00 (5.00, 5.00)	0.88 (0.77, 1.01)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	237.24 (124.47, 452.19)	9885.08 (5186.22, 18841.24)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	66	0.28 (0.27, 0.28)	8739.81 (5138.08, 14866.30)	31766.97 (18694.25, 53981.34)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	4700.63 (3140.44, 7035.93)	52229.20 (34893.77, 78176.98)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	2670.97 (2308.61, 3090.20)	534.19 (461.72, 618.04)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	638.54 (539.77, 755.39)	127.71 (107.95, 151.08)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	209	0.02 (0.02, 0.02)	142.50 (111.73, 181.74)	5937.49 (4655.51, 7572.48)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	0.27 (0.27, 0.27)	1728.91 (1416.31, 2110.50)	6356.27 (5207.01, 7759.20)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	0.09 (0.09, 0.09)	1006.04 (843.06, 1200.52)	11128.22 (9328.13, 13275.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	209	5.00 (5.00, 5.00)	297.63 (262.49, 337.47)	59.53 (52.50, 67.49)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	209	5.00 (5.00, 5.00)	54.78 (49.04, 61.20)	10.96 (9.81, 12.24)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	245.54 (164.92, 365.56)	10230.70 (6871.69, 15231.66)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	3306.86 (2456.37, 4451.82)	12157.59 (9030.79, 16367.00)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)	2222.37 (1678.90, 2941.77)	24692.99 (18654.43, 32686.28)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	533.41 (447.78, 635.41)	106.68 (89.56, 127.08)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)	93.20 (78.76, 110.29)	18.64 (15.75, 22.06)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.93, 1.02)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.28 (0.26, 0.30)	0.27 (0.27, 0.27)	0.97 (0.91, 1.03)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.21 (4.92, 5.52)	5.20 (4.81, 5.63)	1.00 (0.90, 1.10)
Age $\geq$ 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)	5.10 (4.91, 5.30)	1.02 (0.98, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	51	0.02 (0.02, 0.02)	76.86 (48.35, 122.19)	3202.46 (2014.43, 5091.17)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	51	0.27 (0.27, 0.27)	965.09 (707.47, 1316.51)	3548.12 (2601.01, 4840.10)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	51	0.09 (0.09, 0.09)	420.90 (332.51, 532.78)	4676.65 (3694.60, 5919.75)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)	160.70 (129.30, 199.73)	32.14 (25.86, 39.95)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)	35.58 (29.52, 42.90)	7.12 (5.90, 8.58)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	209	0.02 (0.02, 0.02)	2308.03 (1759.79, 3027.06)	96167.81 (73324.67, 126127.35)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	209	0.27 (0.27, 0.27)	81305.19 (65362.65, 101136.27)	298916.14 (240303.85, 371824.51)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	209	0.09 (0.09, 0.09)	50226.61 (41911.60, 60191.27)	555579.69 (463765.92, 665570.23)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	209	5.00 (5.00, 5.00)	3912.11 (3712.74, 4122.17)	782.42 (742.55, 824.43)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	209	5.00 (5.00, 5.00)	1036.61 (969.60, 1108.25)	207.32 (193.92, 221.65)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	8537.62 (5399.20, 13500.34)	355734.28 (224966.53, 562514.26)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	213733.98 (164102.55, 278376.03)	785786.69 (603318.18, 1023441.27)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)	117092.61 (100398.77, 136562.23)	1301029.02 (1115541.90, 1517358.06)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.93, 1.02)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.28 (0.26, 0.30)	0.28 (0.27, 0.29)	0.99 (0.92, 1.07)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.21 (4.92, 5.52)	5.00 (5.00, 5.00)	0.96 (0.91, 1.02)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	51	0.02 (0.02, 0.02)	1240.86 (730.63, 2107.41)	51702.69 (30443.10, 87808.67)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	51	0.27 (0.27, 0.27)	47194.06 (31924.84, 69766.35)	173507.58 (117370.73, 256493.93)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	51	0.09 (0.09, 0.09)	27187.35 (19327.74, 38243.05)	302081.63 (214752.71, 424922.75)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)	3820.05 (3587.39, 4067.80)	764.01 (717.48, 813.56)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)	966.74 (862.78, 1083.23)	193.35 (172.56, 216.65)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	171	0.02 (0.02, 0.02)	127.70 (95.38, 170.98)	5321.00 (3974.32, 7124.01)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	0.27 (0.27, 0.27)	1843.38 (1438.70, 2361.89)	6777.13 (5289.33, 8683.43)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	0.09 (0.09, 0.09)	1172.98 (947.44, 1452.22)	13033.15 (10527.07, 16135.83)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	171	5.00 (5.00, 5.00)	301.90 (263.07, 346.45)	60.38 (52.61, 69.29)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	171	5.00 (5.00, 5.00)	58.44 (51.62, 66.17)	11.69 (10.32, 13.23)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	61	0.02 (0.02, 0.02)	199.80 (124.50, 320.63)	8324.99 (5187.65, 13359.68)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	0.27 (0.27, 0.27)	2954.11 (1911.61, 4565.12)	10860.69 (7028.00, 16783.53)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	0.09 (0.09, 0.09)	1934.06 (1397.99, 2675.69)	21489.58 (15533.26, 29729.88)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)	513.27 (409.68, 643.06)	102.65 (81.94, 128.61)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5.00 (5.00, 5.00)	88.39 (71.66, 109.01)	17.68 (14.33, 21.80)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.02 (0.02, 0.02)	0.03 (0.02, 0.03)	1.08 (0.97, 1.21)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.25 (4.78, 5.77)	5.32 (4.71, 6.00)	1.01 (0.99, 1.04)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)	5.34 (4.88, 5.83)	1.07 (0.98, 1.17)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)	51.56 (33.71, 78.88)	2148.51 (1404.45, 3286.77)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)	677.97 (457.85, 1003.93)	2492.55 (1683.27, 3690.91)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)	476.71 (350.51, 648.35)	5296.79 (3894.54, 7203.92)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	55	5.00 (5.00, 5.00)	143.32 (118.11, 173.90)	28.66 (23.62, 34.78)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	55	5.00 (5.00, 5.00)	33.56 (27.62, 40.77)	6.71 (5.52, 8.15)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	171	0.02 (0.02, 0.02)	2505.91 (1801.29, 3486.15)	104412.83 (75053.78, 145256.36)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	0.27 (0.27, 0.27)	80316.62 (61529.72, 104839.74)	295281.70 (226212.19, 385440.23)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	0.09 (0.09, 0.09)	56479.52 (45561.67, 70013.59)	627550.20 (506240.74, 777928.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	171	5.00 (5.00, 5.00)	3845.51 (3584.99, 4124.95)	769.10 (717.00, 824.99)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	171	5.00 (5.00, 5.00)	1077.72 (1010.35, 1149.59)	215.54 (202.07, 229.92)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	61	0.02 (0.02, 0.02)	5189.23 (3093.99, 8703.35)	216217.72 (128916.21, 362639.44)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	0.27 (0.27, 0.27)	181405.13 (130182.84, 252781.57)	666930.64 (478613.38, 929344.02)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	0.09 (0.09, 0.09)	90612.57 (70108.72, 117112.92)	1006806.30 (778985.82, 1301254.64)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)	4378.56 (4334.07, 4423.50)	875.71 (866.81, 884.70)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5.00 (5.00, 5.00)	1268.02 (1230.99, 1306.17)	253.60 (246.20, 261.23)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	1.03 (0.97, 1.10)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.02 (0.98, 1.07)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.25 (4.78, 5.77)	5.27 (4.91, 5.65)	1.00 (0.89, 1.13)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)	5.17 (4.85, 5.51)	1.03 (0.97, 1.10)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)	1184.28 (725.51, 1933.14)	49344.88 (30229.62, 80547.39)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)	30376.55 (19660.22, 46934.12)	111678.50 (72280.20, 172551.93)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)	19362.40 (13429.80, 27915.71)	215137.74 (149219.99, 310174.58)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	55	5.00 (5.00, 5.00)	3656.25 (3380.78, 3954.16)	731.25 (676.16, 790.83)
Age $\geq$ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	55	5.00 (5.00, 5.00)	775.16 (678.37, 885.76)	155.03 (135.67, 177.15)

Table 7a. The ratios of GMTs/GMCs between groups by Age

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Age</b>							
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (0.99, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.98 (0.94, 1.03)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.03)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.18 (4.94, 5.44)	5.20 (4.86, 5.56)	1.00 (0.92, 1.08)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.42 (5.02, 5.84)	0.92 (0.86, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.28)	0.99 (0.99, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	135.22 (112.92, 161.93)	42.12 (34.51, 51.42)	3.21 (2.45, 4.20)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	1681.67 (1444.09, 1958.34)	506.41 (432.08, 593.53)	3.32 (2.67, 4.14)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	1034.69 (905.25, 1182.64)	297.42 (260.00, 340.24)	3.48 (2.88, 4.21)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	300.67 (274.90, 328.85)	195.28 (178.46, 213.69)	1.54 (1.36, 1.75)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	56.40 (52.20, 60.94)	40.83 (37.60, 44.34)	1.38 (1.23, 1.55)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	215.14 (157.35, 294.15)	97.74 (69.73, 137.01)	2.20 (1.39, 3.49)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	3078.35 (2381.76, 3978.65)	751.13 (555.65, 1015.38)	4.10 (2.76, 6.09)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1989.81 (1606.86, 2464.03)	506.46 (386.68, 663.35)	3.93 (2.78, 5.54)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	519.49 (449.75, 600.04)	352.52 (303.27, 409.77)	1.47 (1.20, 1.82)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	90.63 (79.17, 103.75)	73.22 (63.73, 84.14)	1.24 (1.02, 1.50)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	1.04 (0.98, 1.10)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.21 (4.90, 5.55)	5.11 (4.89, 5.35)	1.02 (0.94, 1.10)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.19 (4.97, 5.42)	5.20 (4.95, 5.46)	1.00 (0.93, 1.07)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	63.53 (47.73, 84.55)	17.67 (12.92, 24.18)	3.59 (2.35, 5.49)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	816.01 (640.86, 1039.03)	230.33 (171.67, 309.04)	3.54 (2.42, 5.18)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	466.50 (387.65, 561.39)	117.76 (93.32, 148.59)	3.96 (2.94, 5.33)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	149.29 (130.52, 170.77)	85.93 (73.97, 99.82)	1.74 (1.42, 2.12)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	35.02 (30.81, 39.81)	22.72 (19.77, 26.10)	1.54 (1.28, 1.86)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	2265.90 (1840.03, 2790.34)	679.74 (540.11, 855.46)	3.33 (2.44, 4.55)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	77977.39 (65963.24, 92179.73)	21981.52 (18138.77, 26638.36)	3.55 (2.75, 4.58)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	50792.16 (44281.28, 58260.36)	14740.85 (12625.30, 17210.89)	3.45 (2.80, 4.24)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	3788.56 (3623.56, 3961.06)	3890.10 (3768.66, 4015.46)	0.97 (0.92, 1.03)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1039.78 (994.45, 1087.18)	950.73 (905.07, 998.69)	1.09 (1.02, 1.17)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6188.40 (4440.93, 8623.49)	2030.31 (1316.69, 3130.69)	3.05 (1.77, 5.26)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	193950.66 (157822.35, 238349.39)	73759.13 (56470.30, 96341.06)	2.63 (1.88, 3.68)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	102895.16 (88557.76, 119553.76)	43080.81 (33568.40, 55288.80)	2.39 (1.79, 3.20)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	4391.29 (4368.90, 4413.79)	4363.56 (4297.51, 4430.63)	1.01 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1278.15 (1258.33, 1298.29)	1281.61 (1267.10, 1296.29)	1.00 (0.98, 1.02)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	1.01 (0.98, 1.04)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (0.96, 1.03)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.12 (4.95, 5.30)	5.25 (4.95, 5.58)	0.98 (0.91, 1.05)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.08 (4.93, 5.23)	5.00 (5.00, 5.00)	1.02 (0.99, 1.05)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	1288.66 (915.52, 1813.87)	226.08 (153.33, 333.35)	5.70 (3.40, 9.56)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	38082.49 (28751.10, 50442.46)	8551.22 (6162.12, 11866.59)	4.45 (2.89, 6.86)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	22900.37 (17987.61, 29154.91)	4036.58 (3112.40, 5235.19)	5.67 (3.98, 8.09)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3703.20 (3519.25, 3896.77)	2715.40 (2449.49, 3010.18)	1.36 (1.22, 1.53)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	865.00 (796.62, 939.26)	660.57 (594.65, 733.78)	1.31 (1.15, 1.50)

Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Risk for Severe Covid-19</b>							
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.02)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.98 (0.93, 1.04)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.02)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.19 (4.96, 5.44)	5.20 (4.84, 5.59)	1.00 (0.92, 1.09)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.45 (5.02, 5.92)	0.92 (0.84, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	1.02 (0.98, 1.05)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	59.16 (48.92, 71.53)	52.17 (42.20, 64.51)	1.13 (0.85, 1.51)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	706.64 (593.89, 840.81)	635.07 (537.48, 750.37)	1.11 (0.87, 1.42)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	427.84 (370.56, 493.98)	373.75 (324.02, 431.11)	1.14 (0.93, 1.40)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	208.58 (189.63, 229.42)	216.27 (196.67, 237.84)	0.96 (0.84, 1.10)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	42.83 (39.33, 46.64)	44.10 (40.44, 48.10)	0.97 (0.86, 1.10)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	115.77 (83.76, 160.00)	113.58 (79.89, 161.47)	1.02 (0.63, 1.64)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1156.08 (879.41, 1519.79)	943.63 (687.58, 1295.04)	1.23 (0.80, 1.87)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	727.15 (585.27, 903.44)	643.23 (483.57, 855.60)	1.13 (0.79, 1.62)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	377.53 (325.30, 438.14)	381.26 (325.94, 445.96)	0.99 (0.80, 1.23)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	77.79 (67.85, 89.18)	75.91 (65.68, 87.72)	1.02 (0.84, 1.25)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.98, 1.03)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.12 (4.89, 5.36)	5.15 (4.90, 5.41)	0.99 (0.93, 1.06)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.18 (4.98, 5.38)	5.21 (4.94, 5.49)	0.99 (0.93, 1.06)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	21.13 (15.29, 29.20)	23.53 (17.04, 32.48)	0.90 (0.57, 1.42)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	257.09 (197.28, 335.03)	311.94 (230.08, 422.94)	0.82 (0.55, 1.24)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	160.84 (127.18, 203.40)	154.49 (121.47, 196.50)	1.04 (0.74, 1.46)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	89.95 (77.53, 104.37)	98.16 (84.13, 114.55)	0.92 (0.74, 1.14)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	23.87 (20.36, 27.98)	25.11 (21.81, 28.91)	0.95 (0.77, 1.18)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	906.59 (720.34, 1141.00)	868.32 (681.00, 1107.17)	1.04 (0.75, 1.46)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	28328.44 (23519.92, 34120.02)	28979.32 (23635.90, 35530.74)	0.98 (0.74, 1.29)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	19610.61 (16434.08, 23401.12)	19033.81 (16203.87, 22358.00)	1.03 (0.81, 1.31)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	3523.35 (3346.50, 3709.55)	4009.36 (3886.63, 4135.95)	0.88 (0.83, 0.93)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	926.51 (882.15, 973.09)	985.90 (936.10, 1038.36)	0.94 (0.88, 1.01)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2526.99 (1768.29, 3611.23)	2525.90 (1606.20, 3972.20)	1.00 (0.56, 1.78)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	91621.85 (70437.56, 119177.38)	88394.64 (67041.37, 116549.11)	1.04 (0.71, 1.52)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	54061.61 (43165.62, 67707.99)	50206.27 (38782.90, 64994.34)	1.08 (0.76, 1.52)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	4393.54 (4375.15, 4412.02)	4361.32 (4291.66, 4432.12)	1.01 (0.99, 1.02)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1271.70 (1248.53, 1295.30)	1283.84 (1269.43, 1298.41)	0.99 (0.97, 1.01)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	1.02 (0.99, 1.05)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.02)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	0.98 (0.95, 1.01)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.13 (4.95, 5.32)	5.26 (4.93, 5.61)	0.98 (0.91, 1.05)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.06 (4.94, 5.18)	5.00 (5.00, 5.00)	1.01 (0.99, 1.04)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	307.20 (207.85, 454.04)	327.29 (219.32, 488.42)	0.94 (0.53, 1.65)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	10327.84 (7549.43, 14128.78)	12016.26 (8561.45, 16865.18)	0.86 (0.54, 1.37)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	6014.07 (4448.47, 8130.66)	5674.85 (4338.98, 7422.01)	1.06 (0.70, 1.59)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	2718.16 (2455.97, 3008.34)	2948.35 (2657.33, 3271.25)	0.92 (0.80, 1.07)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	682.53 (615.52, 756.84)	702.69 (631.26, 782.22)	0.97 (0.84, 1.13)

Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Age &lt; 65, Risk for Severe Covid-19</b>							
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	0.99 (0.93, 1.06)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.12 (4.89, 5.37)	5.23 (4.79, 5.70)	0.98 (0.89, 1.08)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.55 (5.03, 6.12)	0.90 (0.82, 0.99)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	1.03 (0.98, 1.08)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	36.39 (28.23, 46.91)	43.84 (34.34, 55.98)	0.83 (0.58, 1.18)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	437.81 (344.38, 556.57)	526.96 (435.27, 637.96)	0.83 (0.61, 1.13)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	264.47 (219.21, 319.06)	307.12 (260.83, 361.62)	0.86 (0.67, 1.10)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	173.73 (153.25, 196.96)	201.62 (180.72, 224.94)	0.86 (0.73, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	37.60 (33.49, 42.22)	41.76 (37.79, 46.15)	0.90 (0.77, 1.05)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	99.72 (64.74, 153.58)	97.28 (64.91, 145.81)	1.03 (0.57, 1.85)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	777.66 (541.96, 1115.87)	745.01 (518.42, 1070.66)	1.04 (0.63, 1.74)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	468.31 (357.12, 614.13)	515.90 (371.91, 715.64)	0.91 (0.59, 1.39)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	340.95 (281.03, 413.65)	355.30 (296.69, 425.49)	0.96 (0.74, 1.25)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	71.82 (60.57, 85.16)	73.56 (62.25, 86.92)	0.98 (0.77, 1.24)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.15 (4.86, 5.46)	0.97 (0.92, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.09 (4.92, 5.26)	5.23 (4.91, 5.58)	0.97 (0.90, 1.04)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	12.24 (8.33, 17.97)	19.33 (13.24, 28.22)	0.63 (0.37, 1.09)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	149.77 (110.72, 202.59)	255.84 (178.88, 365.91)	0.59 (0.37, 0.94)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	86.71 (66.41, 113.22)	126.89 (95.74, 168.17)	0.68 (0.46, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	69.41 (58.60, 82.21)	90.52 (75.49, 108.56)	0.77 (0.60, 0.98)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	19.25 (15.84, 23.39)	23.66 (20.04, 27.93)	0.81 (0.63, 1.05)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	560.63 (409.64, 767.29)	716.48 (541.55, 947.90)	0.78 (0.51, 1.19)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	17472.27 (13596.10, 22453.51)	23404.58 (18505.98, 29599.85)	0.75 (0.53, 1.05)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	12580.73 (9832.00, 16097.92)	15393.07 (12788.38, 18528.27)	0.82 (0.60, 1.11)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	3575.02 (3338.57, 3828.21)	3980.92 (3841.01, 4125.93)	0.90 (0.83, 0.97)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	914.61 (858.56, 974.31)	960.84 (904.68, 1020.49)	0.95 (0.87, 1.04)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1902.80 (1205.14, 3004.33)	2061.58 (1220.54, 3482.17)	0.92 (0.46, 1.85)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	67610.00 (47829.52, 95570.95)	75287.86 (54682.18, 103658.30)	0.90 (0.56, 1.44)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	39349.13 (29030.17, 53336.03)	44010.56 (32609.52, 59397.66)	0.89 (0.58, 1.37)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	4404.00 (4404.00, 4404.00)	4354.09 (4272.80, 4436.92)	1.01 (0.99, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1275.97 (1248.80, 1303.74)	1282.95 (1266.22, 1299.90)	0.99 (0.97, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	1.02 (0.98, 1.05)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	0.98 (0.94, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.13 (4.88, 5.39)	5.29 (4.90, 5.71)	0.97 (0.88, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	142.10 (91.48, 220.73)	253.21 (158.15, 405.39)	0.56 (0.29, 1.07)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	4948.71 (3495.42, 7006.23)	9772.30 (6562.44, 14552.17)	0.51 (0.30, 0.86)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	2931.01 (2088.69, 4113.03)	4364.50 (3193.16, 5965.53)	0.67 (0.42, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	2273.93 (1978.20, 2613.86)	2835.57 (2506.26, 3208.15)	0.80 (0.67, 0.97)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	611.05 (532.94, 700.61)	673.25 (593.30, 763.96)	0.91 (0.75, 1.09)

MOCK

Table 7d. The ratios of GMTs/GMCs between groups by Age  $\geq 65$ , Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Age <math>\geq 65</math>, Risk for Severe Covid-19</b>							
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.98 (0.95, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	1.02 (0.98, 1.06)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.30 (4.84, 5.81)	5.06 (4.94, 5.19)	1.05 (0.95, 1.15)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	126.00 (96.14, 165.12)	145.49 (114.83, 184.34)	0.87 (0.60, 1.24)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	1488.25 (1185.88, 1867.71)	1908.52 (1561.57, 2332.56)	0.78 (0.58, 1.06)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	904.30 (734.70, 1113.04)	1189.57 (1009.03, 1402.40)	0.76 (0.58, 0.99)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	277.19 (240.49, 319.49)	327.08 (293.94, 363.95)	0.85 (0.71, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	52.45 (46.52, 59.13)	60.81 (55.26, 66.92)	0.86 (0.74, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	151.49 (95.56, 240.15)	281.53 (186.82, 424.24)	0.54 (0.29, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	2362.04 (1646.89, 3387.74)	3771.45 (2654.40, 5358.61)	0.63 (0.38, 1.04)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1606.84 (1190.41, 2168.95)	2344.17 (1749.97, 3140.14)	0.69 (0.45, 1.04)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	453.62 (362.16, 568.16)	576.39 (480.42, 691.54)	0.79 (0.59, 1.05)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	89.81 (71.63, 112.61)	91.26 (77.48, 107.50)	0.98 (0.74, 1.30)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.03 (0.02, 0.03)	0.98 (0.87, 1.09)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.30 (4.74, 5.93)	5.13 (4.88, 5.39)	1.03 (0.91, 1.17)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.31 (4.90, 5.77)	5.06 (4.94, 5.19)	1.05 (0.96, 1.14)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	63.50 (38.43, 104.92)	63.54 (45.04, 89.64)	1.00 (0.54, 1.84)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	763.61 (506.19, 1151.95)	849.85 (631.19, 1144.26)	0.90 (0.54, 1.49)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	558.42 (417.87, 746.23)	417.85 (329.69, 529.60)	1.34 (0.92, 1.94)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	151.67 (118.19, 194.63)	147.86 (126.79, 172.43)	1.03 (0.77, 1.38)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	36.80 (28.80, 47.03)	33.98 (29.49, 39.14)	1.08 (0.82, 1.44)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	1914.94 (1394.03, 2630.48)	2697.29 (2068.92, 3516.52)	0.71 (0.47, 1.07)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	60081.37 (46341.27, 77895.40)	102147.24 (83423.06, 125074.05)	0.59 (0.42, 0.82)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	39122.16 (31191.96, 49068.51)	66558.70 (57689.44, 76791.54)	0.59 (0.45, 0.77)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	3444.45 (3188.14, 3721.38)	4181.18 (4025.45, 4342.93)	0.82 (0.76, 0.90)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	945.34 (874.68, 1021.70)	1147.54 (1104.96, 1191.76)	0.82 (0.76, 0.90)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	4213.38 (2421.25, 7331.98)	8309.47 (5616.48, 12293.69)	0.51 (0.26, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	158431.51 (109869.90, 228456.95)	226487.29 (180806.57, 283709.21)	0.70 (0.46, 1.08)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	95825.62 (72784.81, 126160.25)	108666.46 (92603.25, 127516.04)	0.88 (0.64, 1.21)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	4374.76 (4323.89, 4426.24)	4404.00 (4404.00, 4404.00)	0.99 (0.98, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1264.03 (1221.93, 1307.59)	1289.09 (1277.63, 1300.64)	0.98 (0.95, 1.02)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	1.03 (0.97, 1.09)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.04)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	0.98 (0.94, 1.02)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.13 (4.88, 5.41)	5.11 (4.90, 5.34)	1.00 (0.94, 1.07)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.15 (4.86, 5.47)	5.00 (5.00, 5.00)	1.03 (0.97, 1.09)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	1452.28 (771.39, 2734.19)	1197.71 (810.06, 1770.88)	1.21 (0.58, 2.55)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	45474.93 (28432.89, 72731.60)	34162.73 (24106.42, 48414.17)	1.33 (0.74, 2.39)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	25591.02 (16600.20, 39451.37)	21394.59 (16094.94, 28439.27)	1.20 (0.71, 2.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3894.22 (3653.98, 4150.25)	3590.91 (3343.07, 3857.11)	1.08 (0.99, 1.19)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	852.95 (748.49, 971.99)	872.47 (784.15, 970.73)	0.98 (0.83, 1.16)

MOCK

Table 7e. The ratios of GMTs/GMCs between groups by Sex

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Sex</b>							
Male vs Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.00 (1.00, 1.01)
Male vs Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.98 (0.93, 1.04)
Male vs Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.02)
Male vs Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.15 (4.98, 5.33)	5.23 (4.79, 5.70)	0.99 (0.90, 1.08)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.40 (4.87, 5.98)	5.26 (4.92, 5.63)	1.03 (0.91, 1.16)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.02)
Male vs Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	57.82 (45.60, 73.33)	51.22 (41.00, 63.99)	1.13 (0.81, 1.57)
Male vs Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	681.55 (555.77, 835.80)	633.48 (534.99, 750.10)	1.08 (0.82, 1.41)
Male vs Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	420.65 (359.92, 491.63)	364.25 (311.46, 426.00)	1.15 (0.92, 1.45)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	217.28 (194.80, 242.36)	211.66 (191.57, 233.87)	1.03 (0.88, 1.19)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	47.25 (42.60, 52.41)	41.18 (37.76, 44.92)	1.15 (1.00, 1.31)
Male vs Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	103.53 (70.69, 151.62)	123.64 (82.97, 184.24)	0.84 (0.48, 1.46)
Male vs Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	936.15 (684.43, 1280.45)	1037.69 (709.82, 1517.01)	0.90 (0.55, 1.48)
Male vs Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	673.42 (504.28, 899.30)	653.26 (466.86, 914.08)	1.03 (0.66, 1.62)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	382.63 (318.90, 459.09)	378.50 (318.95, 449.17)	1.01 (0.79, 1.30)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	74.57 (62.54, 88.93)	77.85 (67.00, 90.46)	0.96 (0.76, 1.21)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.97, 1.02)
Male vs Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.08 (4.92, 5.25)	5.18 (4.88, 5.49)	0.98 (0.92, 1.05)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.47 (5.00, 5.98)	5.01 (4.99, 5.04)	1.09 (1.00, 1.19)
Male vs Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	23.85 (17.23, 33.02)	22.03 (14.63, 33.16)	1.08 (0.64, 1.83)
Male vs Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	332.38 (240.94, 458.51)	266.03 (184.99, 382.56)	1.25 (0.76, 2.04)
Male vs Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	166.44 (126.58, 218.86)	145.66 (110.56, 191.88)	1.14 (0.77, 1.70)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	99.48 (85.42, 115.85)	92.84 (76.24, 113.04)	1.07 (0.83, 1.38)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	26.51 (23.14, 30.38)	23.15 (19.32, 27.74)	1.15 (0.91, 1.44)
Male vs Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	964.29 (726.31, 1280.25)	817.13 (636.69, 1048.71)	1.18 (0.81, 1.72)
Male vs Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	29949.43 (23839.38, 37625.49)	27926.21 (22536.53, 34604.84)	1.07 (0.78, 1.47)
Male vs Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	21361.84 (17840.87, 25577.69)	17648.07 (14802.31, 21040.93)	1.21 (0.94, 1.56)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	3855.51 (3697.30, 4020.48)	3878.20 (3746.51, 4014.51)	0.99 (0.94, 1.05)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	977.55 (919.07, 1039.74)	962.46 (913.57, 1013.97)	1.02 (0.94, 1.10)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2220.59 (1292.35, 3815.54)	2810.33 (1757.86, 4492.97)	0.79 (0.39, 1.62)
Male vs Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	88480.82 (65501.35, 119522.04)	89713.68 (65367.74, 123127.17)	0.99 (0.64, 1.53)
Male vs Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	58390.04 (43171.97, 78972.47)	45764.31 (34756.65, 60258.18)	1.28 (0.85, 1.92)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	4399.17 (4390.79, 4407.57)	4344.18 (4248.84, 4441.66)	1.01 (0.99, 1.04)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1283.96 (1264.40, 1303.82)	1278.44 (1263.07, 1294.00)	1.00 (0.98, 1.02)
Male vs Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.02 (0.99, 1.04)
Male vs Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.00 (1.00, 1.01)
Male vs Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.10)	0.09 (0.09, 0.09)	1.02 (0.97, 1.08)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.31 (4.87, 5.79)	5.16 (4.90, 5.43)	1.03 (0.93, 1.14)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.04 (4.96, 5.13)	5.00 (5.00, 5.00)	1.01 (0.99, 1.03)
Male vs Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	391.29 (254.31, 602.07)	263.24 (162.81, 425.63)	1.49 (0.77, 2.87)
Male vs Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	12275.65 (8418.55, 17899.95)	10928.07 (7403.08, 16131.49)	1.12 (0.65, 1.94)
Male vs Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	6758.41 (5128.32, 8906.64)	4857.03 (3467.68, 6803.03)	1.39 (0.89, 2.17)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	2696.77 (2381.21, 3054.15)	3114.10 (2797.61, 3466.39)	0.87 (0.73, 1.02)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	703.13 (622.65, 794.01)	692.52 (613.67, 781.50)	1.02 (0.85, 1.21)

Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Hispanic or Latino ethnicity</b>							
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	1.01 (0.94, 1.09)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	1.03 (0.97, 1.08)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.24 (4.78, 5.74)	5.21 (4.89, 5.55)	1.00 (0.90, 1.12)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.39 (5.02, 5.78)	0.93 (0.87, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.28)	0.99 (0.98, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	63.21 (44.51, 89.77)	54.20 (44.68, 65.75)	1.17 (0.78, 1.74)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	539.45 (386.73, 752.46)	686.21 (589.76, 798.44)	0.79 (0.54, 1.13)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	366.44 (273.19, 491.52)	384.98 (337.53, 439.10)	0.95 (0.69, 1.32)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	248.23 (216.65, 284.42)	214.68 (196.65, 234.35)	1.16 (0.98, 1.36)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	41.62 (34.78, 49.81)	44.41 (41.04, 48.06)	0.94 (0.77, 1.14)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	136.74 (59.78, 312.77)	112.19 (81.06, 155.28)	1.22 (0.50, 2.97)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1270.84 (806.27, 2003.08)	1021.87 (764.35, 1366.13)	1.24 (0.72, 2.14)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1040.69 (625.19, 1732.34)	695.86 (541.96, 893.47)	1.50 (0.85, 2.64)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	393.53 (273.84, 565.53)	382.63 (331.07, 442.23)	1.03 (0.70, 1.52)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	78.34 (65.78, 93.31)	77.42 (67.34, 89.00)	1.01 (0.81, 1.27)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.17 (4.94, 5.41)	0.97 (0.92, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.95 (4.60, 7.69)	5.14 (4.96, 5.33)	1.16 (0.89, 1.50)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	23.92 (10.32, 55.44)	22.96 (16.96, 31.07)	1.04 (0.43, 2.54)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	496.64 (276.37, 892.46)	318.94 (239.85, 424.12)	1.56 (0.81, 2.99)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	287.88 (179.44, 461.85)	165.46 (133.44, 205.17)	1.74 (1.03, 2.93)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	114.14 (88.90, 146.56)	97.56 (83.83, 113.53)	1.17 (0.87, 1.57)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	30.69 (24.78, 38.02)	24.68 (21.63, 28.16)	1.24 (0.97, 1.60)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	915.33 (578.36, 1448.63)	880.11 (703.00, 1101.85)	1.04 (0.62, 1.74)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	27907.77 (17886.70, 43543.17)	28854.69 (24011.94, 34674.13)	0.97 (0.60, 1.57)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	20620.30 (14504.89, 29314.04)	19042.41 (16470.50, 22015.94)	1.08 (0.74, 1.59)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	4147.78 (4002.17, 4298.70)	3831.04 (3707.28, 3958.92)	1.08 (1.03, 1.14)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1034.99 (950.37, 1127.13)	957.59 (913.02, 1004.33)	1.08 (0.98, 1.19)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	4382.06 (2340.31, 8205.09)	2473.81 (1618.17, 3781.88)	1.77 (0.83, 3.78)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	119917.54 (68592.88, 209645.90)	89206.01 (69172.12, 115042.19)	1.34 (0.73, 2.49)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	52252.53 (36597.87, 74603.43)	51544.02 (40654.47, 65350.41)	1.01 (0.66, 1.56)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	4404.00 (4404.00, 4404.00)	4365.45 (4296.93, 4435.06)	1.01 (0.99, 1.02)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1276.07 (1239.72, 1313.49)	1290.15 (1284.90, 1295.42)	0.99 (0.96, 1.02)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.10 (0.08, 0.13)	0.09 (0.09, 0.09)	1.13 (0.90, 1.42)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.25 (4.77, 5.79)	5.24 (4.96, 5.54)	1.00 (0.90, 1.12)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.02 (4.98, 5.07)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	581.71 (187.88, 1801.05)	336.43 (234.77, 482.13)	1.73 (0.53, 5.67)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	16833.03 (9066.10, 31253.89)	12857.18 (9400.17, 17585.55)	1.31 (0.65, 2.63)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	12188.18 (8469.64, 17539.33)	6068.65 (4737.21, 7774.30)	2.01 (1.29, 3.13)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3075.77 (2557.94, 3698.44)	2930.19 (2689.43, 3192.49)	1.05 (0.86, 1.29)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	923.80 (804.97, 1060.18)	692.83 (629.31, 762.77)	1.33 (1.13, 1.58)

MOCK

Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
<b>Underrepresented minority status</b>							
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.01 (1.00, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (0.99, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.98 (0.91, 1.05)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.02)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.11 (4.97, 5.26)	5.34 (4.80, 5.94)	0.96 (0.86, 1.07)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.22 (4.79, 5.69)	5.51 (4.97, 6.11)	0.95 (0.83, 1.08)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.28)	0.99 (0.97, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	53.98 (43.08, 67.63)	59.21 (45.66, 76.78)	0.91 (0.65, 1.29)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	613.00 (505.30, 743.66)	720.77 (587.83, 883.78)	0.85 (0.64, 1.13)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	371.80 (316.06, 437.37)	402.33 (338.00, 478.91)	0.92 (0.73, 1.17)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	215.96 (194.92, 239.26)	224.04 (198.81, 252.46)	0.96 (0.82, 1.13)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	41.69 (37.81, 45.97)	46.46 (41.55, 51.95)	0.90 (0.77, 1.04)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	124.79 (83.23, 187.09)	120.20 (77.64, 186.10)	1.04 (0.57, 1.88)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1188.11 (867.30, 1627.58)	1065.40 (713.58, 1590.69)	1.12 (0.67, 1.86)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	815.95 (632.13, 1053.23)	710.20 (507.15, 994.54)	1.15 (0.75, 1.75)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	389.60 (321.08, 472.73)	391.38 (322.62, 474.79)	1.00 (0.76, 1.31)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	76.39 (65.91, 88.54)	78.13 (65.41, 93.32)	0.98 (0.78, 1.23)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.98 (0.96, 1.01)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.05 (4.96, 5.14)	5.07 (4.93, 5.22)	0.99 (0.96, 1.03)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.27 (4.87, 5.71)	5.23 (4.92, 5.55)	1.01 (0.91, 1.11)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	30.50 (21.44, 43.40)	20.17 (13.43, 30.30)	1.51 (0.88, 2.59)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	409.36 (295.30, 567.48)	307.28 (203.24, 464.59)	1.33 (0.79, 2.26)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	194.97 (149.44, 254.37)	163.54 (122.72, 217.93)	1.19 (0.81, 1.76)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	109.46 (93.20, 128.56)	95.17 (76.97, 117.67)	1.15 (0.88, 1.50)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	27.84 (23.93, 32.38)	24.57 (20.22, 29.85)	1.13 (0.89, 1.45)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	744.66 (565.55, 980.50)	1046.04 (764.11, 1431.99)	0.71 (0.47, 1.08)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	28480.91 (22789.35, 35593.90)	30425.03 (23631.47, 39171.61)	0.94 (0.67, 1.31)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	19177.21 (16106.10, 22833.93)	19667.85 (16047.10, 24105.54)	0.98 (0.75, 1.27)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	3960.65 (3820.47, 4105.97)	3839.39 (3676.62, 4009.37)	1.03 (0.98, 1.09)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	984.47 (930.22, 1041.88)	980.52 (920.61, 1044.34)	1.00 (0.92, 1.09)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	3272.33 (2068.84, 5175.94)	2480.77 (1372.57, 4483.72)	1.32 (0.62, 2.79)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	98855.57 (71157.44, 137335.23)	87192.72 (61818.93, 122981.26)	1.13 (0.70, 1.82)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	51861.14 (39504.06, 68083.57)	50498.11 (37815.39, 67434.42)	1.03 (0.69, 1.53)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	4398.18 (4386.82, 4409.58)	4398.86 (4389.76, 4407.99)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1274.98 (1246.00, 1304.63)	1289.52 (1281.76, 1297.33)	0.99 (0.97, 1.01)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.98, 1.03)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (1.00, 1.01)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.10)	0.09 (0.09, 0.09)	1.03 (0.96, 1.10)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.07 (4.93, 5.21)	5.42 (4.94, 5.95)	0.93 (0.85, 1.03)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.04 (4.96, 5.11)	0.99 (0.98, 1.01)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	487.26 (317.22, 748.47)	331.39 (196.04, 560.21)	1.47 (0.75, 2.90)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	16697.08 (10951.84, 25456.21)	11323.25 (7351.20, 17441.53)	1.47 (0.81, 2.70)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	7572.41 (5551.38, 10329.23)	6308.99 (4523.19, 8799.84)	1.20 (0.76, 1.89)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3119.84 (2781.29, 3499.60)	2851.13 (2536.03, 3205.37)	1.09 (0.93, 1.29)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	762.56 (683.89, 850.29)	664.80 (580.17, 761.78)	1.15 (0.96, 1.37)

MOCK

Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Arm</b>							
Vaccine vs Placebo	Negative	-	Day 29	Anti N IgG (IU/ml)	99.6% (97.5%, 100%)	99.3% (97.2%, 99.8%)	99.3% (97.2%, 99.8%)
Vaccine vs Placebo	Negative	-	Day 29	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID50	99.6% (98.3%, 99.8%)	97.9% (88.3%, 99.6%)	97.9% (88.3%, 99.6%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID80	85.1% (81.7%, 88%)	92.7% (84.7%, 95.9%)	92.7% (84.7%, 95.9%)
Vaccine vs Placebo	Positive	-	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID50	1.5% (0.4%, 5.2%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID80	30.3% (21.4%, 38.4%)	10.1% (6.3%, 15.8%)	10.1% (6.3%, 15.8%)
Vaccine vs Placebo	Negative	-	Day 57	Anti N IgG (IU/ml)	100% (100%, 100%)	99.2% (96.9%, 99.8%)	99.2% (96.9%, 99.8%)
Vaccine vs Placebo	Negative	-	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	99.8% (98.5%, 100%)	99.8% (98.5%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	98.3% (92%, 99.7%)	98.3% (92%, 99.7%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID50	100% (100%, 100%)	97.4% (89.2%, 99.4%)	97.4% (89.2%, 99.4%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID80	100% (100%, 100%)	99.6% (97.5%, 100%)	99.6% (97.5%, 100%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Vaccine vs Placebo	Positive	-	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Baseline SARS-CoV-2</b>							
Positive vs Negative	-	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti N IgG (IU/ml)	99.6% (97.5%, 100%)	99.3% (97.2%, 99.8%)	99.3% (97.2%, 99.8%)
Positive vs Negative	-	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID50	0.2% (0.1%, 0.5%)	0.1% (0%, 0.4%)	0.1% (0%, 0.4%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID50	98.3% (94.4%, 99.4%)	97.9% (88.3%, 99.7%)	97.9% (88.3%, 99.7%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID80	10.5% (4.3%, 14.8%)	2.7% (1.6%, 4.6%)	2.7% (1.6%, 4.6%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID80	65.3% (57.6%, 72.3%)	85.4% (75.7%, 90.2%)	85.4% (75.7%, 90.2%)
Positive vs Negative	-	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti N IgG (IU/ml)	100% (100%, 100%)	99.2% (96.9%, 99.8%)	99.2% (96.9%, 99.8%)
Positive vs Negative	-	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	99.8% (98.5%, 100%)	99.8% (98.5%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Positive vs Negative	-	Placebo	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	98.3% (92%, 99.7%)	98.3% (92%, 99.7%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID50	100% (100%, 100%)	97.4% (89.2%, 99.4%)	97.4% (89.2%, 99.4%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID80	100% (100%, 100%)	99.6% (97.5%, 100%)	99.6% (97.5%, 100%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Age</b>							
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	1.5% (0.2%, 10.4%)	3% (0.7%, 11.7%)	3% (0.7%, 11.7%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-0.8% (-2.3%, -0.3%)	-0.3% (-1.9%, 0%)	-0.3% (-1.9%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0.9% (0.1%, 6.2%)	-1.6% (-15.4%, 4.1%)	-1.6% (-15.4%, 4.1%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	7.2% (2.4%, 12.1%)	0.1% (-2.3%, 2.8%)	0.1% (-2.3%, 2.8%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.8% (-12.4%, 8.1%)	-0.8% (-12.4%, 8.1%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	0.8% (-4.3%, 5.9%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	1.4% (-4.6%, 8.9%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	22.2% (10.5%, 33.2%)	6.6% (-0.8%, 14.2%)	6.6% (-0.8%, 14.2%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	1% (-2.6%, 9.9%)	1% (-2.6%, 9.9%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0.9% (0.1%, 6.2%)	0.9% (0.1%, 6.2%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	-0.2% (-10.2%, 8.9%)	-0.2% (-10.2%, 8.9%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0.6% (-13.4%, 9.5%)	0.6% (-13.4%, 9.5%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	1.5% (0.2%, 10.4%)	1.5% (0.2%, 10.4%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Risk for Severe Covid-19</b>							
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	-0.5% (-3.6%, -0.1%)	0.7% (-2.6%, 7.9%)	0.7% (-2.6%, 7.9%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-0.6% (-1.8%, -0.2%)	-0.2% (-1.4%, 0%)	-0.2% (-1.4%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	-0.3% (-2.1%, 0%)	-2.9% (-16.4%, -0.5%)	-2.9% (-16.4%, -0.5%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-7% (-12.5%, -1.1%)	-1.6% (-4.3%, 1.5%)	-1.6% (-4.3%, 1.5%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-1% (-13.7%, 7.4%)	-1% (-13.7%, 7.4%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	-1.3% (-6.5%, 5.8%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	2.1% (-3.3%, 10%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-10.8% (-23.2%, 2.3%)	-6.2% (-15.3%, 3.3%)	-6.2% (-15.3%, 3.3%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	2.6% (0.6%, 10.2%)	2.6% (0.6%, 10.2%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0.7% (0.1%, 4.9%)	0.7% (0.1%, 4.9%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	-2.4% (-11.3%, -0.5%)	-2.4% (-11.3%, -0.5%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-2% (-14.8%, 5.6%)	-2% (-14.8%, 5.6%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	1.2% (0.2%, 8.3%)	1.2% (0.2%, 8.3%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Age &lt; 65, Risk for Severe Covid-19</b>							
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-3.2% (-21.1%, -0.4%)	-3.2% (-21.1%, -0.4%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-10.2% (-17.8%, -2.5%)	-0.7% (-4.6%, 3%)	-0.7% (-4.6%, 3%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-3.1% (-18.9%, 11.2%)	-3.1% (-18.9%, 11.2%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	-1.2% (-9%, 7.3%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	4.3% (-3.4%, 13.5%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-20.6% (-35.6%, -4%)	-8.2% (-20.2%, 3.8%)	-8.2% (-20.2%, 3.8%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	2.3% (0.3%, 16%)	2.3% (0.3%, 16%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	-2.2% (-15.3%, -0.3%)	-2.2% (-15.3%, -0.3%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-3.2% (-21.1%, -0.4%)	-3.2% (-21.1%, -0.4%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age  $\geq 65$ , Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Age <math>\geq 65</math>, Risk for Severe Covid-19</b>							
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	-3.1% (-20.2%, -0.4%)	-0.1% (-17.4%, 16.8%)	-0.1% (-17.4%, 16.8%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-1.7% (-4.5%, -0.6%)	-0.5% (-3.6%, -0.1%)	-0.5% (-3.6%, -0.1%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	-1.8% (-12.4%, -0.2%)	-1.8% (-12.4%, -0.2%)	-1.8% (-12.4%, -0.2%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-7.5% (-13.1%, -2%)	-4.5% (-8.4%, -1.6%)	-4.5% (-8.4%, -1.6%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	4.2% (-7.3%, 20.2%)	4.2% (-7.3%, 20.2%)
Age $\geq 65$ At-risk vs Age $\geq 65$ Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	-2.2% (-14.7%, -0.3%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-4.2% (-15.1%, 5.1%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-0.2% (-15.9%, 13.2%)	-6% (-18.8%, 3.2%)	-6% (-18.8%, 3.2%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	3% (0.4%, 19.6%)	3% (0.4%, 19.6%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	1.7% (0.2%, 12%)	1.7% (0.2%, 12%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	-3.1% (-20.2%, -0.4%)	-3.1% (-20.2%, -0.4%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.1% (-17.4%, 16.8%)	-0.1% (-17.4%, 16.8%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	3% (0.4%, 19.6%)	3% (0.4%, 19.6%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age $\geq$ 65 At-risk vs Age $\geq$ 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Sex</b>							
Male vs Female	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	-0.6% (-4.4%, -0.1%)	0.2% (-3.6%, 5.6%)	0.2% (-3.6%, 5.6%)
Male vs Female	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	0.3% (0.1%, 0.9%)	0.1% (0%, 0.7%)	0.1% (0%, 0.7%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	-0.4% (-2.6%, 0%)	-3.6% (-19.1%, -0.6%)	-3.6% (-19.1%, -0.6%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	4.8% (-1.7%, 10.9%)	1.7% (-1.7%, 4.8%)	1.7% (-1.7%, 4.8%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	10% (2.7%, 26.9%)	10% (2.7%, 26.9%)
Male vs Female	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	3% (0.8%, 10.4%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-3.7% (-13.9%, 6.6%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	1.9% (-12.8%, 16.5%)	10.4% (1.3%, 21%)	10.4% (1.3%, 21%)
Male vs Female	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	1.8% (0.4%, 7.4%)	1.8% (0.4%, 7.4%)
Male vs Female	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0.5% (0.1%, 3.6%)	0.5% (0.1%, 3.6%)
Male vs Female	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	2.5% (-2.1%, 19.4%)	2.5% (-2.1%, 19.4%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	4.7% (-1.1%, 24.1%)	4.7% (-1.1%, 24.1%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0.9% (0.1%, 6.2%)	0.9% (0.1%, 6.2%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Hispanic or Latino ethnicity</b>							
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	-0.4% (-3.1%, -0.1%)	-0.9% (-3.4%, -0.2%)	-0.9% (-3.4%, -0.2%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	0.2% (0%, 0.5%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	-0.2% (-1.8%, 0%)	-2.5% (-14%, -0.4%)	-2.5% (-14%, -0.4%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-1.1% (-13%, 7.2%)	-0.9% (-10.8%, 2.5%)	-0.9% (-10.8%, 2.5%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	15.4% (-2.6%, 57.1%)	15.4% (-2.6%, 57.1%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	1.9% (0.5%, 6.8%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	5.5% (2.3%, 12.6%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	20.4% (2%, 32.7%)	7.6% (-7.8%, 14.6%)	7.6% (-7.8%, 14.6%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	-0.9% (-3.7%, -0.2%)	-0.9% (-3.7%, -0.2%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	13.8% (1%, 61.5%)	13.8% (1%, 61.5%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-3.1% (-13%, -0.7%)	-3.1% (-13%, -0.7%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.4% (-3.1%, -0.1%)	-0.4% (-3.1%, -0.1%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
<b>Underrepresented minority status</b>							
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	-0.7% (-5.3%, -0.1%)	-1.5% (-5.9%, -0.4%)	-1.5% (-5.9%, -0.4%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-0.1% (-0.7%, 0.7%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0.6% (0.1%, 4.5%)	0.6% (0.1%, 4.5%)	0.6% (0.1%, 4.5%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-1.7% (-8.6%, 5.6%)	-0.1% (-3.7%, 3.6%)	-0.1% (-3.7%, 3.6%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0.5% (-16.2%, 17.5%)	0.5% (-16.2%, 17.5%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	1.9% (-1.6%, 11.6%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-0.8% (-10.7%, 9.6%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	9.5% (-6.3%, 24.5%)	12% (4.5%, 23%)	12% (4.5%, 23%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0.5% (-4.2%, 8.1%)	0.5% (-4.2%, 8.1%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0.6% (0.1%, 4.5%)	0.6% (0.1%, 4.5%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	3.2% (-2.5%, 24.2%)	3.2% (-2.5%, 24.2%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-5.4% (-21.4%, -1.2%)	-5.4% (-21.4%, -1.2%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.7% (-5.3%, -0.1%)	-0.7% (-5.3%, -0.1%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Negative							
		Vaccine				Placebo			
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	899 13221/13221 = 100.0% (100.0%, 100.0%)	54.02 (45.95, 63.51)	155 95.2/13285 = 0.7% (0.2%, 2.8%)	0.02 (0.02, 0.02)	99.3% (97.2%, 99.8%)	2230.91 (1896.77, 2623.92)		
Day 29	Anti RBD IgG (IU/ml)	899 13221/13221 = 100.0% (100.0%, 100.0%)	654.16 (574.81, 744.45)	155 0/13285 = 0.0% (0.0%, 0.0%)	0.27 (0.27, 0.27)	100% (100%, 100%)	2404.99 (2113.29, 2736.96)		
Day 29	Anti Spike IgG (IU/ml)	899 13221/13221 = 100.0% (100.0%, 100.0%)	388.03 (347.63, 433.11)	155 0/13285 = 0.0% (0.0%, 0.0%)	0.09 (0.09, 0.09)	100% (100%, 100%)	4311.39 (3862.60, 4812.32)		
Day 29	Pseudovirus-nAb ID50	899 13213.6/13221 = 99.9% (99.6%, 100.0%)	214.11 (198.95, 230.43)	155 275.8/13285 = 2.1% (0.3%, 11.7%)	5.14 (4.95, 5.33)	97.9% (88.3%, 99.6%)	41.67 (38.38, 45.25)		
Day 29	Pseudovirus-nAb ID80	899 12857.6/13221 = 97.3% (95.4%, 98.4%)	43.74 (40.91, 46.77)	155 598.6/13285 = 4.5% (1.6%, 12.3%)	5.20 (5.00, 5.40)	92.7% (84.7%, 95.9%)	8.42 (7.79, 9.10)		
Day 57	Anti N IgG (IU/ml)	899 13221/13221 = 100.0% (100.0%, 100.0%)	878.77 (729.29, 1058.88)	155 102.4/13285 = 0.8% (0.2%, 3.1%)	0.02 (0.02, 0.02)	99.2% (96.9%, 99.8%)	36372.46 (30178.65, 43837.48)		
Day 57	Anti RBD IgG (IU/ml)	899 13221/13221 = 100.0% (100.0%, 100.0%)	28797.32 (24648.34, 33644.68)	155 27.4/13285 = 0.2% (0.0%, 1.5%)	0.27 (0.27, 0.27)	99.8% (98.5%, 100%)	105699.77 (90468.10, 123495.94)		
Day 57	Anti Spike IgG (IU/ml)	899 13221/13221 = 100.0% (100.0%, 100.0%)	19192.06 (16926.15, 21761.30)	155 220.4/13285 = 1.7% (0.3%, 8.0%)	0.09 (0.09, 0.09)	98.3% (92%, 99.7%)	210282.47 (185067.10, 238933.44)		
Day 57	Pseudovirus-nAb ID50	899 13221/13221 = 100.0% (100.0%, 100.0%)	3868.22 (3766.31, 3972.89)	155 343.7/13285 = 2.6% (0.6%, 10.8%)	5.22 (4.98, 5.47)	97.4% (89.2%, 99.4%)	740.68 (701.91, 781.59)		
Day 57	Pseudovirus-nAb ID80	899 13221/13221 = 100.0% (100.0%, 100.0%)	969.06 (931.18, 1008.48)	155 47.6/13285 = 0.4% (0.0%, 2.5%)	5.02 (4.98, 5.05)	99.6% (97.5%, 100%)	193.11 (185.44, 201.09)		

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Positive							
		Vaccine				Placebo			
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	278 1474/1474 = 100.0% (100.0%, 100.0%)	114.10 (86.34, 150.78)	274 1377/1377 = 100.0% (100.0%, 100.0%)	22.94 (17.73, 29.69)	0% (0%, 0%)	4.97 (3.40, 7.27)		
Day 29	Anti RBD IgG (IU/ml)	278 1474/1474 = 100.0% (100.0%, 100.0%)	990.44 (772.01, 1270.66)	274 1377/1377 = 100.0% (100.0%, 100.0%)	298.16 (234.40, 379.27)	0% (0%, 0%)	3.32 (2.35, 4.70)		
Day 29	Anti Spike IgG (IU/ml)	278 1474/1474 = 100.0% (100.0%, 100.0%)	662.31 (530.09, 827.52)	274 1377/1377 = 100.0% (100.0%, 100.0%)	155.95 (128.82, 188.81)	0% (0%, 0%)	4.25 (3.17, 5.70)		
Day 29	Pseudovirus-nAb ID50	278 1474/1474 = 100.0% (100.0%, 100.0%)	380.36 (335.84, 430.79)	274 1377/1377 = 100.0% (100.0%, 100.0%)	96.18 (85.05, 108.77)	0% (0%, 0%)	3.95 (3.32, 4.71)		
Day 29	Pseudovirus-nAb ID80	278 1474/1474 = 100.0% (100.0%, 100.0%)	76.35 (68.07, 85.64)	274 1238.1/1377 = 89.9% (84.2%, 93.7%)	24.82 (22.14, 27.81)	10.1% (6.3%, 15.8%)	3.08 (2.62, 3.62)		
Day 57	Anti N IgG (IU/ml)	278 1474/1474 = 100.0% (100.0%, 100.0%)	2526.16 (1771.45, 3602.41)	274 1377/1377 = 100.0% (100.0%, 100.0%)	322.49 (234.41, 443.66)	0% (0%, 0%)	7.83 (4.86, 12.62)		
Day 57	Anti RBD IgG (IU/ml)	278 1474/1474 = 100.0% (100.0%, 100.0%)	89153.56 (71592.48, 111022.25)	274 1377/1377 = 100.0% (100.0%, 100.0%)	11598.60 (8863.79, 15177.20)	0% (0%, 0%)	7.69 (5.43, 10.88)		
Day 57	Anti Spike IgG (IU/ml)	278 1474/1474 = 100.0% (100.0%, 100.0%)	51099.69 (41691.19, 62631.42)	274 1377/1377 = 100.0% (100.0%, 100.0%)	5752.35 (4635.25, 7138.66)	0% (0%, 0%)	8.88 (6.60, 11.95)		
Day 57	Pseudovirus-nAb ID50	278 1474/1474 = 100.0% (100.0%, 100.0%)	4368.98 (4315.56, 4423.07)	274 1377/1377 = 100.0% (100.0%, 100.0%)	2892.88 (2662.61, 3143.08)	0% (0%, 0%)	1.51 (1.39, 1.64)		
Day 57	Pseudovirus-nAb ID80	278 1474/1474 = 100.0% (100.0%, 100.0%)	1280.94 (1268.63, 1293.36)	274 1377/1377 = 100.0% (100.0%, 100.0%)	697.93 (640.72, 760.25)	0% (0%, 0%)	1.84 (1.68, 2.00)		

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)

Visit	Marker	Vaccine Recipients						Comparison	
		Baseline SARS-CoV-2 Positive			Baseline SARS-CoV-2 Negative				
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	114.10 (86.34, 150.78)	899	13221/13221 = 100.0% (100.0%, 100.0%)	54.02 (45.95, 63.51)	0% (0%, 0%)	2.11 (1.53, 2.92)
Day 29	Anti RBD IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	990.44 (772.01, 1270.66)	899	13221/13221 = 100.0% (100.0%, 100.0%)	654.16 (574.81, 744.45)	0% (0%, 0%)	1.51 (1.14, 2.00)
Day 29	Anti Spike IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	662.31 (530.09, 827.52)	899	13221/13221 = 100.0% (100.0%, 100.0%)	388.03 (347.63, 433.11)	0% (0%, 0%)	1.71 (1.33, 2.19)
Day 29	Pseudovirus-nAb ID50	278	1474/1474 = 100.0% (100.0%, 100.0%)	380.36 (335.84, 430.79)	899	13213.6/13221 = 99.9% (99.6%, 100.0%)	214.11 (198.95, 230.43)	0.1% (0%, 0.4%)	1.78 (1.54, 2.05)
Day 29	Pseudovirus-nAb ID80	278	1474/1474 = 100.0% (100.0%, 100.0%)	76.35 (68.07, 85.64)	899	12857.6/13221 = 97.3% (95.4%, 98.4%)	43.74 (40.91, 46.77)	2.7% (1.6%, 4.6%)	1.75 (1.53, 1.99)
Day 57	Anti N IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	2526.16 (1771.45, 3602.41)	899	13221/13221 = 100.0% (100.0%, 100.0%)	878.77 (729.29, 1058.88)	0% (0%, 0%)	2.87 (1.93, 4.29)
Day 57	Anti RBD IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	89153.56 (71592.48, 111022.25)	899	13221/13221 = 100.0% (100.0%, 100.0%)	28797.32 (24648.34, 33644.68)	0% (0%, 0%)	3.10 (2.37, 4.05)
Day 57	Anti Spike IgG (IU/ml)	278	1474/1474 = 100.0% (100.0%, 100.0%)	51099.69 (41691.19, 62631.42)	899	13221/13221 = 100.0% (100.0%, 100.0%)	19192.06 (16926.15, 21761.30)	0% (0%, 0%)	2.66 (2.10, 3.38)
Day 57	Pseudovirus-nAb ID50	278	1474/1474 = 100.0% (100.0%, 100.0%)	4368.98 (4315.56, 4423.07)	899	13221/13221 = 100.0% (100.0%, 100.0%)	3868.22 (3766.31, 3972.89)	0% (0%, 0%)	1.13 (1.10, 1.16)
Day 57	Pseudovirus-nAb ID80	278	1474/1474 = 100.0% (100.0%, 100.0%)	1280.94 (1268.63, 1293.36)	899	13221/13221 = 100.0% (100.0%, 100.0%)	969.06 (931.18, 1008.48)	0% (0%, 0%)	1.32 (1.27, 1.38)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 12. Antibody levels in the per-protocol cohort (placebo recipients)

Visit	Marker	Placebo Recipients						
		Baseline SARS-CoV-2 Positive			Baseline SARS-CoV-2 Negative			Comparison
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR	
Day 29	Anti N IgG (IU/ml)	274 1377/1377 = 100.0% (100.0%, 100.0%)	22.94 (17.73, 29.69)	155	95.2/13285 = 0.7% (0.2%, 2.8%)	0.02 (0.02, 0.02)	99.3% (97.2%, 99.8%)	947.53 (732.05, 1226.44)
Day 29	Anti RBD IgG (IU/ml)	274 1377/1377 = 100.0% (100.0%, 100.0%)	298.16 (234.40, 379.27)	155	0/13285 = 0.0% (0.0%, 0.0%)	0.27 (0.27, 0.27)	100% (100%, 100%)	1096.18 (861.76, 1394.38)
Day 29	Anti Spike IgG (IU/ml)	274 1377/1377 = 100.0% (100.0%, 100.0%)	155.95 (128.82, 188.81)	155	0/13285 = 0.0% (0.0%, 0.0%)	0.09 (0.09, 0.09)	100% (100%, 100%)	1732.82 (1431.29, 2097.88)
Day 29	Pseudovirus-nAb ID50	274 1377/1377 = 100.0% (100.0%, 100.0%)	96.18 (85.05, 108.77)	155	275.8/13285 = 2.1% (0.3%, 11.7%)	5.14 (4.95, 5.33)	97.9% (88.3%, 99.7%)	18.72 (16.46, 21.29)
Day 29	Pseudovirus-nAb ID80	274 1238.1/1377 = 89.9% (84.2%, 93.7%)	24.82 (22.14, 27.81)	155	598.6/13285 = 4.5% (1.6%, 12.3%)	5.20 (5.00, 5.40)	85.4% (75.7%, 90.2%)	4.78 (4.23, 5.39)
Day 57	Anti N IgG (IU/ml)	274 1377/1377 = 100.0% (100.0%, 100.0%)	322.49 (234.41, 443.66)	155	102.4/13285 = 0.8% (0.2%, 3.1%)	0.02 (0.02, 0.02)	99.2% (96.9%, 99.8%)	13347.78 (9700.96, 18365.53)
Day 57	Anti RBD IgG (IU/ml)	274 1377/1377 = 100.0% (100.0%, 100.0%)	11598.60 (8863.79, 15177.20)	155	27.4/13285 = 0.2% (0.0%, 1.5%)	0.27 (0.27, 0.27)	99.8% (98.5%, 100%)	42572.35 (32533.68, 55708.57)
Day 57	Anti Spike IgG (IU/ml)	274 1377/1377 = 100.0% (100.0%, 100.0%)	5752.35 (4635.25, 7138.66)	155	220.4/13285 = 1.7% (0.3%, 8.0%)	0.09 (0.09, 0.09)	98.3% (92%, 99.7%)	63027.02 (50725.03, 78312.52)
Day 57	Pseudovirus-nAb ID50	274 1377/1377 = 100.0% (100.0%, 100.0%)	2892.88 (2662.61, 3143.08)	155	343.7/13285 = 2.6% (0.6%, 10.8%)	5.22 (4.98, 5.47)	97.4% (89.2%, 99.4%)	553.92 (503.64, 609.23)
Day 57	Pseudovirus-nAb ID80	274 1377/1377 = 100.0% (100.0%, 100.0%)	697.93 (640.72, 760.25)	155	47.6/13285 = 0.4% (0.0%, 2.5%)	5.02 (4.98, 5.05)	99.6% (97.5%, 100%)	139.08 (127.64, 151.54)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

## Chapter 2

# Graphical Description of Immunogenicity Data

### 2.1 Pairs plots of antibody markers for overall per-protocol cohort

### 2.1.1 Baseline SARS-CoV-2 Negative




Figure 2.1: Pair plots of D29 Ab markers: baseline negative vaccine arm




Figure 2.2: Pair plots of D57 Ab markers: baseline negative vaccine arm




Figure 2.3: Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.4: Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm

## Binding Antibody to N: baseline negative vaccine arm




Figure 2.5: Pair plots of D1, D29 and D57 Binding Antibody to N: baseline negative vaccine arm




Figure 2.6: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm




Figure 2.7: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm




Figure 2.8: Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline negative vaccine arm

## PsV Neutralization 80% Titer: baseline negative vaccine arm




Figure 2.9: Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline negative vaccine arm

### 2.1.2 Baseline SARS-CoV-2 Positive




Figure 2.10: Pair plots of D29 Ab markers: baseline positive vaccine arm




Figure 2.11: Pair plots of D57 Ab markers: baseline positive vaccine arm




Figure 2.12: Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.13: Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.14: Pair plots of D1, D29 and D57 Binding Antibody to N: baseline positive vaccine arm




Figure 2.15: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm




Figure 2.16: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm

## PsV Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.17: Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.18: Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline positive vaccine arm

MOCK

## 2.2 RCDF plots of antibody markers for overall per-protocol cohort




Figure 2.19: RCDF plots for D29 Ab markers: by baseline status x randomization arm




Figure 2.20: RCDF plots for D57 Ab markers: by baseline status x randomization arm




Figure 2.21: RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.22: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.23: RCDF plots for D29 bAb markers: by baseline status for the vaccine arm




Figure 2.24: RCDF plots for D29 nAb markers: by baseline status for the vaccine arm




Figure 2.25: RCDF plots for D57 bAb markers: by baseline status for the vaccine arm




Figure 2.26: RCDF plots for D57 nAb markers: by baseline status for the vaccine arm




Figure 2.27: RCDF plots for D29 over D1 fold-rise bAb markers: by baseline status for the vaccine arm




Figure 2.28: RCDF plots for D29 over D1 fold-rise nAb markers: by baseline status for the vaccine arm




Figure 2.29: RCDF plots for D57 fold-rise over D1 bAb markers: by baseline status for the vaccine arm




Figure 2.30: RCDF plots for D57 fold-rise over D1 nAb markers: by baseline status for the vaccine arm




Figure 2.31: RCDF plots for D29 bAb markers: baseline negative vaccine arm




Figure 2.32: RCDF plots for D29 nAb markers: baseline negative vaccine arm




Figure 2.33: RCDF plots for D57 bAb markers: baseline negative vaccine arm




Figure 2.34: RCDF plots for D57 nonAb markers: baseline negative vaccine arm




Figure 2.35: RCDF plots for D29 fold-rise over D1 bAb markers: baseline negative vaccine arm




Figure 2.36: RCDF plots for D29 fold-rise over D1 nAb markers: baseline negative vaccine arm




Figure 2.37: RCDF plots for D57 fold-rise over D1 bAb markers: baseline negative vaccine arm




Figure 2.38: RCDF plots for D57 fold-rise over D1 nAb markers: baseline negative vaccine arm




Figure 2.39: RCDF plots for D29 bAb markers: baseline positive vaccine arm




Figure 2.40: RCDF plots for D29 nAb markers: baseline positive vaccine arm




Figure 2.41: RCDF plots for D57 bAb markers: baseline positive vaccine arm




Figure 2.42: RCDF plots for D57 nonAb markers: baseline positive vaccine arm




Figure 2.43: RCDF plots for D29 fold-rise over D1 bAb markers: baseline/positive vaccine arm




Figure 2.44: RCDF plots for D29 fold-rise over D1 nAb markers: baseline/positive vaccine arm




Figure 2.45: RCDF plots for D57 fold-rise over D1 bAb markers: baseline/positive vaccine arm




Figure 2.46: RCDF plots for D57 fold-rise over D1 nAb markers: baseline/positive vaccine arm

### 2.3 Scatter plots of antibody markers versus age for overall per-protocol cohort

MOCK

### 2.3.1 Baseline SARS-CoV-2 negative




Figure 2.47: Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm




Figure 2.48: Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm

### 2.3.2 Baseline SARS-CoV-2 positive




Figure 2.49: Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm




Figure 2.50: Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm

## 2.4 Box plots of antibody markers for overall per-protocol cohort

MOCK

### 2.4.1 Baseline SARS-CoV-2 negative




Figure 2.51: Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms




Figure 2.52: Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms




Figure 2.53: Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms




Figure 2.54: Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms

### 2.4.2 Baseline SARS-CoV-2 positive




Figure 2.55: Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms




Figure 2.56: Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms




Figure 2.57: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms




Figure 2.58: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms

### 2.4.3 Baseline negative vs. positive vaccine recipients




Figure 2.59: Boxplots of D29 Ab markers: baseline positive + negative vaccine arm




Figure 2.60: Boxplots of D57 Ab markers: baseline positive + negative vaccine arm




Figure 2.61: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm




Figure 2.62: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm

#### 2.4.4 Baseline negative vs. positive placebo recipients




Figure 2.63: Boxplots of D29 Ab markers: baseline positive + negative placebo arm




Figure 2.64: Boxplots of D57 Ab markers: baseline positive + negative placebo arm




Figure 2.65: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm




Figure 2.66: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm

**2.5 Spaghetti plots of antibody markers over time for the overall per-protocol cohort**

MOCK

### 2.5.1 Baseline SARS-CoV-2 negative




Figure 2.67: Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm

### 2.5.2 Baseline SARS-CoV-2 positive




Figure 2.68: Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT481

**2.6 RCDF plots of antibody markers by demographics for per-protocol cohort**

MOCK

### 2.6.1 Baseline SARS-CoV-2 negative




Figure 2.69: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT483




Figure 2.70: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.71: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT485




Figure 2.72: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.73: RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT487




Figure 2.74: RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.75: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT489




Figure 2.76: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.77: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT491




Figure 2.78: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.79: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT493




Figure 2.80: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.81: RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT495




Figure 2.82: RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.83: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT497




Figure 2.84: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.85: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT499




Figure 2.86: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.87: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT501




Figure 2.88: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.




Figure 2.89: RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT503




Figure 2.90: RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.91: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT505




Figure 2.92: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.93: RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT507




Figure 2.94: RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.




Figure 2.95: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT509




Figure 2.96: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.




Figure 2.97: RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT511




Figure 2.98: RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.99: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT513




Figure 2.100: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.101: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT515




Figure 2.102: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.103: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT517




Figure 2.104: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

### 2.6.2 Baseline SARS-CoV-2 positive




Figure 2.105: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT519




Figure 2.106: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.107: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT521




Figure 2.108: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.109: RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT523




Figure 2.110: RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.111: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT525




Figure 2.112: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.113: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT527




Figure 2.114: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.115: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT529




Figure 2.116: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.117: RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT531




Figure 2.118: RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.119: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT533




Figure 2.120: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.121: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT535




Figure 2.122: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.123: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT537




Figure 2.124: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.125: RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT539




Figure 2.126: RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.127: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT541




Figure 2.128: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.129: RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT543




Figure 2.130: RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.




Figure 2.131: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT545




Figure 2.132: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.133: RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT547




Figure 2.134: RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.135: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT549




Figure 2.136: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.137: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT551




Figure 2.138: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.139: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT553




Figure 2.140: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

## 2.7 Boxplots of antibody markers by demographics for per-protocol cohort

MOCK

### 2.7.1 Baseline SARS-CoV-2 negative




Figure 2.141: Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.




Figure 2.142: Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT557




Figure 2.143: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.144: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT559




Figure 2.145: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.




Figure 2.146: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT561




Figure 2.147: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.




Figure 2.148: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT563




Figure 2.149: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.150: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT565




Figure 2.151: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.152: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

*2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT567*

**2.7.2 Baseline SARS-CoV-2 positive**

MOCK




Figure 2.153: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT569




Figure 2.154: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.




Figure 2.155: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT571




Figure 2.156: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.157: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT573




Figure 2.158: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.159: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT575




Figure 2.160: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.161: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT577




Figure 2.162: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.163: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT579




Figure 2.164: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.165: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT581




Figure 2.166: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.167: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT583




Figure 2.168: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.169: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT585




Figure 2.170: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.